call_id,hcp_id,rep_id,call_date,call_note_raw,call_summary_target
CALL_000000,HCP_00476,REP_048,2024-01-06,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_000001,HCP_01280,REP_079,2024-06-27,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000002,HCP_00124,REP_022,2024-03-04,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_000003,HCP_02237,REP_045,2024-03-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000004,HCP_00220,REP_041,2024-02-03,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000005,HCP_02729,REP_078,2024-01-19,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000006,HCP_01923,REP_072,2024-01-02,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000007,HCP_02786,REP_068,2024-04-10,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000008,HCP_00205,REP_036,2024-01-18,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000009,HCP_03659,REP_013,2024-03-19,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000010,HCP_00456,REP_066,2024-01-16,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000011,HCP_01801,REP_024,2024-07-12,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000012,HCP_03729,REP_017,2024-03-03,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000013,HCP_02568,REP_048,2024-01-06,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_000014,HCP_04494,REP_005,2024-01-10,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_000015,HCP_02329,REP_025,2024-01-04,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000016,HCP_03388,REP_071,2024-01-06,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000017,HCP_01025,REP_057,2024-04-24,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_000018,HCP_03729,REP_050,2024-03-14,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_000019,HCP_04286,REP_027,2024-01-26,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_000020,HCP_04780,REP_026,2024-01-17,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_000021,HCP_04368,REP_020,2024-01-07,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000022,HCP_02425,REP_052,2024-01-31,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_000023,HCP_01081,REP_063,2024-01-18,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_000024,HCP_01096,REP_051,2024-01-14,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000025,HCP_03299,REP_004,2024-01-04,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_000026,HCP_04844,REP_030,2024-02-28,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000027,HCP_00971,REP_044,2024-01-24,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_000028,HCP_00731,REP_047,2024-01-08,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000029,HCP_02002,REP_029,2024-01-22,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_000030,HCP_04521,REP_045,2024-01-29,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_000031,HCP_00844,REP_046,2024-01-06,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000032,HCP_00121,REP_008,2024-01-01,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000033,HCP_03584,REP_018,2024-01-30,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000034,HCP_04421,REP_040,2024-02-05,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_000035,HCP_03399,REP_065,2024-05-07,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_000036,HCP_01443,REP_033,2024-01-11,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000037,HCP_00009,REP_051,2024-04-20,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_000038,HCP_01826,REP_036,2024-02-03,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_000039,HCP_02969,REP_042,2024-02-16,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000040,HCP_04837,REP_025,2024-02-23,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000041,HCP_04168,REP_000,2024-01-11,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000042,HCP_02883,REP_029,2024-02-02,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000043,HCP_01933,REP_035,2024-01-20,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000044,HCP_03201,REP_013,2024-01-31,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000045,HCP_00130,REP_073,2024-02-06,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_000046,HCP_00839,REP_028,2024-06-08,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000047,HCP_01369,REP_053,2024-02-29,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000048,HCP_03796,REP_056,2024-01-11,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000049,HCP_04326,REP_070,2024-01-29,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000050,HCP_00376,REP_016,2024-03-20,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_000051,HCP_04302,REP_012,2024-01-31,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000052,HCP_01478,REP_064,2024-02-13,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_000053,HCP_03683,REP_000,2024-01-09,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000054,HCP_01281,REP_055,2024-03-02,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_000055,HCP_00511,REP_071,2024-04-04,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_000056,HCP_04702,REP_079,2024-03-18,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000057,HCP_02278,REP_063,2024-01-20,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_000058,HCP_01684,REP_020,2024-01-17,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000059,HCP_00585,REP_052,2024-01-17,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000060,HCP_01417,REP_063,2024-02-04,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_000061,HCP_00516,REP_023,2024-02-13,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000062,HCP_03392,REP_005,2024-04-26,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000063,HCP_04003,REP_010,2024-01-24,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000064,HCP_00708,REP_066,2024-01-01,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_000065,HCP_00240,REP_011,2024-02-02,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_000066,HCP_00361,REP_009,2024-06-14,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000067,HCP_03348,REP_011,2024-01-29,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000068,HCP_00134,REP_027,2024-01-30,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_000069,HCP_04412,REP_076,2024-02-17,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_000070,HCP_02277,REP_038,2024-03-28,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000071,HCP_03994,REP_053,2024-01-09,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000072,HCP_03301,REP_024,2024-01-28,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_000073,HCP_01137,REP_013,2024-02-02,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000074,HCP_00955,REP_066,2024-02-09,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000075,HCP_00833,REP_051,2024-01-03,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000076,HCP_02249,REP_023,2024-02-12,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000077,HCP_02810,REP_002,2024-04-29,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000078,HCP_00577,REP_006,2024-01-29,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000079,HCP_03768,REP_045,2024-01-07,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000080,HCP_02350,REP_061,2024-02-21,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_000081,HCP_02779,REP_054,2024-02-21,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_000082,HCP_00834,REP_011,2024-01-20,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000083,HCP_01085,REP_038,2024-01-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000084,HCP_02895,REP_046,2024-01-18,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000085,HCP_04487,REP_000,2024-01-12,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000086,HCP_00092,REP_063,2024-04-01,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_000087,HCP_02336,REP_060,2024-02-27,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000088,HCP_00546,REP_011,2024-01-13,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_000089,HCP_03956,REP_053,2024-03-09,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_000090,HCP_03954,REP_052,2024-01-31,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000091,HCP_02931,REP_070,2024-03-28,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_000092,HCP_04658,REP_040,2024-01-19,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_000093,HCP_02336,REP_017,2024-03-14,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_000094,HCP_02064,REP_008,2024-01-17,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_000095,HCP_02715,REP_059,2024-01-03,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_000096,HCP_03844,REP_010,2024-01-10,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000097,HCP_04738,REP_066,2024-01-22,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_000098,HCP_03538,REP_058,2024-02-27,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000099,HCP_01422,REP_071,2024-01-24,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000100,HCP_04178,REP_018,2024-02-06,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000101,HCP_04852,REP_009,2024-01-25,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_000102,HCP_00087,REP_077,2024-01-03,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_000103,HCP_03359,REP_068,2024-01-16,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000104,HCP_04205,REP_068,2024-01-08,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000105,HCP_02178,REP_058,2024-02-05,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000106,HCP_01648,REP_054,2024-01-16,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_000107,HCP_04775,REP_056,2024-02-15,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000108,HCP_02496,REP_038,2024-09-13,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000109,HCP_03542,REP_002,2024-01-22,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_000110,HCP_02973,REP_011,2024-01-24,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000111,HCP_01600,REP_008,2024-02-09,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_000112,HCP_04735,REP_027,2024-06-06,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000113,HCP_01216,REP_027,2024-01-13,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_000114,HCP_02707,REP_032,2024-02-12,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_000115,HCP_04101,REP_006,2024-01-17,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_000116,HCP_01249,REP_025,2024-01-26,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_000117,HCP_02098,REP_049,2024-03-26,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000118,HCP_02337,REP_074,2024-02-02,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000119,HCP_04873,REP_061,2024-01-17,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_000120,HCP_02684,REP_029,2024-02-01,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000121,HCP_03131,REP_071,2024-02-12,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_000122,HCP_00280,REP_059,2024-02-28,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_000123,HCP_04834,REP_029,2024-04-04,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_000124,HCP_01810,REP_057,2024-03-18,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_000125,HCP_04396,REP_027,2024-01-07,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_000126,HCP_00476,REP_061,2024-01-17,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_000127,HCP_01297,REP_016,2024-01-02,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000128,HCP_04385,REP_018,2024-02-06,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000129,HCP_01995,REP_012,2024-02-12,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_000130,HCP_00171,REP_028,2024-01-01,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_000131,HCP_04120,REP_058,2024-01-12,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000132,HCP_04478,REP_000,2024-03-26,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000133,HCP_02760,REP_031,2024-01-02,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_000134,HCP_01739,REP_011,2024-01-17,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000135,HCP_00642,REP_002,2024-01-03,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000136,HCP_01528,REP_077,2024-01-29,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000137,HCP_00936,REP_046,2024-02-09,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_000138,HCP_02017,REP_071,2024-01-06,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000139,HCP_00629,REP_073,2024-01-09,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_000140,HCP_03742,REP_042,2024-05-03,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_000141,HCP_01869,REP_033,2024-04-06,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_000142,HCP_03287,REP_032,2024-03-12,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_000143,HCP_02526,REP_054,2024-01-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000144,HCP_04222,REP_009,2024-01-08,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000145,HCP_02253,REP_034,2024-04-12,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000146,HCP_04714,REP_007,2024-01-10,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000147,HCP_03872,REP_013,2024-01-23,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000148,HCP_04599,REP_042,2024-01-09,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_000149,HCP_02918,REP_068,2024-03-24,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000150,HCP_03667,REP_015,2024-02-17,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000151,HCP_03329,REP_062,2024-03-13,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000152,HCP_04369,REP_039,2024-01-09,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000153,HCP_00524,REP_077,2024-03-15,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_000154,HCP_02156,REP_005,2024-04-27,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000155,HCP_00145,REP_002,2024-02-12,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_000156,HCP_02146,REP_074,2024-01-04,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000157,HCP_03465,REP_063,2024-01-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000158,HCP_00883,REP_060,2024-01-30,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000159,HCP_00579,REP_029,2024-01-01,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000160,HCP_03735,REP_018,2024-02-13,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000161,HCP_01569,REP_058,2024-06-25,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000162,HCP_01872,REP_049,2024-01-28,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_000163,HCP_04595,REP_061,2024-01-26,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_000164,HCP_04654,REP_022,2024-01-17,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000165,HCP_04287,REP_018,2024-02-16,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000166,HCP_04565,REP_074,2024-04-24,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000167,HCP_00312,REP_055,2024-03-02,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000168,HCP_00955,REP_017,2024-01-21,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000169,HCP_01486,REP_001,2024-01-15,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_000170,HCP_03914,REP_021,2024-01-31,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000171,HCP_04320,REP_008,2024-02-25,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000172,HCP_01362,REP_018,2024-01-01,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_000173,HCP_01167,REP_013,2024-02-04,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000174,HCP_01141,REP_024,2024-02-25,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000175,HCP_00571,REP_074,2024-01-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000176,HCP_01009,REP_022,2024-03-27,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_000177,HCP_03132,REP_071,2024-02-09,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_000178,HCP_01663,REP_038,2024-01-26,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000179,HCP_00372,REP_028,2024-01-24,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_000180,HCP_03565,REP_052,2024-02-10,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_000181,HCP_02161,REP_037,2024-01-02,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_000182,HCP_00131,REP_065,2024-02-08,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_000183,HCP_01802,REP_013,2024-02-28,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000184,HCP_03136,REP_019,2024-01-05,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000185,HCP_02601,REP_034,2024-03-08,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000186,HCP_04506,REP_032,2024-04-30,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000187,HCP_04966,REP_064,2024-02-11,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_000188,HCP_00252,REP_032,2024-04-01,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000189,HCP_02707,REP_038,2024-01-25,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_000190,HCP_01529,REP_048,2024-02-22,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_000191,HCP_01763,REP_062,2024-03-13,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000192,HCP_00804,REP_010,2024-06-09,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_000193,HCP_00812,REP_063,2024-03-17,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000194,HCP_04743,REP_063,2024-02-07,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000195,HCP_04886,REP_022,2024-04-18,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000196,HCP_01739,REP_041,2024-01-13,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000197,HCP_03352,REP_036,2024-01-02,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_000198,HCP_01823,REP_036,2024-01-05,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000199,HCP_03903,REP_064,2024-02-20,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_000200,HCP_03714,REP_077,2024-01-04,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_000201,HCP_03168,REP_031,2024-03-03,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_000202,HCP_01269,REP_049,2024-01-12,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_000203,HCP_01569,REP_022,2024-01-03,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000204,HCP_03910,REP_033,2024-01-19,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_000205,HCP_00509,REP_057,2024-01-05,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000206,HCP_01879,REP_064,2024-01-26,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000207,HCP_01435,REP_069,2024-01-08,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000208,HCP_00991,REP_012,2024-01-13,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_000209,HCP_03029,REP_052,2024-02-12,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000210,HCP_04236,REP_041,2024-05-01,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000211,HCP_03825,REP_020,2024-01-19,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000212,HCP_00188,REP_030,2024-01-07,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000213,HCP_04073,REP_018,2024-01-08,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_000214,HCP_02124,REP_068,2024-01-24,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000215,HCP_04906,REP_034,2024-02-27,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_000216,HCP_00849,REP_070,2024-01-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000217,HCP_00504,REP_017,2024-01-08,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000218,HCP_01645,REP_014,2024-03-01,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_000219,HCP_00241,REP_067,2024-04-06,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000220,HCP_00188,REP_060,2024-01-29,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_000221,HCP_02986,REP_036,2024-02-15,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_000222,HCP_02534,REP_018,2024-01-24,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000223,HCP_00927,REP_073,2024-01-28,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_000224,HCP_03057,REP_062,2024-02-05,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_000225,HCP_04340,REP_023,2024-01-05,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_000226,HCP_01226,REP_027,2024-01-04,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000227,HCP_01716,REP_012,2024-02-07,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000228,HCP_02352,REP_077,2024-02-22,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000229,HCP_02131,REP_053,2024-02-21,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_000230,HCP_02117,REP_007,2024-03-13,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_000231,HCP_00985,REP_055,2024-01-05,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000232,HCP_03821,REP_005,2024-01-22,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000233,HCP_04034,REP_010,2024-03-15,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000234,HCP_01560,REP_062,2024-02-29,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_000235,HCP_03731,REP_026,2024-03-10,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_000236,HCP_04875,REP_038,2024-04-19,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_000237,HCP_00235,REP_023,2024-01-06,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000238,HCP_04790,REP_017,2024-01-08,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_000239,HCP_00710,REP_008,2024-05-14,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000240,HCP_01370,REP_023,2024-02-05,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000241,HCP_01674,REP_042,2024-01-15,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000242,HCP_02847,REP_053,2024-02-03,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000243,HCP_00895,REP_055,2024-01-07,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_000244,HCP_04022,REP_003,2024-01-09,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000245,HCP_03847,REP_048,2024-02-11,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000246,HCP_02784,REP_029,2024-04-19,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_000247,HCP_01575,REP_036,2024-02-08,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_000248,HCP_03783,REP_049,2024-03-21,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000249,HCP_01463,REP_072,2024-01-15,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000250,HCP_02245,REP_018,2024-03-07,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000251,HCP_01829,REP_014,2024-01-04,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000252,HCP_04442,REP_015,2024-02-05,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000253,HCP_03603,REP_071,2024-01-11,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000254,HCP_00550,REP_052,2024-03-24,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_000255,HCP_01075,REP_004,2024-02-04,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000256,HCP_01590,REP_025,2024-01-04,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_000257,HCP_04166,REP_058,2024-01-12,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000258,HCP_04577,REP_020,2024-02-05,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000259,HCP_01950,REP_011,2024-01-25,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_000260,HCP_04223,REP_028,2024-01-04,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_000261,HCP_03433,REP_052,2024-02-25,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000262,HCP_02848,REP_058,2024-02-04,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_000263,HCP_04208,REP_017,2024-01-25,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000264,HCP_00073,REP_009,2024-02-28,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000265,HCP_03470,REP_074,2024-02-10,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000266,HCP_04271,REP_022,2024-01-01,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000267,HCP_01447,REP_037,2024-01-13,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000268,HCP_02950,REP_043,2024-01-22,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_000269,HCP_04688,REP_026,2024-02-28,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_000270,HCP_03009,REP_052,2024-01-16,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000271,HCP_04363,REP_043,2024-02-18,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000272,HCP_01041,REP_007,2024-05-05,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000273,HCP_03587,REP_007,2024-08-10,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000274,HCP_02603,REP_013,2024-01-08,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000275,HCP_04539,REP_010,2024-02-02,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_000276,HCP_04314,REP_048,2024-01-29,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000277,HCP_01527,REP_064,2024-01-17,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_000278,HCP_02715,REP_021,2024-03-31,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000279,HCP_00371,REP_012,2024-02-13,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_000280,HCP_04116,REP_020,2024-01-01,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000281,HCP_04841,REP_030,2024-01-06,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000282,HCP_02238,REP_042,2024-02-22,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000283,HCP_02733,REP_035,2024-01-03,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000284,HCP_03481,REP_016,2024-01-15,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000285,HCP_04623,REP_068,2024-04-20,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000286,HCP_03517,REP_063,2024-01-15,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000287,HCP_01357,REP_000,2024-03-04,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000288,HCP_02665,REP_046,2024-01-09,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_000289,HCP_01469,REP_066,2024-01-01,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_000290,HCP_03125,REP_072,2024-01-23,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000291,HCP_03316,REP_062,2024-02-10,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000292,HCP_01483,REP_076,2024-03-13,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_000293,HCP_03864,REP_013,2024-04-17,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_000294,HCP_03834,REP_035,2024-01-02,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000295,HCP_03993,REP_012,2024-02-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000296,HCP_02106,REP_038,2024-01-06,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_000297,HCP_04090,REP_033,2024-05-23,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_000298,HCP_03053,REP_034,2024-01-31,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_000299,HCP_02349,REP_065,2024-01-12,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000300,HCP_01998,REP_034,2024-01-29,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000301,HCP_00505,REP_074,2024-03-09,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_000302,HCP_02728,REP_031,2024-01-10,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000303,HCP_04730,REP_006,2024-01-15,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_000304,HCP_01119,REP_055,2024-03-12,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_000305,HCP_02701,REP_027,2024-01-02,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000306,HCP_02237,REP_016,2024-02-28,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000307,HCP_01953,REP_007,2024-01-04,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000308,HCP_02317,REP_045,2024-01-05,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_000309,HCP_02431,REP_043,2024-01-01,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000310,HCP_04762,REP_075,2024-01-04,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000311,HCP_04058,REP_068,2024-01-04,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_000312,HCP_03846,REP_046,2024-03-13,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_000313,HCP_03470,REP_066,2024-02-15,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000314,HCP_04006,REP_069,2024-01-08,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000315,HCP_02574,REP_003,2024-02-14,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000316,HCP_02414,REP_008,2024-07-25,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000317,HCP_02551,REP_054,2024-03-07,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_000318,HCP_01240,REP_005,2024-01-07,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000319,HCP_03733,REP_033,2024-04-07,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_000320,HCP_01059,REP_046,2024-01-08,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_000321,HCP_01427,REP_070,2024-04-07,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000322,HCP_04851,REP_002,2024-01-13,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_000323,HCP_02963,REP_028,2024-01-04,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_000324,HCP_04950,REP_058,2024-01-16,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000325,HCP_00937,REP_043,2024-01-31,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_000326,HCP_00334,REP_026,2024-06-08,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_000327,HCP_01615,REP_055,2024-01-16,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_000328,HCP_01599,REP_047,2024-04-13,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000329,HCP_04517,REP_072,2024-02-16,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_000330,HCP_01634,REP_047,2024-01-02,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_000331,HCP_02146,REP_069,2024-01-16,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_000332,HCP_01361,REP_054,2024-01-07,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000333,HCP_01257,REP_056,2024-01-31,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_000334,HCP_02238,REP_027,2024-02-26,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_000335,HCP_03517,REP_017,2024-01-24,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000336,HCP_02027,REP_052,2024-08-13,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000337,HCP_03421,REP_045,2024-02-29,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000338,HCP_02170,REP_074,2024-04-09,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000339,HCP_00312,REP_007,2024-01-04,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_000340,HCP_02395,REP_075,2024-01-08,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_000341,HCP_04877,REP_027,2024-01-01,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000342,HCP_03111,REP_002,2024-01-02,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_000343,HCP_04654,REP_022,2024-01-30,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000344,HCP_02750,REP_068,2024-03-23,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000345,HCP_01235,REP_041,2024-03-05,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_000346,HCP_02499,REP_059,2024-01-17,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000347,HCP_02277,REP_073,2024-03-31,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_000348,HCP_01228,REP_000,2024-06-21,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000349,HCP_01178,REP_057,2024-01-02,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000350,HCP_00691,REP_048,2024-01-18,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000351,HCP_00862,REP_053,2024-01-16,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000352,HCP_00814,REP_040,2024-01-05,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000353,HCP_01599,REP_053,2024-03-25,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000354,HCP_04824,REP_073,2024-03-02,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000355,HCP_04224,REP_030,2024-01-21,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000356,HCP_03265,REP_058,2024-02-23,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_000357,HCP_04094,REP_049,2024-02-02,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_000358,HCP_04082,REP_011,2024-02-27,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000359,HCP_03027,REP_050,2024-02-06,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_000360,HCP_04112,REP_041,2024-01-09,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_000361,HCP_02210,REP_077,2024-02-12,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_000362,HCP_02230,REP_056,2024-02-20,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000363,HCP_01225,REP_035,2024-01-20,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_000364,HCP_00692,REP_054,2024-01-26,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000365,HCP_00192,REP_020,2024-05-29,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000366,HCP_01873,REP_065,2024-03-02,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000367,HCP_01290,REP_024,2024-04-23,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000368,HCP_04491,REP_059,2024-01-14,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000369,HCP_01011,REP_038,2024-01-29,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000370,HCP_01879,REP_074,2024-01-13,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000371,HCP_00743,REP_014,2024-01-22,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_000372,HCP_03034,REP_027,2024-02-17,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_000373,HCP_03962,REP_023,2024-02-23,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_000374,HCP_04594,REP_076,2024-05-17,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_000375,HCP_04786,REP_011,2024-01-22,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000376,HCP_04579,REP_065,2024-05-20,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000377,HCP_01225,REP_013,2024-01-10,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_000378,HCP_00314,REP_076,2024-01-03,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000379,HCP_04433,REP_032,2024-02-07,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_000380,HCP_04177,REP_011,2024-01-22,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000381,HCP_03500,REP_035,2024-05-03,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000382,HCP_02349,REP_021,2024-06-21,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_000383,HCP_04071,REP_020,2024-01-15,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_000384,HCP_04189,REP_050,2024-01-16,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000385,HCP_02271,REP_032,2024-01-28,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000386,HCP_02615,REP_067,2024-02-16,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_000387,HCP_01831,REP_028,2024-01-10,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000388,HCP_03941,REP_032,2024-05-15,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000389,HCP_00024,REP_033,2024-01-09,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000390,HCP_03416,REP_054,2024-01-17,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_000391,HCP_04580,REP_012,2024-01-03,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000392,HCP_03070,REP_054,2024-01-02,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_000393,HCP_02693,REP_075,2024-02-04,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000394,HCP_02249,REP_022,2024-05-06,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_000395,HCP_04060,REP_021,2024-05-01,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_000396,HCP_02957,REP_060,2024-02-11,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_000397,HCP_04760,REP_069,2024-01-15,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000398,HCP_02202,REP_017,2024-01-25,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000399,HCP_03575,REP_064,2024-01-14,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_000400,HCP_02902,REP_020,2024-01-19,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000401,HCP_01951,REP_069,2024-05-25,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_000402,HCP_04707,REP_057,2024-02-07,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_000403,HCP_04423,REP_000,2024-01-13,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_000404,HCP_02548,REP_078,2024-01-06,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000405,HCP_02668,REP_032,2024-02-05,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_000406,HCP_02793,REP_076,2024-01-04,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_000407,HCP_00810,REP_038,2024-01-19,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000408,HCP_01437,REP_045,2024-02-19,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_000409,HCP_02206,REP_052,2024-01-03,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000410,HCP_02270,REP_018,2024-02-17,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_000411,HCP_03978,REP_048,2024-01-26,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_000412,HCP_02052,REP_021,2024-01-01,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000413,HCP_03546,REP_079,2024-02-01,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000414,HCP_00542,REP_046,2024-03-20,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000415,HCP_00599,REP_042,2024-01-11,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_000416,HCP_04398,REP_019,2024-01-09,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000417,HCP_01792,REP_021,2024-04-13,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_000418,HCP_03125,REP_019,2024-01-09,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000419,HCP_02896,REP_040,2024-01-18,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_000420,HCP_04592,REP_042,2024-01-06,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000421,HCP_02001,REP_059,2024-01-05,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_000422,HCP_00134,REP_076,2024-01-26,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000423,HCP_02780,REP_079,2024-02-06,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000424,HCP_03604,REP_012,2024-01-21,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_000425,HCP_03825,REP_019,2024-02-18,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_000426,HCP_02971,REP_056,2024-01-13,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000427,HCP_00786,REP_023,2024-01-27,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000428,HCP_01597,REP_061,2024-01-20,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_000429,HCP_00844,REP_068,2024-02-09,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_000430,HCP_02194,REP_018,2024-02-25,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_000431,HCP_01630,REP_060,2024-01-09,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000432,HCP_03574,REP_004,2024-02-01,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000433,HCP_02550,REP_039,2024-01-15,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000434,HCP_00678,REP_009,2024-02-10,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_000435,HCP_04476,REP_003,2024-01-06,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_000436,HCP_02101,REP_077,2024-01-05,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_000437,HCP_03076,REP_032,2024-01-02,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000438,HCP_00635,REP_079,2024-01-04,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000439,HCP_03975,REP_004,2024-05-06,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_000440,HCP_04493,REP_040,2024-02-17,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000441,HCP_02284,REP_067,2024-07-07,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_000442,HCP_00440,REP_041,2024-02-29,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_000443,HCP_00489,REP_008,2024-01-05,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_000444,HCP_01521,REP_043,2024-01-03,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000445,HCP_04396,REP_060,2024-01-01,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_000446,HCP_01678,REP_057,2024-01-13,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_000447,HCP_02828,REP_038,2024-05-01,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000448,HCP_03604,REP_028,2024-01-31,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_000449,HCP_02439,REP_040,2024-01-18,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000450,HCP_00913,REP_046,2024-01-03,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_000451,HCP_02379,REP_059,2024-01-06,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000452,HCP_04638,REP_011,2024-01-04,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000453,HCP_01200,REP_051,2024-01-21,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_000454,HCP_02487,REP_007,2024-02-08,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000455,HCP_02325,REP_065,2024-01-30,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000456,HCP_00324,REP_041,2024-01-01,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_000457,HCP_00947,REP_053,2024-02-25,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000458,HCP_03160,REP_009,2024-01-24,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_000459,HCP_00444,REP_035,2024-01-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000460,HCP_04965,REP_024,2024-01-22,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_000461,HCP_04600,REP_033,2024-01-06,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000462,HCP_02799,REP_011,2024-04-06,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_000463,HCP_00492,REP_022,2024-01-04,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000464,HCP_02479,REP_017,2024-01-30,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000465,HCP_04585,REP_071,2024-01-30,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_000466,HCP_04394,REP_078,2024-01-26,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000467,HCP_04324,REP_044,2024-01-07,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_000468,HCP_03461,REP_048,2024-02-25,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_000469,HCP_01245,REP_006,2024-03-11,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_000470,HCP_02970,REP_044,2024-01-22,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_000471,HCP_00928,REP_058,2024-01-07,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000472,HCP_04120,REP_079,2024-01-25,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000473,HCP_03203,REP_076,2024-01-11,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_000474,HCP_02687,REP_045,2024-01-17,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_000475,HCP_04954,REP_033,2024-01-20,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_000476,HCP_00156,REP_036,2024-01-05,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000477,HCP_01876,REP_021,2024-01-02,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000478,HCP_00215,REP_045,2024-03-09,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_000479,HCP_01981,REP_028,2024-01-09,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000480,HCP_02592,REP_003,2024-01-19,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000481,HCP_03830,REP_078,2024-02-07,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_000482,HCP_01107,REP_026,2024-02-24,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000483,HCP_01015,REP_078,2024-01-07,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000484,HCP_02845,REP_067,2024-03-23,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_000485,HCP_04282,REP_076,2024-01-18,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_000486,HCP_00068,REP_006,2024-01-06,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_000487,HCP_02229,REP_072,2024-02-09,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000488,HCP_04456,REP_003,2024-02-21,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000489,HCP_01726,REP_005,2024-05-26,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000490,HCP_04653,REP_028,2024-01-25,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000491,HCP_01772,REP_025,2024-01-05,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000492,HCP_02645,REP_061,2024-03-09,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000493,HCP_04790,REP_060,2024-01-06,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_000494,HCP_00722,REP_047,2024-01-24,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000495,HCP_01194,REP_074,2024-01-25,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_000496,HCP_04638,REP_069,2024-09-05,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000497,HCP_01193,REP_001,2024-01-04,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_000498,HCP_04384,REP_036,2024-01-02,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000499,HCP_03801,REP_052,2024-01-03,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_000500,HCP_03943,REP_028,2024-05-28,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_000501,HCP_04982,REP_040,2024-06-17,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000502,HCP_00070,REP_057,2024-01-17,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000503,HCP_04418,REP_005,2024-01-22,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000504,HCP_04296,REP_074,2024-01-31,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000505,HCP_04601,REP_018,2024-01-12,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_000506,HCP_00860,REP_069,2024-03-22,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000507,HCP_04902,REP_056,2024-01-08,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_000508,HCP_03953,REP_022,2024-01-04,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000509,HCP_02008,REP_075,2024-01-19,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000510,HCP_03670,REP_066,2024-01-06,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000511,HCP_00639,REP_049,2024-01-18,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_000512,HCP_03191,REP_003,2024-01-03,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000513,HCP_02926,REP_024,2024-02-21,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_000514,HCP_00366,REP_034,2024-03-26,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000515,HCP_03580,REP_073,2024-02-20,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_000516,HCP_04235,REP_067,2024-05-05,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_000517,HCP_01027,REP_017,2024-01-09,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000518,HCP_03510,REP_075,2024-01-15,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_000519,HCP_04492,REP_065,2024-01-25,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000520,HCP_04605,REP_078,2024-04-14,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_000521,HCP_04811,REP_026,2024-02-09,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000522,HCP_04725,REP_022,2024-03-08,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000523,HCP_03691,REP_013,2024-03-03,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000524,HCP_03996,REP_019,2024-01-25,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000525,HCP_01843,REP_049,2024-01-25,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000526,HCP_03819,REP_029,2024-02-19,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_000527,HCP_03130,REP_078,2024-03-03,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_000528,HCP_04531,REP_002,2024-01-04,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_000529,HCP_03755,REP_059,2024-01-04,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000530,HCP_01225,REP_039,2024-01-03,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000531,HCP_01204,REP_067,2024-03-01,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000532,HCP_01128,REP_030,2024-02-29,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000533,HCP_04825,REP_075,2024-01-19,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000534,HCP_04337,REP_022,2024-01-29,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_000535,HCP_01156,REP_023,2024-01-22,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000536,HCP_04233,REP_011,2024-03-10,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000537,HCP_01246,REP_007,2024-01-14,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000538,HCP_02741,REP_011,2024-01-23,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_000539,HCP_03507,REP_071,2024-01-03,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000540,HCP_01308,REP_031,2024-02-21,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000541,HCP_04099,REP_054,2024-02-25,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000542,HCP_02484,REP_046,2024-01-05,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000543,HCP_03454,REP_047,2024-01-31,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_000544,HCP_03368,REP_044,2024-01-09,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000545,HCP_00714,REP_028,2024-01-11,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_000546,HCP_01161,REP_048,2024-01-29,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000547,HCP_04867,REP_046,2024-01-05,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000548,HCP_02631,REP_024,2024-02-11,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000549,HCP_01169,REP_007,2024-02-09,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000550,HCP_03918,REP_051,2024-01-27,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000551,HCP_01992,REP_043,2024-02-11,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000552,HCP_02870,REP_009,2024-03-24,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000553,HCP_02724,REP_066,2024-03-26,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_000554,HCP_00377,REP_064,2024-05-12,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000555,HCP_02190,REP_056,2024-02-10,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_000556,HCP_00569,REP_033,2024-01-05,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_000557,HCP_03369,REP_024,2024-05-07,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000558,HCP_02908,REP_035,2024-01-28,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000559,HCP_01421,REP_000,2024-01-17,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000560,HCP_00746,REP_078,2024-01-15,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_000561,HCP_04106,REP_013,2024-03-21,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000562,HCP_00976,REP_054,2024-01-10,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000563,HCP_00033,REP_051,2024-04-10,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_000564,HCP_00077,REP_022,2024-02-26,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_000565,HCP_04685,REP_016,2024-01-18,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000566,HCP_02083,REP_014,2024-01-12,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000567,HCP_03547,REP_010,2024-01-01,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000568,HCP_04671,REP_039,2024-01-26,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000569,HCP_01803,REP_027,2024-02-19,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000570,HCP_01749,REP_038,2024-01-26,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_000571,HCP_01411,REP_053,2024-01-21,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000572,HCP_03808,REP_048,2024-01-07,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000573,HCP_03396,REP_049,2024-01-02,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000574,HCP_02656,REP_004,2024-03-12,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000575,HCP_04851,REP_010,2024-01-25,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000576,HCP_01084,REP_030,2024-03-13,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000577,HCP_04872,REP_068,2024-01-06,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000578,HCP_01516,REP_057,2024-03-22,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000579,HCP_00932,REP_047,2024-01-31,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000580,HCP_04038,REP_072,2024-02-25,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000581,HCP_00406,REP_047,2024-02-08,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000582,HCP_01912,REP_044,2024-01-01,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_000583,HCP_04880,REP_063,2024-03-14,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_000584,HCP_00092,REP_072,2024-04-30,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000585,HCP_04476,REP_030,2024-01-05,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000586,HCP_01639,REP_042,2024-05-02,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_000587,HCP_04480,REP_051,2024-01-08,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_000588,HCP_00188,REP_009,2024-02-13,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000589,HCP_01747,REP_063,2024-02-24,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000590,HCP_01758,REP_040,2024-01-09,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000591,HCP_01999,REP_016,2024-01-10,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000592,HCP_03115,REP_018,2024-01-07,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_000593,HCP_02222,REP_033,2024-04-07,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_000594,HCP_03729,REP_057,2024-01-28,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_000595,HCP_03930,REP_038,2024-01-11,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_000596,HCP_02545,REP_038,2024-01-12,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000597,HCP_02025,REP_058,2024-01-31,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000598,HCP_00341,REP_064,2024-01-25,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_000599,HCP_02198,REP_034,2024-02-10,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000600,HCP_02813,REP_000,2024-04-02,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000601,HCP_04631,REP_074,2024-02-18,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000602,HCP_01967,REP_027,2024-01-04,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000603,HCP_00516,REP_006,2024-01-29,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_000604,HCP_04366,REP_074,2024-01-04,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000605,HCP_04946,REP_037,2024-01-08,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_000606,HCP_02259,REP_012,2024-02-19,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000607,HCP_02150,REP_071,2024-02-09,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000608,HCP_04626,REP_015,2024-01-26,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000609,HCP_00316,REP_074,2024-01-17,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000610,HCP_00459,REP_074,2024-01-04,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000611,HCP_04999,REP_005,2024-01-02,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000612,HCP_03350,REP_030,2024-01-10,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000613,HCP_00016,REP_078,2024-02-07,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000614,HCP_03225,REP_041,2024-02-08,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_000615,HCP_01705,REP_024,2024-01-07,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000616,HCP_03215,REP_007,2024-01-01,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_000617,HCP_00690,REP_033,2024-01-05,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_000618,HCP_01521,REP_019,2024-02-08,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000619,HCP_01876,REP_013,2024-01-18,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_000620,HCP_02024,REP_047,2024-01-05,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_000621,HCP_03909,REP_019,2024-02-17,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000622,HCP_04469,REP_046,2024-01-01,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000623,HCP_04974,REP_028,2024-07-16,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000624,HCP_03640,REP_026,2024-01-19,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_000625,HCP_00928,REP_033,2024-01-16,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000626,HCP_02470,REP_002,2024-01-15,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_000627,HCP_00036,REP_025,2024-05-18,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000628,HCP_03693,REP_068,2024-04-11,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000629,HCP_04269,REP_064,2024-01-28,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000630,HCP_00499,REP_059,2024-01-06,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_000631,HCP_03998,REP_059,2024-02-17,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000632,HCP_02118,REP_037,2024-01-04,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000633,HCP_01426,REP_032,2024-02-11,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_000634,HCP_03427,REP_050,2024-01-04,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_000635,HCP_04330,REP_018,2024-08-13,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000636,HCP_03773,REP_059,2024-03-28,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_000637,HCP_01973,REP_002,2024-03-23,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_000638,HCP_02550,REP_076,2024-01-08,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_000639,HCP_03818,REP_068,2024-01-05,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000640,HCP_03448,REP_057,2024-03-14,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000641,HCP_00741,REP_039,2024-03-31,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_000642,HCP_01933,REP_020,2024-01-27,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_000643,HCP_04423,REP_067,2024-01-20,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_000644,HCP_00056,REP_076,2024-01-12,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_000645,HCP_04249,REP_051,2024-01-10,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000646,HCP_04078,REP_068,2024-01-19,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000647,HCP_03149,REP_034,2024-01-01,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000648,HCP_04794,REP_014,2024-01-01,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_000649,HCP_02821,REP_049,2024-01-25,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000650,HCP_03449,REP_069,2024-02-13,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000651,HCP_02138,REP_066,2024-06-05,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000652,HCP_04510,REP_005,2024-01-06,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000653,HCP_03992,REP_017,2024-01-05,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_000654,HCP_03937,REP_017,2024-01-09,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_000655,HCP_01995,REP_038,2024-01-11,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_000656,HCP_04960,REP_012,2024-03-08,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000657,HCP_00008,REP_016,2024-02-06,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000658,HCP_04201,REP_017,2024-02-05,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_000659,HCP_02803,REP_068,2024-01-08,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_000660,HCP_04299,REP_036,2024-03-01,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_000661,HCP_04680,REP_012,2024-01-22,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000662,HCP_00825,REP_023,2024-06-12,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000663,HCP_01905,REP_005,2024-02-02,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_000664,HCP_03212,REP_071,2024-01-12,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000665,HCP_01456,REP_018,2024-01-05,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_000666,HCP_03974,REP_001,2024-01-02,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000667,HCP_04134,REP_071,2024-01-09,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_000668,HCP_02937,REP_059,2024-02-04,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000669,HCP_00290,REP_077,2024-01-08,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000670,HCP_03113,REP_049,2024-04-06,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000671,HCP_00061,REP_069,2024-02-27,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000672,HCP_01289,REP_036,2024-02-19,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000673,HCP_01059,REP_012,2024-01-01,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000674,HCP_02880,REP_063,2024-02-05,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_000675,HCP_02386,REP_063,2024-03-14,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_000676,HCP_01741,REP_070,2024-01-10,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000677,HCP_01473,REP_054,2024-04-28,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000678,HCP_00597,REP_001,2024-04-05,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_000679,HCP_00281,REP_079,2024-02-24,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000680,HCP_02174,REP_078,2024-01-17,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_000681,HCP_01629,REP_077,2024-01-04,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000682,HCP_00118,REP_029,2024-01-23,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_000683,HCP_02766,REP_067,2024-05-05,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_000684,HCP_02328,REP_021,2024-02-10,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000685,HCP_04850,REP_006,2024-06-15,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000686,HCP_00761,REP_048,2024-02-12,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000687,HCP_04587,REP_043,2024-01-04,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_000688,HCP_04553,REP_058,2024-03-10,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_000689,HCP_04762,REP_074,2024-01-21,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_000690,HCP_04901,REP_011,2024-03-17,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000691,HCP_01573,REP_076,2024-01-08,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000692,HCP_01463,REP_024,2024-01-11,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000693,HCP_00717,REP_027,2024-01-10,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_000694,HCP_04421,REP_003,2024-02-20,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000695,HCP_00247,REP_070,2024-01-18,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_000696,HCP_04286,REP_045,2024-01-18,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000697,HCP_02647,REP_055,2024-02-04,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000698,HCP_02107,REP_029,2024-01-11,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_000699,HCP_02882,REP_050,2024-05-30,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_000700,HCP_04717,REP_024,2024-01-03,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_000701,HCP_00877,REP_056,2024-04-16,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_000702,HCP_04650,REP_065,2024-01-11,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_000703,HCP_02243,REP_074,2024-02-17,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_000704,HCP_02645,REP_079,2024-01-27,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000705,HCP_02880,REP_079,2024-03-06,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_000706,HCP_04278,REP_008,2024-01-19,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000707,HCP_01796,REP_065,2024-01-22,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_000708,HCP_00434,REP_056,2024-02-16,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_000709,HCP_04515,REP_024,2024-01-03,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000710,HCP_04432,REP_026,2024-01-27,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_000711,HCP_04093,REP_068,2024-01-02,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000712,HCP_02997,REP_043,2024-03-23,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000713,HCP_03528,REP_016,2024-05-17,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_000714,HCP_04083,REP_041,2024-02-03,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_000715,HCP_00591,REP_074,2024-01-08,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_000716,HCP_04465,REP_026,2024-02-27,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000717,HCP_01578,REP_016,2024-01-29,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000718,HCP_00731,REP_061,2024-03-29,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000719,HCP_03735,REP_049,2024-01-05,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000720,HCP_02249,REP_045,2024-05-18,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_000721,HCP_04516,REP_071,2024-05-05,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_000722,HCP_01562,REP_048,2024-01-22,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000723,HCP_03041,REP_026,2024-01-12,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_000724,HCP_00255,REP_075,2024-01-07,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000725,HCP_02900,REP_012,2024-02-17,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_000726,HCP_03664,REP_039,2024-02-27,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000727,HCP_02427,REP_035,2024-02-07,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000728,HCP_04181,REP_018,2024-01-29,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_000729,HCP_02132,REP_051,2024-01-18,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000730,HCP_03482,REP_004,2024-04-25,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_000731,HCP_04833,REP_069,2024-01-04,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000732,HCP_04221,REP_012,2024-01-02,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000733,HCP_02544,REP_014,2024-05-02,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_000734,HCP_04107,REP_055,2024-01-22,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000735,HCP_02687,REP_062,2024-01-30,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_000736,HCP_03723,REP_029,2024-03-02,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000737,HCP_03930,REP_019,2024-03-04,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000738,HCP_04091,REP_063,2024-02-18,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_000739,HCP_01824,REP_002,2024-01-30,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000740,HCP_04004,REP_029,2024-01-09,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000741,HCP_01042,REP_070,2024-01-20,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000742,HCP_01069,REP_013,2024-01-03,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_000743,HCP_00744,REP_016,2024-01-05,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_000744,HCP_00865,REP_040,2024-01-17,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000745,HCP_03640,REP_041,2024-01-17,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_000746,HCP_00314,REP_050,2024-01-25,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_000747,HCP_03655,REP_063,2024-03-24,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000748,HCP_03390,REP_050,2024-09-01,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_000749,HCP_04293,REP_030,2024-02-05,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000750,HCP_01199,REP_020,2024-03-20,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_000751,HCP_01431,REP_070,2024-02-13,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_000752,HCP_03470,REP_039,2024-02-03,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000753,HCP_01564,REP_056,2024-01-11,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000754,HCP_03957,REP_027,2024-02-29,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000755,HCP_00331,REP_063,2024-01-22,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000756,HCP_04438,REP_029,2024-01-12,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_000757,HCP_04489,REP_066,2024-02-06,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_000758,HCP_03893,REP_041,2024-01-24,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000759,HCP_03620,REP_020,2024-03-26,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000760,HCP_01749,REP_016,2024-06-29,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_000761,HCP_02969,REP_052,2024-01-02,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_000762,HCP_03604,REP_038,2024-01-16,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000763,HCP_02272,REP_025,2024-05-24,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000764,HCP_03523,REP_062,2024-01-09,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_000765,HCP_00839,REP_075,2024-01-20,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_000766,HCP_03634,REP_063,2024-01-01,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_000767,HCP_02625,REP_067,2024-01-01,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_000768,HCP_01375,REP_073,2024-01-21,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000769,HCP_03914,REP_032,2024-02-09,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_000770,HCP_00563,REP_026,2024-01-24,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000771,HCP_00451,REP_035,2024-01-18,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_000772,HCP_02383,REP_079,2024-02-08,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000773,HCP_02566,REP_059,2024-01-01,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_000774,HCP_03680,REP_060,2024-01-17,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000775,HCP_03327,REP_034,2024-01-05,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000776,HCP_01046,REP_019,2024-01-16,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_000777,HCP_00555,REP_077,2024-02-03,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000778,HCP_02890,REP_005,2024-01-05,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000779,HCP_00244,REP_067,2024-01-06,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_000780,HCP_00375,REP_054,2024-01-06,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_000781,HCP_03284,REP_037,2024-01-04,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_000782,HCP_01411,REP_065,2024-01-01,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000783,HCP_02529,REP_015,2024-04-23,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000784,HCP_00555,REP_004,2024-01-09,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000785,HCP_01996,REP_057,2024-03-23,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000786,HCP_03305,REP_041,2024-01-07,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_000787,HCP_04827,REP_006,2024-01-22,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000788,HCP_00961,REP_039,2024-01-05,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000789,HCP_03915,REP_068,2024-01-06,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_000790,HCP_02088,REP_027,2024-01-16,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_000791,HCP_00813,REP_067,2024-03-16,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000792,HCP_02275,REP_044,2024-02-03,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000793,HCP_00481,REP_038,2024-01-01,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_000794,HCP_04346,REP_025,2024-02-22,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000795,HCP_03908,REP_004,2024-02-04,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_000796,HCP_03550,REP_029,2024-01-06,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_000797,HCP_02741,REP_021,2024-01-23,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000798,HCP_01351,REP_071,2024-01-15,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_000799,HCP_01431,REP_052,2024-02-02,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_000800,HCP_01619,REP_045,2024-01-03,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_000801,HCP_01823,REP_015,2024-03-16,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000802,HCP_02216,REP_030,2024-04-20,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_000803,HCP_04553,REP_068,2024-01-17,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000804,HCP_01906,REP_005,2024-01-22,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_000805,HCP_03044,REP_011,2024-03-15,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_000806,HCP_01562,REP_057,2024-06-10,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000807,HCP_00551,REP_009,2024-01-10,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000808,HCP_04143,REP_018,2024-01-06,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_000809,HCP_03870,REP_013,2024-01-12,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_000810,HCP_01841,REP_015,2024-06-14,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_000811,HCP_04177,REP_079,2024-01-05,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_000812,HCP_03663,REP_070,2024-02-06,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000813,HCP_03076,REP_037,2024-02-01,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000814,HCP_04222,REP_074,2024-01-11,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000815,HCP_01990,REP_062,2024-07-07,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000816,HCP_00421,REP_047,2024-01-23,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000817,HCP_02111,REP_004,2024-01-24,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000818,HCP_04757,REP_064,2024-03-24,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000819,HCP_01824,REP_046,2024-01-01,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000820,HCP_04030,REP_042,2024-01-10,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000821,HCP_04333,REP_036,2024-01-05,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_000822,HCP_01917,REP_011,2024-01-02,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000823,HCP_00539,REP_021,2024-02-07,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000824,HCP_03942,REP_057,2024-02-25,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_000825,HCP_01057,REP_045,2024-02-29,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_000826,HCP_01632,REP_041,2024-03-21,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_000827,HCP_02523,REP_030,2024-07-06,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_000828,HCP_02554,REP_058,2024-01-03,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_000829,HCP_02655,REP_016,2024-01-12,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000830,HCP_02357,REP_023,2024-01-19,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_000831,HCP_03556,REP_073,2024-01-16,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000832,HCP_03930,REP_004,2024-04-18,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_000833,HCP_03330,REP_066,2024-02-29,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000834,HCP_01554,REP_044,2024-01-11,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_000835,HCP_01759,REP_061,2024-01-16,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_000836,HCP_00577,REP_053,2024-01-07,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000837,HCP_03516,REP_068,2024-02-12,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_000838,HCP_04716,REP_042,2024-03-06,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_000839,HCP_00971,REP_003,2024-01-16,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_000840,HCP_01229,REP_069,2024-02-13,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000841,HCP_01552,REP_024,2024-01-15,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000842,HCP_01875,REP_010,2024-01-31,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_000843,HCP_03009,REP_066,2024-01-30,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000844,HCP_02403,REP_032,2024-01-08,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_000845,HCP_00795,REP_075,2024-01-31,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000846,HCP_00690,REP_069,2024-01-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000847,HCP_03467,REP_009,2024-03-31,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000848,HCP_02389,REP_049,2024-01-25,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_000849,HCP_00200,REP_017,2024-02-01,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000850,HCP_00306,REP_026,2024-01-18,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_000851,HCP_04192,REP_053,2024-01-12,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_000852,HCP_01495,REP_065,2024-01-11,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000853,HCP_00772,REP_046,2024-01-26,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_000854,HCP_00185,REP_027,2024-01-14,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_000855,HCP_04323,REP_073,2024-02-02,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000856,HCP_03764,REP_005,2024-03-21,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000857,HCP_02113,REP_049,2024-01-24,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000858,HCP_01865,REP_003,2024-02-19,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_000859,HCP_00378,REP_000,2024-02-12,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000860,HCP_04919,REP_042,2024-01-08,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_000861,HCP_03323,REP_030,2024-02-12,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_000862,HCP_02692,REP_074,2024-02-03,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000863,HCP_00181,REP_001,2024-02-18,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_000864,HCP_03227,REP_028,2024-03-05,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_000865,HCP_00802,REP_000,2024-01-21,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000866,HCP_04494,REP_064,2024-02-21,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_000867,HCP_00389,REP_033,2024-02-22,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000868,HCP_00217,REP_053,2024-01-27,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000869,HCP_02220,REP_039,2024-01-26,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_000870,HCP_02963,REP_046,2024-02-01,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000871,HCP_01121,REP_004,2024-02-15,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000872,HCP_01402,REP_002,2024-01-29,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000873,HCP_00254,REP_014,2024-01-17,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_000874,HCP_04956,REP_021,2024-01-24,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_000875,HCP_04714,REP_023,2024-01-23,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_000876,HCP_01066,REP_071,2024-05-31,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000877,HCP_04604,REP_010,2024-01-08,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000878,HCP_00163,REP_029,2024-02-14,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000879,HCP_01695,REP_039,2024-01-26,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_000880,HCP_00612,REP_056,2024-01-25,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_000881,HCP_03566,REP_047,2024-05-08,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000882,HCP_00838,REP_047,2024-01-29,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_000883,HCP_03443,REP_071,2024-02-03,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000884,HCP_04615,REP_031,2024-02-08,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_000885,HCP_00002,REP_078,2024-01-02,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_000886,HCP_02700,REP_021,2024-04-15,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000887,HCP_03822,REP_051,2024-01-03,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000888,HCP_00325,REP_035,2024-01-18,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_000889,HCP_04305,REP_048,2024-03-27,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_000890,HCP_02545,REP_007,2024-02-23,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_000891,HCP_04922,REP_070,2024-02-19,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000892,HCP_02929,REP_012,2024-03-23,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000893,HCP_03162,REP_017,2024-01-11,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000894,HCP_01201,REP_040,2024-06-29,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000895,HCP_02347,REP_020,2024-01-05,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000896,HCP_02165,REP_063,2024-03-12,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_000897,HCP_01662,REP_053,2024-01-03,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_000898,HCP_03211,REP_050,2024-04-15,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_000899,HCP_01705,REP_002,2024-01-12,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_000900,HCP_01654,REP_037,2024-01-12,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_000901,HCP_00596,REP_055,2024-01-14,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_000902,HCP_04660,REP_058,2024-03-27,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_000903,HCP_02783,REP_066,2024-01-08,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000904,HCP_03569,REP_030,2024-02-14,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000905,HCP_01524,REP_048,2024-01-17,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000906,HCP_04526,REP_074,2024-01-14,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_000907,HCP_03565,REP_035,2024-01-25,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000908,HCP_02642,REP_049,2024-01-24,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000909,HCP_04096,REP_048,2024-01-20,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000910,HCP_03502,REP_036,2024-01-04,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_000911,HCP_04240,REP_069,2024-01-07,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_000912,HCP_03595,REP_037,2024-04-04,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000913,HCP_01708,REP_073,2024-01-11,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_000914,HCP_01659,REP_025,2024-03-08,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000915,HCP_00284,REP_043,2024-01-10,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_000916,HCP_04386,REP_062,2024-02-13,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000917,HCP_02330,REP_042,2024-04-04,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_000918,HCP_04461,REP_079,2024-01-01,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000919,HCP_02525,REP_042,2024-01-04,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_000920,HCP_00192,REP_012,2024-01-16,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000921,HCP_04716,REP_010,2024-01-04,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_000922,HCP_00590,REP_035,2024-03-01,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000923,HCP_04496,REP_054,2024-01-23,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000924,HCP_00216,REP_079,2024-01-24,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000925,HCP_04914,REP_021,2024-01-06,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000926,HCP_04970,REP_076,2024-01-17,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000927,HCP_04865,REP_053,2024-02-03,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000928,HCP_03645,REP_078,2024-01-23,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000929,HCP_01587,REP_018,2024-02-11,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_000930,HCP_01677,REP_000,2024-01-12,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000931,HCP_00532,REP_053,2024-01-18,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000932,HCP_03270,REP_077,2024-08-16,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_000933,HCP_01425,REP_029,2024-02-28,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_000934,HCP_03777,REP_057,2024-01-02,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000935,HCP_03550,REP_033,2024-01-06,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000936,HCP_02878,REP_078,2024-01-08,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000937,HCP_00242,REP_021,2024-01-24,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_000938,HCP_03119,REP_027,2024-05-30,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000939,HCP_01121,REP_077,2024-03-30,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_000940,HCP_00951,REP_011,2024-01-18,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_000941,HCP_01163,REP_072,2024-01-05,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000942,HCP_02557,REP_007,2024-02-10,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000943,HCP_03285,REP_007,2024-01-02,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_000944,HCP_04433,REP_044,2024-01-17,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_000945,HCP_04667,REP_075,2024-01-15,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_000946,HCP_00280,REP_063,2024-02-23,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000947,HCP_04805,REP_070,2024-03-14,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_000948,HCP_03134,REP_075,2024-01-14,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_000949,HCP_01832,REP_062,2024-02-05,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000950,HCP_02776,REP_035,2024-03-06,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_000951,HCP_03287,REP_006,2024-01-15,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_000952,HCP_01252,REP_044,2024-01-16,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_000953,HCP_00471,REP_005,2024-01-10,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000954,HCP_00224,REP_039,2024-01-10,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_000955,HCP_00111,REP_014,2024-01-11,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_000956,HCP_00903,REP_043,2024-02-12,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_000957,HCP_01463,REP_043,2024-04-01,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000958,HCP_03633,REP_066,2024-03-06,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_000959,HCP_00709,REP_034,2024-02-16,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_000960,HCP_00565,REP_072,2024-03-29,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_000961,HCP_04937,REP_029,2024-01-05,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_000962,HCP_04547,REP_070,2024-01-06,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_000963,HCP_02285,REP_026,2024-01-05,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_000964,HCP_02366,REP_012,2024-02-18,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000965,HCP_00749,REP_004,2024-01-12,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_000966,HCP_03193,REP_022,2024-01-11,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_000967,HCP_00096,REP_001,2024-01-02,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_000968,HCP_01399,REP_044,2024-02-18,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000969,HCP_02968,REP_046,2024-04-06,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_000970,HCP_00268,REP_008,2024-01-01,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_000971,HCP_03002,REP_062,2024-01-29,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_000972,HCP_04546,REP_069,2024-01-07,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_000973,HCP_02670,REP_063,2024-03-30,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_000974,HCP_04603,REP_054,2024-02-12,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000975,HCP_00746,REP_023,2024-01-20,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_000976,HCP_04523,REP_077,2024-01-02,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000977,HCP_00233,REP_065,2024-03-27,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_000978,HCP_03945,REP_048,2024-03-14,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_000979,HCP_02895,REP_020,2024-02-10,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_000980,HCP_03534,REP_075,2024-06-17,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_000981,HCP_04087,REP_057,2024-01-22,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000982,HCP_01244,REP_038,2024-07-18,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000983,HCP_02422,REP_054,2024-03-14,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_000984,HCP_00027,REP_047,2024-01-14,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000985,HCP_00149,REP_032,2024-01-26,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_000986,HCP_02630,REP_024,2024-02-09,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_000987,HCP_00172,REP_003,2024-02-23,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_000988,HCP_02461,REP_033,2024-01-08,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_000989,HCP_04934,REP_039,2024-03-17,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_000990,HCP_02122,REP_031,2024-02-17,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_000991,HCP_04865,REP_063,2024-03-28,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_000992,HCP_04391,REP_025,2024-02-10,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_000993,HCP_03557,REP_007,2024-01-27,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000994,HCP_01176,REP_055,2024-01-08,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_000995,HCP_00809,REP_047,2024-03-31,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_000996,HCP_01214,REP_034,2024-04-25,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_000997,HCP_01186,REP_009,2024-02-01,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_000998,HCP_00065,REP_039,2024-04-09,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_000999,HCP_04664,REP_012,2024-01-14,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_001000,HCP_04448,REP_065,2024-02-22,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_001001,HCP_01482,REP_004,2024-02-07,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001002,HCP_01678,REP_042,2024-03-19,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_001003,HCP_04954,REP_042,2024-01-17,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_001004,HCP_00362,REP_046,2024-02-13,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_001005,HCP_02635,REP_013,2024-06-30,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001006,HCP_04721,REP_042,2024-03-25,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_001007,HCP_04854,REP_023,2024-01-12,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001008,HCP_04732,REP_041,2024-02-06,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001009,HCP_02170,REP_006,2024-01-17,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_001010,HCP_03764,REP_009,2024-01-04,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001011,HCP_00126,REP_003,2024-01-03,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001012,HCP_01954,REP_064,2024-03-11,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_001013,HCP_01832,REP_064,2024-05-01,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001014,HCP_01604,REP_016,2024-02-17,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_001015,HCP_04806,REP_064,2024-01-13,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001016,HCP_01780,REP_003,2024-02-01,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_001017,HCP_01909,REP_038,2024-03-19,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001018,HCP_00465,REP_021,2024-03-27,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001019,HCP_01264,REP_008,2024-04-19,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_001020,HCP_04005,REP_046,2024-02-11,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001021,HCP_02846,REP_002,2024-01-24,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_001022,HCP_03194,REP_027,2024-01-26,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001023,HCP_02846,REP_031,2024-01-18,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_001024,HCP_00670,REP_005,2024-01-10,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001025,HCP_01747,REP_018,2024-02-10,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001026,HCP_02687,REP_064,2024-01-30,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_001027,HCP_00249,REP_018,2024-01-17,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_001028,HCP_01271,REP_033,2024-01-06,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001029,HCP_00523,REP_042,2024-03-05,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_001030,HCP_02187,REP_022,2024-01-01,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_001031,HCP_02300,REP_005,2024-02-19,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001032,HCP_03219,REP_019,2024-03-28,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001033,HCP_00073,REP_044,2024-03-06,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001034,HCP_00783,REP_054,2024-01-28,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_001035,HCP_02254,REP_030,2024-03-13,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_001036,HCP_04389,REP_079,2024-01-06,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001037,HCP_00126,REP_034,2024-02-04,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_001038,HCP_02088,REP_064,2024-03-17,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001039,HCP_03341,REP_030,2024-01-27,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001040,HCP_00854,REP_000,2024-04-19,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_001041,HCP_00613,REP_040,2024-01-05,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001042,HCP_01756,REP_002,2024-01-01,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001043,HCP_00931,REP_036,2024-02-01,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001044,HCP_03775,REP_065,2024-01-26,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001045,HCP_00265,REP_075,2024-02-26,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001046,HCP_01038,REP_009,2024-01-22,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_001047,HCP_02406,REP_032,2024-01-02,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001048,HCP_04720,REP_020,2024-02-29,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_001049,HCP_01293,REP_074,2024-05-01,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001050,HCP_03650,REP_070,2024-02-14,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_001051,HCP_03872,REP_019,2024-03-04,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_001052,HCP_04671,REP_004,2024-01-06,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_001053,HCP_03607,REP_006,2024-02-04,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_001054,HCP_04752,REP_019,2024-01-01,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001055,HCP_04929,REP_034,2024-02-06,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_001056,HCP_01658,REP_036,2024-01-29,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001057,HCP_03784,REP_074,2024-01-30,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001058,HCP_04523,REP_014,2024-02-02,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001059,HCP_04312,REP_001,2024-07-22,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_001060,HCP_03985,REP_039,2024-02-02,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001061,HCP_00643,REP_007,2024-01-21,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001062,HCP_02512,REP_054,2024-01-28,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001063,HCP_00139,REP_019,2024-01-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001064,HCP_04074,REP_021,2024-04-17,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_001065,HCP_04865,REP_069,2024-01-16,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001066,HCP_02088,REP_028,2024-01-11,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001067,HCP_02258,REP_032,2024-01-17,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001068,HCP_02619,REP_067,2024-01-02,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001069,HCP_03439,REP_015,2024-01-23,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001070,HCP_02226,REP_078,2024-05-10,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_001071,HCP_03874,REP_005,2024-04-02,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_001072,HCP_03659,REP_016,2024-01-02,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_001073,HCP_00166,REP_028,2024-01-14,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001074,HCP_02966,REP_029,2024-02-05,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_001075,HCP_00307,REP_074,2024-02-28,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001076,HCP_02243,REP_069,2024-01-07,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_001077,HCP_04870,REP_020,2024-01-17,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001078,HCP_04499,REP_027,2024-04-22,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_001079,HCP_01609,REP_001,2024-02-20,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001080,HCP_02689,REP_060,2024-01-15,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_001081,HCP_00395,REP_036,2024-03-07,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_001082,HCP_00274,REP_010,2024-01-06,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_001083,HCP_02628,REP_013,2024-01-19,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_001084,HCP_00990,REP_047,2024-01-23,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001085,HCP_01589,REP_058,2024-02-28,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001086,HCP_02458,REP_019,2024-02-07,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001087,HCP_03331,REP_009,2024-02-02,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_001088,HCP_04805,REP_079,2024-01-25,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_001089,HCP_00464,REP_073,2024-01-01,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001090,HCP_01777,REP_051,2024-01-30,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001091,HCP_03318,REP_043,2024-01-11,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_001092,HCP_00471,REP_011,2024-01-20,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_001093,HCP_04221,REP_033,2024-01-12,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001094,HCP_00557,REP_004,2024-02-07,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_001095,HCP_03908,REP_069,2024-01-31,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001096,HCP_03245,REP_038,2024-03-24,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001097,HCP_01639,REP_077,2024-02-03,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001098,HCP_03498,REP_000,2024-01-05,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_001099,HCP_02474,REP_060,2024-02-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001100,HCP_03554,REP_065,2024-01-05,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001101,HCP_03163,REP_028,2024-01-22,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_001102,HCP_04857,REP_074,2024-02-05,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_001103,HCP_02291,REP_049,2024-02-08,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001104,HCP_03131,REP_034,2024-02-03,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001105,HCP_03780,REP_041,2024-01-29,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_001106,HCP_03983,REP_002,2024-02-21,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_001107,HCP_01455,REP_049,2024-02-06,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_001108,HCP_02395,REP_048,2024-01-29,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001109,HCP_03579,REP_012,2024-02-10,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_001110,HCP_03833,REP_019,2024-02-12,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001111,HCP_01225,REP_074,2024-01-05,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001112,HCP_01427,REP_073,2024-02-22,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001113,HCP_02461,REP_034,2024-02-16,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_001114,HCP_03056,REP_011,2024-02-28,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_001115,HCP_02717,REP_057,2024-04-07,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_001116,HCP_01299,REP_002,2024-01-23,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001117,HCP_02976,REP_050,2024-02-05,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_001118,HCP_02265,REP_058,2024-01-18,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001119,HCP_00229,REP_009,2024-02-09,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_001120,HCP_01816,REP_059,2024-04-02,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001121,HCP_03561,REP_040,2024-02-01,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_001122,HCP_02360,REP_014,2024-02-14,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_001123,HCP_03600,REP_060,2024-02-26,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_001124,HCP_00751,REP_069,2024-04-04,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_001125,HCP_03151,REP_055,2024-01-13,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_001126,HCP_00492,REP_078,2024-02-21,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_001127,HCP_04905,REP_060,2024-01-06,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001128,HCP_02696,REP_035,2024-05-09,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001129,HCP_02100,REP_072,2024-03-03,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_001130,HCP_02647,REP_053,2024-04-12,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_001131,HCP_00520,REP_031,2024-01-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001132,HCP_02339,REP_006,2024-01-19,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001133,HCP_04567,REP_037,2024-02-02,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001134,HCP_02250,REP_053,2024-01-23,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_001135,HCP_03512,REP_057,2024-01-13,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001136,HCP_04395,REP_058,2024-01-05,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001137,HCP_00573,REP_062,2024-01-12,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_001138,HCP_02477,REP_005,2024-01-15,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_001139,HCP_00022,REP_066,2024-01-15,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_001140,HCP_00174,REP_057,2024-04-08,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001141,HCP_02847,REP_078,2024-02-11,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_001142,HCP_01260,REP_028,2024-01-18,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001143,HCP_00064,REP_060,2024-04-03,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_001144,HCP_03251,REP_049,2024-01-16,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001145,HCP_04546,REP_023,2024-01-02,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001146,HCP_00414,REP_049,2024-01-06,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001147,HCP_01742,REP_063,2024-02-11,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001148,HCP_01161,REP_079,2024-03-08,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001149,HCP_02841,REP_023,2024-01-08,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001150,HCP_03381,REP_057,2024-05-18,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_001151,HCP_00773,REP_019,2024-01-14,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001152,HCP_02658,REP_019,2024-01-02,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001153,HCP_00581,REP_045,2024-01-22,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001154,HCP_00967,REP_071,2024-01-05,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_001155,HCP_00496,REP_016,2024-01-14,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001156,HCP_02579,REP_045,2024-03-05,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001157,HCP_03292,REP_054,2024-02-04,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_001158,HCP_03617,REP_079,2024-01-21,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001159,HCP_03366,REP_019,2024-01-11,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001160,HCP_00041,REP_012,2024-01-08,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_001161,HCP_00499,REP_026,2024-02-01,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_001162,HCP_02242,REP_049,2024-01-22,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_001163,HCP_04483,REP_049,2024-02-23,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_001164,HCP_02045,REP_051,2024-01-31,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_001165,HCP_01703,REP_071,2024-01-04,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_001166,HCP_03292,REP_075,2024-02-22,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001167,HCP_00043,REP_069,2024-01-24,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_001168,HCP_02465,REP_063,2024-02-06,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_001169,HCP_01427,REP_047,2024-01-31,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001170,HCP_03482,REP_069,2024-01-01,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_001171,HCP_01802,REP_037,2024-01-04,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001172,HCP_00255,REP_074,2024-01-09,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_001173,HCP_01376,REP_066,2024-01-14,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_001174,HCP_02573,REP_070,2024-01-14,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_001175,HCP_04913,REP_013,2024-03-05,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001176,HCP_00191,REP_052,2024-01-14,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_001177,HCP_01394,REP_005,2024-01-11,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001178,HCP_01382,REP_033,2024-04-16,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001179,HCP_01407,REP_026,2024-01-02,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001180,HCP_02507,REP_068,2024-01-10,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001181,HCP_00144,REP_063,2024-01-05,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001182,HCP_01703,REP_009,2024-02-04,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_001183,HCP_01891,REP_079,2024-02-25,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_001184,HCP_04591,REP_049,2024-01-29,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001185,HCP_03911,REP_060,2024-02-19,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001186,HCP_02849,REP_022,2024-03-16,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001187,HCP_02051,REP_007,2024-01-02,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001188,HCP_03763,REP_056,2024-05-01,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_001189,HCP_04692,REP_012,2024-01-29,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001190,HCP_01961,REP_042,2024-01-04,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001191,HCP_02076,REP_072,2024-02-11,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_001192,HCP_01212,REP_055,2024-03-03,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001193,HCP_04327,REP_029,2024-02-02,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_001194,HCP_02997,REP_005,2024-01-17,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001195,HCP_00718,REP_026,2024-03-17,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001196,HCP_03197,REP_064,2024-02-11,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_001197,HCP_03460,REP_018,2024-01-04,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_001198,HCP_01737,REP_006,2024-02-22,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001199,HCP_00312,REP_064,2024-01-24,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001200,HCP_00984,REP_074,2024-01-14,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_001201,HCP_02273,REP_050,2024-01-22,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001202,HCP_01250,REP_063,2024-02-03,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001203,HCP_02874,REP_023,2024-03-03,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_001204,HCP_04100,REP_046,2024-02-10,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001205,HCP_02639,REP_061,2024-02-18,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001206,HCP_00237,REP_002,2024-01-05,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_001207,HCP_04685,REP_077,2024-01-05,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001208,HCP_01521,REP_066,2024-01-14,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001209,HCP_01070,REP_000,2024-01-01,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001210,HCP_04830,REP_030,2024-02-10,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_001211,HCP_02047,REP_062,2024-03-17,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_001212,HCP_04685,REP_056,2024-01-04,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001213,HCP_02036,REP_018,2024-01-13,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_001214,HCP_02012,REP_057,2024-06-15,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_001215,HCP_01965,REP_073,2024-03-24,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001216,HCP_01686,REP_029,2024-02-04,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001217,HCP_01745,REP_008,2024-01-03,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001218,HCP_00143,REP_057,2024-01-18,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_001219,HCP_01992,REP_028,2024-05-12,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_001220,HCP_02854,REP_022,2024-01-28,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_001221,HCP_03239,REP_063,2024-02-26,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_001222,HCP_03311,REP_071,2024-04-29,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001223,HCP_03839,REP_029,2024-01-05,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001224,HCP_00873,REP_055,2024-02-08,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_001225,HCP_04822,REP_056,2024-04-02,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001226,HCP_04990,REP_036,2024-01-23,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001227,HCP_01348,REP_042,2024-01-24,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_001228,HCP_00098,REP_028,2024-02-24,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001229,HCP_01808,REP_064,2024-01-13,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001230,HCP_03346,REP_064,2024-02-04,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001231,HCP_01220,REP_045,2024-01-18,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001232,HCP_03687,REP_002,2024-01-26,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001233,HCP_01482,REP_012,2024-04-08,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001234,HCP_01791,REP_038,2024-01-04,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_001235,HCP_01916,REP_021,2024-01-09,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_001236,HCP_03835,REP_056,2024-03-27,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001237,HCP_02246,REP_051,2024-01-31,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_001238,HCP_03721,REP_007,2024-01-02,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001239,HCP_03855,REP_019,2024-02-03,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_001240,HCP_04900,REP_043,2024-04-16,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_001241,HCP_01744,REP_006,2024-01-20,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_001242,HCP_03729,REP_049,2024-01-09,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001243,HCP_01719,REP_006,2024-01-27,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001244,HCP_03084,REP_003,2024-01-24,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001245,HCP_04676,REP_005,2024-02-03,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_001246,HCP_04763,REP_070,2024-01-02,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_001247,HCP_03914,REP_069,2024-01-24,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001248,HCP_02215,REP_010,2024-01-26,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_001249,HCP_03107,REP_051,2024-04-15,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001250,HCP_02195,REP_027,2024-01-01,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_001251,HCP_00977,REP_024,2024-02-15,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_001252,HCP_02257,REP_013,2024-02-27,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_001253,HCP_04131,REP_022,2024-02-29,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_001254,HCP_04166,REP_050,2024-03-23,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001255,HCP_01649,REP_002,2024-02-01,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001256,HCP_00208,REP_040,2024-01-26,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_001257,HCP_04344,REP_044,2024-01-30,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001258,HCP_01543,REP_043,2024-02-29,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001259,HCP_02005,REP_019,2024-02-11,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001260,HCP_02401,REP_047,2024-01-01,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_001261,HCP_04325,REP_006,2024-02-26,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001262,HCP_04371,REP_021,2024-01-10,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001263,HCP_00613,REP_039,2024-02-02,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001264,HCP_04932,REP_014,2024-02-22,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_001265,HCP_03531,REP_033,2024-02-17,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_001266,HCP_04226,REP_024,2024-02-25,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001267,HCP_02722,REP_016,2024-01-15,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001268,HCP_00644,REP_003,2024-02-06,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001269,HCP_01869,REP_015,2024-01-31,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_001270,HCP_01125,REP_066,2024-01-20,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001271,HCP_03918,REP_056,2024-04-12,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001272,HCP_03755,REP_014,2024-02-25,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_001273,HCP_03272,REP_047,2024-04-09,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001274,HCP_00419,REP_035,2024-03-07,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001275,HCP_01519,REP_039,2024-01-16,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_001276,HCP_01236,REP_031,2024-01-25,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001277,HCP_04494,REP_011,2024-01-08,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001278,HCP_00754,REP_021,2024-01-04,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001279,HCP_02410,REP_077,2024-03-04,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_001280,HCP_01660,REP_062,2024-01-09,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_001281,HCP_01895,REP_015,2024-01-05,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_001282,HCP_04642,REP_068,2024-01-22,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_001283,HCP_03539,REP_043,2024-06-03,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001284,HCP_00768,REP_063,2024-03-18,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001285,HCP_00044,REP_025,2024-03-01,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001286,HCP_02725,REP_001,2024-01-05,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001287,HCP_03616,REP_024,2024-01-21,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001288,HCP_00406,REP_075,2024-02-24,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_001289,HCP_03092,REP_029,2024-01-14,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_001290,HCP_04408,REP_017,2024-02-13,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001291,HCP_00614,REP_074,2024-01-18,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001292,HCP_03018,REP_027,2024-02-16,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001293,HCP_03327,REP_072,2024-01-06,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001294,HCP_04917,REP_052,2024-02-10,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_001295,HCP_00350,REP_069,2024-03-23,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001296,HCP_00630,REP_064,2024-02-15,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_001297,HCP_03298,REP_014,2024-01-14,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_001298,HCP_03949,REP_029,2024-03-08,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_001299,HCP_04940,REP_073,2024-03-09,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_001300,HCP_03943,REP_009,2024-01-03,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001301,HCP_03007,REP_070,2024-01-05,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001302,HCP_00871,REP_059,2024-02-28,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001303,HCP_02873,REP_019,2024-01-30,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001304,HCP_03379,REP_021,2024-01-26,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_001305,HCP_00052,REP_079,2024-01-08,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_001306,HCP_00510,REP_024,2024-02-16,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001307,HCP_04345,REP_002,2024-01-22,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_001308,HCP_01448,REP_058,2024-02-06,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001309,HCP_04034,REP_071,2024-02-09,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_001310,HCP_00941,REP_036,2024-01-13,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_001311,HCP_02961,REP_065,2024-01-19,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_001312,HCP_04326,REP_035,2024-01-26,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001313,HCP_03285,REP_068,2024-03-17,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_001314,HCP_04910,REP_055,2024-01-03,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_001315,HCP_00109,REP_075,2024-01-11,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_001316,HCP_04908,REP_048,2024-02-08,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_001317,HCP_01497,REP_012,2024-06-15,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001318,HCP_01691,REP_053,2024-02-06,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_001319,HCP_02379,REP_026,2024-01-22,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001320,HCP_04163,REP_072,2024-01-05,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001321,HCP_01030,REP_038,2024-01-25,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_001322,HCP_00764,REP_016,2024-01-20,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_001323,HCP_04342,REP_004,2024-01-02,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001324,HCP_01986,REP_039,2024-01-03,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_001325,HCP_04933,REP_016,2024-02-01,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_001326,HCP_00320,REP_040,2024-01-18,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_001327,HCP_02256,REP_069,2024-01-01,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001328,HCP_00412,REP_033,2024-02-24,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_001329,HCP_02770,REP_016,2024-02-01,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001330,HCP_01375,REP_028,2024-03-24,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_001331,HCP_02392,REP_037,2024-03-03,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_001332,HCP_04741,REP_009,2024-01-09,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_001333,HCP_02738,REP_041,2024-01-14,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_001334,HCP_04883,REP_031,2024-01-17,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_001335,HCP_03166,REP_056,2024-01-17,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001336,HCP_02775,REP_034,2024-01-07,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_001337,HCP_03050,REP_058,2024-02-05,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001338,HCP_00212,REP_036,2024-05-05,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_001339,HCP_04786,REP_068,2024-02-06,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_001340,HCP_03275,REP_011,2024-04-05,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001341,HCP_02965,REP_065,2024-01-19,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001342,HCP_04449,REP_035,2024-01-27,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001343,HCP_03736,REP_033,2024-02-07,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_001344,HCP_03001,REP_067,2024-01-23,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_001345,HCP_04380,REP_020,2024-01-04,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001346,HCP_01329,REP_020,2024-02-20,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_001347,HCP_04265,REP_047,2024-01-01,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_001348,HCP_02607,REP_074,2024-01-23,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001349,HCP_04266,REP_050,2024-01-10,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_001350,HCP_03047,REP_020,2024-04-14,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001351,HCP_02865,REP_072,2024-01-17,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001352,HCP_04826,REP_048,2024-01-26,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_001353,HCP_00924,REP_032,2024-06-06,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_001354,HCP_02717,REP_032,2024-01-24,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001355,HCP_01531,REP_042,2024-01-07,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_001356,HCP_02475,REP_052,2024-01-04,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_001357,HCP_02228,REP_054,2024-03-18,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_001358,HCP_04490,REP_066,2024-03-13,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001359,HCP_03638,REP_078,2024-02-20,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001360,HCP_04476,REP_026,2024-02-21,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_001361,HCP_00941,REP_011,2024-01-03,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_001362,HCP_02794,REP_014,2024-01-16,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001363,HCP_03599,REP_044,2024-01-15,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_001364,HCP_02831,REP_018,2024-04-19,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001365,HCP_03627,REP_065,2024-01-14,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_001366,HCP_01507,REP_008,2024-09-28,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_001367,HCP_02699,REP_029,2024-01-17,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_001368,HCP_02418,REP_030,2024-01-29,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_001369,HCP_02212,REP_000,2024-03-31,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001370,HCP_04156,REP_040,2024-06-19,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_001371,HCP_00023,REP_015,2024-03-01,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_001372,HCP_03009,REP_076,2024-01-11,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_001373,HCP_02470,REP_060,2024-03-25,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001374,HCP_03763,REP_056,2024-01-09,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001375,HCP_03791,REP_030,2024-02-12,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_001376,HCP_01192,REP_027,2024-01-20,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001377,HCP_01302,REP_026,2024-01-19,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001378,HCP_02912,REP_021,2024-02-02,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001379,HCP_03125,REP_014,2024-02-16,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_001380,HCP_02694,REP_020,2024-02-19,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001381,HCP_03006,REP_006,2024-01-13,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_001382,HCP_00198,REP_011,2024-01-06,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_001383,HCP_01410,REP_026,2024-01-16,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001384,HCP_03835,REP_070,2024-03-23,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_001385,HCP_03882,REP_069,2024-01-24,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_001386,HCP_04441,REP_063,2024-01-31,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001387,HCP_03582,REP_070,2024-02-17,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001388,HCP_02846,REP_057,2024-03-02,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_001389,HCP_01850,REP_022,2024-02-28,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_001390,HCP_01719,REP_017,2024-02-13,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_001391,HCP_02528,REP_058,2024-01-28,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_001392,HCP_04330,REP_010,2024-01-08,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001393,HCP_00445,REP_040,2024-02-29,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001394,HCP_01105,REP_008,2024-04-09,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001395,HCP_01655,REP_065,2024-04-15,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001396,HCP_01713,REP_079,2024-03-13,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001397,HCP_00335,REP_013,2024-01-07,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001398,HCP_03726,REP_034,2024-01-10,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001399,HCP_01826,REP_067,2024-01-11,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001400,HCP_00794,REP_046,2024-02-18,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001401,HCP_02135,REP_068,2024-02-03,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_001402,HCP_02194,REP_053,2024-02-28,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_001403,HCP_02264,REP_023,2024-01-18,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001404,HCP_01301,REP_001,2024-01-02,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001405,HCP_01402,REP_027,2024-01-12,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001406,HCP_04294,REP_041,2024-01-04,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_001407,HCP_03363,REP_010,2024-02-13,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001408,HCP_03967,REP_035,2024-02-22,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_001409,HCP_04255,REP_068,2024-04-16,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_001410,HCP_00580,REP_022,2024-02-25,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_001411,HCP_01653,REP_025,2024-01-01,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001412,HCP_03723,REP_069,2024-02-21,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_001413,HCP_02882,REP_000,2024-02-09,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_001414,HCP_03266,REP_076,2024-04-01,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_001415,HCP_03662,REP_066,2024-01-31,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001416,HCP_04714,REP_015,2024-01-08,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001417,HCP_04873,REP_058,2024-02-25,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_001418,HCP_04367,REP_077,2024-01-04,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001419,HCP_00381,REP_063,2024-02-01,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_001420,HCP_03328,REP_073,2024-01-11,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_001421,HCP_01880,REP_011,2024-01-09,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001422,HCP_02980,REP_043,2024-01-17,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001423,HCP_00348,REP_016,2024-03-02,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_001424,HCP_03812,REP_053,2024-07-30,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001425,HCP_00986,REP_039,2024-01-31,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_001426,HCP_01994,REP_061,2024-01-01,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001427,HCP_02691,REP_070,2024-01-30,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_001428,HCP_00417,REP_054,2024-01-05,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001429,HCP_02482,REP_041,2024-01-10,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_001430,HCP_03285,REP_037,2024-03-14,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001431,HCP_04140,REP_049,2024-02-25,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_001432,HCP_04771,REP_031,2024-01-28,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_001433,HCP_03379,REP_029,2024-01-05,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_001434,HCP_04387,REP_057,2024-03-02,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001435,HCP_01410,REP_051,2024-01-08,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001436,HCP_03394,REP_057,2024-01-25,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001437,HCP_00990,REP_074,2024-01-04,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001438,HCP_03028,REP_003,2024-02-04,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_001439,HCP_03080,REP_011,2024-03-11,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_001440,HCP_04338,REP_062,2024-01-08,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001441,HCP_04425,REP_054,2024-01-03,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_001442,HCP_04276,REP_058,2024-01-04,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001443,HCP_00371,REP_070,2024-01-05,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001444,HCP_04041,REP_042,2024-02-05,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_001445,HCP_00307,REP_041,2024-01-18,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_001446,HCP_00131,REP_052,2024-07-08,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_001447,HCP_02423,REP_066,2024-01-11,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_001448,HCP_02546,REP_068,2024-01-06,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_001449,HCP_01704,REP_050,2024-02-28,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001450,HCP_02858,REP_073,2024-01-01,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001451,HCP_00915,REP_078,2024-02-08,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001452,HCP_03589,REP_020,2024-01-27,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_001453,HCP_04727,REP_057,2024-01-10,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001454,HCP_00391,REP_074,2024-02-16,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001455,HCP_01841,REP_041,2024-02-03,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_001456,HCP_03112,REP_012,2024-01-09,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_001457,HCP_00816,REP_054,2024-01-06,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001458,HCP_04559,REP_018,2024-01-09,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001459,HCP_00045,REP_056,2024-03-05,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001460,HCP_00668,REP_032,2024-02-10,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_001461,HCP_03838,REP_072,2024-04-14,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001462,HCP_04288,REP_017,2024-01-20,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001463,HCP_04813,REP_036,2024-01-11,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001464,HCP_00728,REP_075,2024-02-14,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_001465,HCP_01887,REP_005,2024-01-03,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001466,HCP_01929,REP_018,2024-01-06,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001467,HCP_00692,REP_046,2024-01-16,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001468,HCP_03877,REP_054,2024-01-04,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001469,HCP_00714,REP_008,2024-04-16,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_001470,HCP_02507,REP_060,2024-03-16,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001471,HCP_01969,REP_059,2024-01-16,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001472,HCP_02322,REP_061,2024-01-19,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_001473,HCP_02567,REP_023,2024-01-04,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_001474,HCP_01223,REP_024,2024-01-04,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001475,HCP_03332,REP_038,2024-01-08,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_001476,HCP_01779,REP_000,2024-03-02,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001477,HCP_04535,REP_063,2024-01-20,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001478,HCP_04213,REP_042,2024-02-28,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001479,HCP_02642,REP_059,2024-01-14,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001480,HCP_00066,REP_064,2024-01-24,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_001481,HCP_02344,REP_078,2024-01-15,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_001482,HCP_03771,REP_014,2024-01-09,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_001483,HCP_04803,REP_037,2024-01-22,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001484,HCP_01416,REP_008,2024-01-23,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_001485,HCP_04448,REP_070,2024-01-12,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001486,HCP_02894,REP_018,2024-01-02,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001487,HCP_02865,REP_060,2024-01-24,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001488,HCP_00125,REP_016,2024-01-23,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001489,HCP_02753,REP_024,2024-01-11,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001490,HCP_02217,REP_056,2024-01-02,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001491,HCP_04906,REP_047,2024-01-11,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001492,HCP_03164,REP_021,2024-02-12,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_001493,HCP_00694,REP_044,2024-04-13,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_001494,HCP_02728,REP_036,2024-01-24,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_001495,HCP_03079,REP_023,2024-01-10,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_001496,HCP_03922,REP_005,2024-01-17,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001497,HCP_01777,REP_051,2024-01-23,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_001498,HCP_01038,REP_008,2024-02-19,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001499,HCP_01673,REP_020,2024-01-02,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_001500,HCP_02797,REP_016,2024-01-15,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_001501,HCP_02587,REP_039,2024-05-22,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001502,HCP_00510,REP_044,2024-01-14,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_001503,HCP_03673,REP_077,2024-01-28,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001504,HCP_01885,REP_022,2024-01-26,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_001505,HCP_00631,REP_045,2024-04-22,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001506,HCP_04517,REP_073,2024-01-13,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001507,HCP_00434,REP_037,2024-01-25,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_001508,HCP_04859,REP_035,2024-01-07,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_001509,HCP_00843,REP_041,2024-01-03,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_001510,HCP_00741,REP_056,2024-01-05,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001511,HCP_04420,REP_050,2024-01-21,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_001512,HCP_04457,REP_057,2024-01-03,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_001513,HCP_04809,REP_026,2024-03-17,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_001514,HCP_02873,REP_009,2024-02-07,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001515,HCP_04140,REP_025,2024-01-19,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001516,HCP_02523,REP_023,2024-01-01,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_001517,HCP_03171,REP_060,2024-01-03,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001518,HCP_01195,REP_007,2024-01-23,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001519,HCP_02328,REP_075,2024-01-18,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_001520,HCP_02914,REP_035,2024-02-19,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001521,HCP_04086,REP_061,2024-02-24,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001522,HCP_03590,REP_073,2024-02-17,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_001523,HCP_02169,REP_070,2024-01-15,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001524,HCP_01766,REP_028,2024-03-10,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001525,HCP_03875,REP_016,2024-02-05,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_001526,HCP_00058,REP_068,2024-01-09,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_001527,HCP_03411,REP_052,2024-01-18,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_001528,HCP_02414,REP_041,2024-02-28,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001529,HCP_03491,REP_072,2024-02-01,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001530,HCP_01562,REP_021,2024-02-13,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_001531,HCP_00821,REP_032,2024-05-10,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001532,HCP_04428,REP_020,2024-04-30,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_001533,HCP_01882,REP_078,2024-01-01,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_001534,HCP_01375,REP_030,2024-02-18,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_001535,HCP_00636,REP_015,2024-01-14,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_001536,HCP_03846,REP_000,2024-01-17,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001537,HCP_00453,REP_053,2024-03-04,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001538,HCP_00603,REP_019,2024-06-20,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_001539,HCP_00399,REP_065,2024-01-01,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_001540,HCP_01045,REP_031,2024-02-01,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001541,HCP_02704,REP_074,2024-01-10,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_001542,HCP_04116,REP_017,2024-01-25,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_001543,HCP_00476,REP_041,2024-01-05,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_001544,HCP_03213,REP_070,2024-01-06,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_001545,HCP_02352,REP_030,2024-02-15,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001546,HCP_00864,REP_000,2024-01-03,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_001547,HCP_00656,REP_034,2024-01-17,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001548,HCP_02227,REP_009,2024-01-23,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001549,HCP_02694,REP_015,2024-02-01,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001550,HCP_04554,REP_003,2024-01-05,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_001551,HCP_02579,REP_066,2024-01-16,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_001552,HCP_03920,REP_029,2024-02-03,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001553,HCP_04746,REP_025,2024-04-14,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_001554,HCP_01022,REP_026,2024-02-04,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001555,HCP_03363,REP_060,2024-01-03,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001556,HCP_00878,REP_025,2024-04-12,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001557,HCP_02292,REP_053,2024-01-29,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001558,HCP_03729,REP_022,2024-02-09,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_001559,HCP_00811,REP_041,2024-03-06,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_001560,HCP_00579,REP_069,2024-01-27,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001561,HCP_03439,REP_015,2024-04-28,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_001562,HCP_02697,REP_041,2024-01-24,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001563,HCP_04290,REP_062,2024-01-06,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_001564,HCP_01159,REP_036,2024-01-13,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_001565,HCP_00569,REP_006,2024-03-04,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_001566,HCP_00678,REP_024,2024-01-12,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_001567,HCP_00987,REP_072,2024-02-02,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001568,HCP_00890,REP_073,2024-01-18,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001569,HCP_00897,REP_039,2024-02-08,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001570,HCP_03737,REP_008,2024-02-19,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001571,HCP_01543,REP_015,2024-01-05,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_001572,HCP_04712,REP_076,2024-02-14,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_001573,HCP_03042,REP_071,2024-01-27,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001574,HCP_01184,REP_009,2024-05-07,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001575,HCP_01987,REP_060,2024-01-18,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001576,HCP_04745,REP_023,2024-01-23,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001577,HCP_01613,REP_029,2024-01-19,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001578,HCP_01358,REP_010,2024-01-01,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_001579,HCP_03432,REP_024,2024-01-23,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_001580,HCP_04947,REP_004,2024-02-04,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001581,HCP_03015,REP_079,2024-01-01,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001582,HCP_00192,REP_079,2024-03-30,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_001583,HCP_04574,REP_013,2024-03-03,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_001584,HCP_03040,REP_003,2024-04-15,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_001585,HCP_04392,REP_047,2024-01-28,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_001586,HCP_03412,REP_079,2024-02-17,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_001587,HCP_03604,REP_061,2024-01-13,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001588,HCP_01704,REP_013,2024-01-08,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_001589,HCP_01202,REP_053,2024-01-27,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001590,HCP_00834,REP_033,2024-03-18,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001591,HCP_00925,REP_021,2024-03-05,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_001592,HCP_02490,REP_029,2024-02-15,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_001593,HCP_04674,REP_018,2024-01-21,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_001594,HCP_01249,REP_053,2024-01-30,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_001595,HCP_03836,REP_066,2024-01-23,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001596,HCP_01581,REP_055,2024-01-28,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001597,HCP_02065,REP_028,2024-04-10,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_001598,HCP_02174,REP_070,2024-04-07,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_001599,HCP_02051,REP_037,2024-03-02,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_001600,HCP_00305,REP_071,2024-04-09,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_001601,HCP_02392,REP_026,2024-01-15,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001602,HCP_02580,REP_029,2024-01-15,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_001603,HCP_03240,REP_034,2024-01-17,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_001604,HCP_03587,REP_027,2024-01-25,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001605,HCP_04712,REP_062,2024-01-01,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001606,HCP_00208,REP_035,2024-01-02,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_001607,HCP_01588,REP_007,2024-01-18,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001608,HCP_04813,REP_058,2024-04-17,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001609,HCP_04393,REP_076,2024-02-07,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001610,HCP_01279,REP_017,2024-01-25,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001611,HCP_04130,REP_002,2024-01-30,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_001612,HCP_03492,REP_007,2024-01-01,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_001613,HCP_01246,REP_030,2024-01-22,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_001614,HCP_00848,REP_065,2024-01-21,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_001615,HCP_01144,REP_064,2024-02-07,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_001616,HCP_03336,REP_040,2024-01-08,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001617,HCP_04401,REP_028,2024-02-02,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_001618,HCP_00092,REP_004,2024-01-11,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001619,HCP_02186,REP_076,2024-04-07,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_001620,HCP_01674,REP_071,2024-01-06,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_001621,HCP_04976,REP_022,2024-01-10,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_001622,HCP_01836,REP_072,2024-03-28,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_001623,HCP_03927,REP_063,2024-01-17,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_001624,HCP_00076,REP_041,2024-01-05,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001625,HCP_00752,REP_064,2024-01-19,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001626,HCP_00179,REP_022,2024-04-26,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_001627,HCP_00003,REP_040,2024-01-12,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001628,HCP_04427,REP_066,2024-05-09,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_001629,HCP_00195,REP_078,2024-02-09,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001630,HCP_01639,REP_013,2024-02-08,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_001631,HCP_00502,REP_037,2024-02-09,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001632,HCP_01425,REP_039,2024-02-22,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001633,HCP_01355,REP_058,2024-05-06,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001634,HCP_02336,REP_008,2024-01-01,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_001635,HCP_04758,REP_006,2024-01-24,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001636,HCP_01934,REP_061,2024-01-23,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001637,HCP_00016,REP_070,2024-02-03,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001638,HCP_02728,REP_016,2024-02-23,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001639,HCP_00548,REP_012,2024-03-09,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001640,HCP_02043,REP_053,2024-01-18,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001641,HCP_00527,REP_017,2024-06-03,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_001642,HCP_04042,REP_079,2024-01-02,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_001643,HCP_01989,REP_009,2024-01-07,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001644,HCP_00174,REP_067,2024-03-19,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_001645,HCP_00414,REP_070,2024-01-23,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_001646,HCP_00698,REP_028,2024-02-08,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_001647,HCP_00709,REP_052,2024-02-15,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001648,HCP_04360,REP_075,2024-02-09,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_001649,HCP_04048,REP_008,2024-01-01,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001650,HCP_04055,REP_027,2024-01-02,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_001651,HCP_02042,REP_034,2024-02-24,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001652,HCP_03315,REP_023,2024-01-18,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_001653,HCP_00248,REP_010,2024-01-11,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001654,HCP_02595,REP_031,2024-02-02,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_001655,HCP_01678,REP_023,2024-02-23,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_001656,HCP_03509,REP_075,2024-01-21,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001657,HCP_03825,REP_048,2024-01-03,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_001658,HCP_04578,REP_071,2024-02-24,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001659,HCP_00762,REP_064,2024-02-24,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_001660,HCP_04434,REP_066,2024-02-13,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_001661,HCP_03292,REP_049,2024-01-15,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_001662,HCP_03187,REP_030,2024-01-09,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_001663,HCP_02283,REP_068,2024-01-02,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001664,HCP_00341,REP_029,2024-01-02,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001665,HCP_01825,REP_046,2024-01-29,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_001666,HCP_01985,REP_009,2024-02-12,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001667,HCP_01555,REP_048,2024-01-12,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_001668,HCP_00796,REP_078,2024-01-12,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001669,HCP_03795,REP_045,2024-01-06,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001670,HCP_00731,REP_009,2024-01-28,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001671,HCP_00273,REP_048,2024-01-02,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_001672,HCP_01652,REP_071,2024-01-25,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_001673,HCP_04166,REP_007,2024-01-14,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001674,HCP_00316,REP_051,2024-02-11,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001675,HCP_02278,REP_059,2024-02-02,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_001676,HCP_00313,REP_043,2024-02-26,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_001677,HCP_00898,REP_032,2024-01-20,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001678,HCP_01824,REP_063,2024-01-21,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_001679,HCP_01877,REP_016,2024-04-10,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_001680,HCP_01665,REP_021,2024-02-25,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_001681,HCP_01949,REP_022,2024-01-11,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001682,HCP_03404,REP_012,2024-02-01,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001683,HCP_03926,REP_073,2024-01-05,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001684,HCP_03350,REP_001,2024-02-27,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001685,HCP_02622,REP_074,2024-01-05,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_001686,HCP_02224,REP_066,2024-01-21,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001687,HCP_01334,REP_057,2024-01-12,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_001688,HCP_03334,REP_044,2024-02-20,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001689,HCP_00939,REP_049,2024-03-15,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_001690,HCP_00370,REP_043,2024-01-11,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001691,HCP_01959,REP_024,2024-02-14,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_001692,HCP_00477,REP_024,2024-03-31,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_001693,HCP_03221,REP_032,2024-02-12,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_001694,HCP_01447,REP_022,2024-02-06,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001695,HCP_01025,REP_044,2024-04-17,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001696,HCP_04455,REP_057,2024-02-22,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001697,HCP_02873,REP_009,2024-03-11,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001698,HCP_02856,REP_032,2024-01-11,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001699,HCP_03675,REP_039,2024-03-09,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_001700,HCP_04283,REP_028,2024-01-09,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_001701,HCP_04705,REP_078,2024-01-24,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001702,HCP_01220,REP_069,2024-03-11,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_001703,HCP_02391,REP_012,2024-03-07,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_001704,HCP_02915,REP_004,2024-02-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001705,HCP_03535,REP_005,2024-01-13,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_001706,HCP_00693,REP_071,2024-07-01,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_001707,HCP_03776,REP_018,2024-04-08,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_001708,HCP_04549,REP_005,2024-05-23,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001709,HCP_02092,REP_007,2024-01-24,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_001710,HCP_00653,REP_069,2024-05-22,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001711,HCP_02389,REP_008,2024-01-13,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001712,HCP_02279,REP_036,2024-04-16,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001713,HCP_00953,REP_012,2024-01-07,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001714,HCP_02565,REP_032,2024-02-07,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001715,HCP_03052,REP_038,2024-03-09,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_001716,HCP_01854,REP_035,2024-01-10,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_001717,HCP_03971,REP_028,2024-02-25,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001718,HCP_02737,REP_063,2024-02-06,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_001719,HCP_04143,REP_056,2024-01-10,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_001720,HCP_04129,REP_020,2024-01-20,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001721,HCP_04941,REP_040,2024-01-12,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001722,HCP_02221,REP_032,2024-02-06,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_001723,HCP_01669,REP_024,2024-01-28,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_001724,HCP_01029,REP_021,2024-04-15,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001725,HCP_01467,REP_051,2024-02-25,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_001726,HCP_02765,REP_028,2024-03-24,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001727,HCP_03792,REP_029,2024-06-07,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001728,HCP_04794,REP_070,2024-01-04,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001729,HCP_02878,REP_037,2024-01-22,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_001730,HCP_01453,REP_078,2024-03-14,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_001731,HCP_02688,REP_043,2024-02-08,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_001732,HCP_00250,REP_049,2024-02-16,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_001733,HCP_01345,REP_042,2024-02-03,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_001734,HCP_00491,REP_009,2024-04-30,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001735,HCP_01648,REP_018,2024-02-24,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001736,HCP_00166,REP_028,2024-01-15,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001737,HCP_01329,REP_041,2024-01-17,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_001738,HCP_01516,REP_026,2024-02-07,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001739,HCP_04686,REP_072,2024-04-02,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001740,HCP_00179,REP_063,2024-01-10,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_001741,HCP_04239,REP_040,2024-02-09,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001742,HCP_01698,REP_053,2024-01-06,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001743,HCP_02341,REP_030,2024-02-09,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001744,HCP_03916,REP_058,2024-01-04,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_001745,HCP_03450,REP_006,2024-02-13,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001746,HCP_04584,REP_064,2024-02-19,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001747,HCP_02278,REP_024,2024-01-20,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_001748,HCP_01060,REP_042,2024-01-04,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_001749,HCP_02732,REP_062,2024-01-08,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_001750,HCP_02981,REP_006,2024-02-09,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_001751,HCP_03936,REP_057,2024-01-08,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_001752,HCP_03082,REP_008,2024-06-11,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_001753,HCP_00037,REP_060,2024-02-18,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001754,HCP_04125,REP_024,2024-01-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001755,HCP_02429,REP_063,2024-01-06,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001756,HCP_04553,REP_068,2024-01-05,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_001757,HCP_01550,REP_013,2024-01-15,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001758,HCP_02141,REP_027,2024-03-20,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001759,HCP_04230,REP_052,2024-01-07,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_001760,HCP_03769,REP_049,2024-01-20,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_001761,HCP_00461,REP_027,2024-02-16,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001762,HCP_02089,REP_074,2024-03-02,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001763,HCP_01696,REP_063,2024-02-24,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_001764,HCP_03440,REP_024,2024-02-14,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_001765,HCP_01367,REP_012,2024-02-27,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_001766,HCP_00255,REP_037,2024-01-07,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001767,HCP_03657,REP_050,2024-01-24,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001768,HCP_04040,REP_033,2024-01-29,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_001769,HCP_00560,REP_024,2024-02-20,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_001770,HCP_01214,REP_031,2024-04-20,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001771,HCP_04069,REP_003,2024-02-16,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001772,HCP_00324,REP_051,2024-02-15,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001773,HCP_04218,REP_034,2024-01-11,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_001774,HCP_04429,REP_047,2024-01-16,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001775,HCP_02204,REP_036,2024-04-25,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001776,HCP_03976,REP_068,2024-02-02,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_001777,HCP_03171,REP_047,2024-01-22,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_001778,HCP_04287,REP_058,2024-01-07,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_001779,HCP_03586,REP_028,2024-02-09,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001780,HCP_04699,REP_044,2024-02-19,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001781,HCP_00774,REP_056,2024-03-07,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_001782,HCP_02150,REP_068,2024-01-15,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_001783,HCP_00891,REP_001,2024-02-05,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_001784,HCP_02905,REP_008,2024-01-02,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001785,HCP_02378,REP_030,2024-05-25,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001786,HCP_00915,REP_004,2024-01-12,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_001787,HCP_01849,REP_036,2024-01-23,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001788,HCP_02001,REP_030,2024-02-03,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001789,HCP_04777,REP_073,2024-01-14,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_001790,HCP_04812,REP_023,2024-01-21,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001791,HCP_02961,REP_022,2024-02-17,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001792,HCP_01182,REP_008,2024-01-14,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_001793,HCP_00911,REP_041,2024-01-08,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_001794,HCP_00082,REP_062,2024-05-25,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_001795,HCP_02712,REP_012,2024-02-14,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_001796,HCP_04116,REP_045,2024-01-28,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_001797,HCP_04600,REP_076,2024-01-07,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001798,HCP_00554,REP_023,2024-01-13,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001799,HCP_03809,REP_035,2024-02-24,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_001800,HCP_04517,REP_068,2024-01-17,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_001801,HCP_04938,REP_042,2024-02-15,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001802,HCP_03705,REP_009,2024-02-06,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_001803,HCP_03260,REP_049,2024-02-18,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001804,HCP_01053,REP_079,2024-01-18,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_001805,HCP_02933,REP_039,2024-02-20,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001806,HCP_00868,REP_015,2024-01-03,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001807,HCP_04297,REP_042,2024-02-17,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_001808,HCP_00834,REP_062,2024-01-19,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_001809,HCP_04740,REP_041,2024-03-08,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001810,HCP_00138,REP_058,2024-02-10,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001811,HCP_01512,REP_070,2024-04-11,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001812,HCP_04670,REP_031,2024-01-10,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001813,HCP_03485,REP_010,2024-01-14,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001814,HCP_02223,REP_072,2024-02-11,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_001815,HCP_01803,REP_019,2024-02-28,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001816,HCP_01466,REP_030,2024-01-22,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001817,HCP_00156,REP_073,2024-01-01,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001818,HCP_02660,REP_027,2024-03-28,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_001819,HCP_01981,REP_044,2024-02-02,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_001820,HCP_03401,REP_042,2024-01-11,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_001821,HCP_02728,REP_035,2024-01-27,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001822,HCP_03146,REP_026,2024-01-05,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_001823,HCP_04747,REP_072,2024-01-12,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_001824,HCP_02831,REP_009,2024-01-26,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_001825,HCP_02916,REP_039,2024-02-28,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001826,HCP_02215,REP_026,2024-01-31,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_001827,HCP_00267,REP_040,2024-01-08,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001828,HCP_01014,REP_007,2024-01-10,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001829,HCP_03780,REP_073,2024-01-27,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_001830,HCP_00700,REP_031,2024-02-24,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_001831,HCP_03051,REP_016,2024-01-29,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001832,HCP_03837,REP_044,2024-06-26,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001833,HCP_04761,REP_010,2024-03-19,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001834,HCP_00315,REP_053,2024-02-01,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001835,HCP_01432,REP_006,2024-02-25,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001836,HCP_02243,REP_053,2024-01-06,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_001837,HCP_00171,REP_050,2024-04-30,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001838,HCP_04821,REP_072,2024-02-02,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_001839,HCP_03303,REP_000,2024-03-21,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_001840,HCP_01999,REP_048,2024-05-14,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001841,HCP_02624,REP_069,2024-01-03,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_001842,HCP_03252,REP_066,2024-01-17,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_001843,HCP_02947,REP_045,2024-05-31,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001844,HCP_04215,REP_002,2024-01-11,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001845,HCP_03971,REP_065,2024-02-10,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_001846,HCP_04295,REP_029,2024-02-01,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_001847,HCP_03872,REP_012,2024-02-01,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001848,HCP_04005,REP_059,2024-01-02,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_001849,HCP_01552,REP_038,2024-04-28,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_001850,HCP_01390,REP_015,2024-02-06,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001851,HCP_00377,REP_072,2024-02-26,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001852,HCP_03767,REP_050,2024-03-05,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_001853,HCP_01684,REP_049,2024-01-03,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001854,HCP_02920,REP_065,2024-01-20,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_001855,HCP_03725,REP_006,2024-03-23,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_001856,HCP_04129,REP_058,2024-01-19,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001857,HCP_00875,REP_029,2024-02-09,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001858,HCP_02943,REP_067,2024-04-24,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001859,HCP_02283,REP_060,2024-01-19,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001860,HCP_03741,REP_012,2024-02-11,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001861,HCP_03659,REP_065,2024-01-08,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_001862,HCP_04899,REP_058,2024-05-06,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_001863,HCP_03913,REP_071,2024-03-22,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001864,HCP_03746,REP_051,2024-01-20,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_001865,HCP_04894,REP_064,2024-01-22,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_001866,HCP_00435,REP_055,2024-01-13,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_001867,HCP_03401,REP_061,2024-02-22,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_001868,HCP_04082,REP_000,2024-03-14,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_001869,HCP_01024,REP_058,2024-01-12,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_001870,HCP_00973,REP_008,2024-01-27,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_001871,HCP_01567,REP_020,2024-03-13,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_001872,HCP_02955,REP_050,2024-01-03,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_001873,HCP_01468,REP_051,2024-04-26,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001874,HCP_01259,REP_037,2024-01-13,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_001875,HCP_01029,REP_051,2024-01-03,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_001876,HCP_03859,REP_038,2024-04-22,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_001877,HCP_02836,REP_033,2024-02-28,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001878,HCP_01215,REP_038,2024-01-31,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_001879,HCP_00419,REP_012,2024-03-17,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001880,HCP_01313,REP_077,2024-07-18,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001881,HCP_04137,REP_039,2024-01-06,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_001882,HCP_04784,REP_039,2024-01-06,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_001883,HCP_00500,REP_051,2024-04-01,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001884,HCP_01402,REP_035,2024-04-18,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001885,HCP_01762,REP_059,2024-04-20,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001886,HCP_03268,REP_060,2024-02-16,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001887,HCP_00039,REP_064,2024-03-02,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001888,HCP_02687,REP_015,2024-01-03,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_001889,HCP_03890,REP_043,2024-03-16,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_001890,HCP_00069,REP_005,2024-02-13,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001891,HCP_03877,REP_020,2024-05-14,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001892,HCP_04295,REP_050,2024-03-28,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_001893,HCP_03125,REP_018,2024-03-19,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001894,HCP_01414,REP_013,2024-02-20,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001895,HCP_02314,REP_040,2024-01-28,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001896,HCP_03203,REP_023,2024-01-02,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001897,HCP_00364,REP_071,2024-02-15,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001898,HCP_03717,REP_079,2024-01-27,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_001899,HCP_02888,REP_032,2024-01-29,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_001900,HCP_04104,REP_031,2024-01-02,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001901,HCP_00599,REP_049,2024-01-05,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_001902,HCP_03561,REP_063,2024-01-29,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_001903,HCP_02006,REP_026,2024-01-16,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001904,HCP_02010,REP_069,2024-05-13,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001905,HCP_02047,REP_069,2024-01-16,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_001906,HCP_01641,REP_001,2024-01-01,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_001907,HCP_00755,REP_044,2024-01-04,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_001908,HCP_04531,REP_041,2024-01-13,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_001909,HCP_04287,REP_001,2024-01-23,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_001910,HCP_02707,REP_073,2024-02-14,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_001911,HCP_01426,REP_052,2024-01-07,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_001912,HCP_04283,REP_046,2024-03-05,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_001913,HCP_00533,REP_068,2024-03-31,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_001914,HCP_03976,REP_079,2024-03-20,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001915,HCP_04656,REP_003,2024-03-13,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001916,HCP_01363,REP_039,2024-03-16,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_001917,HCP_00117,REP_019,2024-01-12,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001918,HCP_00993,REP_054,2024-01-05,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_001919,HCP_00223,REP_065,2024-03-24,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001920,HCP_04101,REP_031,2024-09-29,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_001921,HCP_02110,REP_004,2024-02-19,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_001922,HCP_03925,REP_029,2024-02-09,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001923,HCP_03180,REP_053,2024-01-12,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_001924,HCP_02546,REP_012,2024-01-16,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_001925,HCP_00318,REP_052,2024-02-15,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_001926,HCP_03291,REP_069,2024-02-03,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_001927,HCP_00002,REP_018,2024-01-21,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001928,HCP_04729,REP_072,2024-02-25,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_001929,HCP_04512,REP_012,2024-01-10,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_001930,HCP_03819,REP_057,2024-01-19,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_001931,HCP_04475,REP_011,2024-01-09,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001932,HCP_02264,REP_052,2024-02-12,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001933,HCP_00251,REP_040,2024-01-31,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_001934,HCP_03667,REP_041,2024-01-10,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_001935,HCP_03745,REP_008,2024-01-05,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001936,HCP_01215,REP_007,2024-01-22,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_001937,HCP_01729,REP_010,2024-01-29,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_001938,HCP_02484,REP_027,2024-01-15,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_001939,HCP_04306,REP_054,2024-01-04,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_001940,HCP_04139,REP_055,2024-01-31,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_001941,HCP_03744,REP_021,2024-03-22,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_001942,HCP_04960,REP_045,2024-01-03,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_001943,HCP_03994,REP_000,2024-02-10,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_001944,HCP_00260,REP_065,2024-02-12,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_001945,HCP_00031,REP_058,2024-01-23,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_001946,HCP_00446,REP_076,2024-02-09,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_001947,HCP_04120,REP_039,2024-01-08,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_001948,HCP_02779,REP_023,2024-01-31,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_001949,HCP_04755,REP_042,2024-01-03,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001950,HCP_02550,REP_064,2024-01-12,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_001951,HCP_00257,REP_017,2024-05-15,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001952,HCP_01308,REP_021,2024-01-19,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_001953,HCP_04841,REP_042,2024-01-13,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001954,HCP_02432,REP_070,2024-01-19,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001955,HCP_00201,REP_030,2024-01-07,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_001956,HCP_00685,REP_023,2024-01-06,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_001957,HCP_02465,REP_032,2024-01-21,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001958,HCP_00114,REP_051,2024-01-25,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_001959,HCP_03836,REP_015,2024-01-18,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_001960,HCP_01504,REP_036,2024-01-31,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_001961,HCP_01926,REP_032,2024-02-21,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001962,HCP_00396,REP_061,2024-01-02,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_001963,HCP_00119,REP_058,2024-01-12,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_001964,HCP_01702,REP_033,2024-01-02,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001965,HCP_01674,REP_040,2024-01-09,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_001966,HCP_03643,REP_021,2024-01-23,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_001967,HCP_03082,REP_035,2024-01-26,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_001968,HCP_02158,REP_004,2024-01-10,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001969,HCP_00636,REP_006,2024-01-11,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001970,HCP_04871,REP_027,2024-05-14,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_001971,HCP_03018,REP_043,2024-01-21,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_001972,HCP_04059,REP_050,2024-02-12,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_001973,HCP_00235,REP_071,2024-03-04,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001974,HCP_01979,REP_007,2024-01-10,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_001975,HCP_01060,REP_043,2024-02-04,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_001976,HCP_00944,REP_025,2024-01-05,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_001977,HCP_00680,REP_001,2024-01-22,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001978,HCP_00902,REP_032,2024-04-13,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_001979,HCP_00242,REP_064,2024-03-01,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_001980,HCP_04195,REP_062,2024-01-14,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_001981,HCP_02042,REP_022,2024-01-20,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_001982,HCP_04521,REP_045,2024-01-29,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_001983,HCP_03957,REP_041,2024-01-19,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001984,HCP_00314,REP_033,2024-09-21,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_001985,HCP_04631,REP_051,2024-01-01,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_001986,HCP_00944,REP_073,2024-01-16,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_001987,HCP_03448,REP_028,2024-01-06,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_001988,HCP_00014,REP_074,2024-01-20,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_001989,HCP_00299,REP_000,2024-02-27,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_001990,HCP_04608,REP_004,2024-02-20,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_001991,HCP_00839,REP_052,2024-04-16,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_001992,HCP_01534,REP_007,2024-01-09,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_001993,HCP_03631,REP_066,2024-01-19,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001994,HCP_03438,REP_007,2024-02-11,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_001995,HCP_04443,REP_041,2024-01-31,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_001996,HCP_00937,REP_068,2024-02-29,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_001997,HCP_03743,REP_062,2024-01-13,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_001998,HCP_04162,REP_024,2024-01-13,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_001999,HCP_03126,REP_034,2024-01-27,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002000,HCP_04181,REP_066,2024-02-27,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_002001,HCP_01023,REP_044,2024-04-09,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_002002,HCP_00531,REP_016,2024-01-17,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002003,HCP_01568,REP_003,2024-01-11,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_002004,HCP_01694,REP_041,2024-02-04,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_002005,HCP_02408,REP_045,2024-03-02,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002006,HCP_02437,REP_007,2024-01-20,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002007,HCP_04888,REP_062,2024-01-11,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_002008,HCP_01452,REP_025,2024-01-08,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002009,HCP_02037,REP_078,2024-05-02,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_002010,HCP_01427,REP_003,2024-01-31,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_002011,HCP_03642,REP_021,2024-01-18,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002012,HCP_04561,REP_022,2024-01-31,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002013,HCP_00901,REP_010,2024-03-17,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_002014,HCP_00913,REP_050,2024-02-08,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002015,HCP_04809,REP_031,2024-03-08,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002016,HCP_00819,REP_025,2024-01-04,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002017,HCP_03440,REP_027,2024-01-10,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_002018,HCP_01719,REP_074,2024-01-03,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_002019,HCP_02956,REP_016,2024-02-02,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002020,HCP_03736,REP_027,2024-01-04,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002021,HCP_00562,REP_015,2024-03-14,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002022,HCP_04913,REP_044,2024-01-27,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002023,HCP_04175,REP_029,2024-01-22,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_002024,HCP_01606,REP_079,2024-02-01,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002025,HCP_01608,REP_002,2024-01-10,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002026,HCP_04876,REP_060,2024-01-28,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_002027,HCP_04016,REP_035,2024-02-25,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_002028,HCP_03387,REP_034,2024-02-09,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002029,HCP_01692,REP_029,2024-02-21,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_002030,HCP_01222,REP_044,2024-06-18,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002031,HCP_01419,REP_023,2024-02-27,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002032,HCP_02246,REP_031,2024-01-09,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002033,HCP_04605,REP_037,2024-01-18,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002034,HCP_00365,REP_018,2024-01-05,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_002035,HCP_00032,REP_068,2024-01-24,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_002036,HCP_04151,REP_034,2024-02-01,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002037,HCP_03949,REP_053,2024-02-27,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_002038,HCP_03593,REP_005,2024-01-28,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_002039,HCP_03903,REP_072,2024-01-20,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002040,HCP_00817,REP_068,2024-01-02,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002041,HCP_02068,REP_038,2024-01-10,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002042,HCP_00854,REP_011,2024-01-17,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002043,HCP_02928,REP_068,2024-01-16,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002044,HCP_00589,REP_008,2024-02-07,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_002045,HCP_01040,REP_055,2024-01-18,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_002046,HCP_04450,REP_010,2024-02-08,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002047,HCP_01384,REP_029,2024-02-10,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_002048,HCP_01291,REP_003,2024-02-09,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_002049,HCP_03970,REP_054,2024-02-22,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_002050,HCP_00515,REP_031,2024-05-23,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_002051,HCP_01931,REP_072,2024-02-10,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002052,HCP_00105,REP_048,2024-03-05,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002053,HCP_02152,REP_076,2024-03-08,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_002054,HCP_02187,REP_031,2024-01-31,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002055,HCP_02462,REP_023,2024-01-07,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002056,HCP_02489,REP_026,2024-02-03,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002057,HCP_00627,REP_065,2024-01-31,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_002058,HCP_02963,REP_048,2024-01-19,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_002059,HCP_00978,REP_054,2024-02-10,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002060,HCP_04891,REP_012,2024-01-21,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_002061,HCP_00270,REP_054,2024-01-04,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_002062,HCP_03420,REP_053,2024-02-25,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_002063,HCP_01400,REP_019,2024-03-01,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002064,HCP_04884,REP_038,2024-03-02,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002065,HCP_01125,REP_045,2024-02-02,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_002066,HCP_04244,REP_027,2024-03-22,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002067,HCP_01580,REP_046,2024-03-28,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_002068,HCP_00352,REP_032,2024-01-06,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_002069,HCP_02238,REP_041,2024-02-03,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002070,HCP_03199,REP_070,2024-01-27,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_002071,HCP_02273,REP_019,2024-03-02,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002072,HCP_01539,REP_038,2024-02-25,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_002073,HCP_02839,REP_027,2024-01-08,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_002074,HCP_03238,REP_030,2024-03-13,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_002075,HCP_03318,REP_062,2024-04-27,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002076,HCP_02357,REP_015,2024-01-14,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_002077,HCP_01870,REP_046,2024-01-10,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002078,HCP_04500,REP_006,2024-02-14,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_002079,HCP_00481,REP_001,2024-01-21,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002080,HCP_02648,REP_065,2024-02-06,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002081,HCP_03075,REP_043,2024-03-16,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_002082,HCP_03865,REP_075,2024-02-06,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002083,HCP_00928,REP_008,2024-01-15,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002084,HCP_01631,REP_072,2024-01-17,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_002085,HCP_02727,REP_004,2024-01-23,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_002086,HCP_03012,REP_011,2024-04-12,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_002087,HCP_04561,REP_007,2024-03-27,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002088,HCP_04945,REP_078,2024-01-18,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002089,HCP_02354,REP_045,2024-01-30,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002090,HCP_02302,REP_022,2024-01-12,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_002091,HCP_02583,REP_009,2024-02-08,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002092,HCP_01671,REP_077,2024-01-01,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002093,HCP_02659,REP_039,2024-07-28,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_002094,HCP_01525,REP_007,2024-05-05,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_002095,HCP_04986,REP_049,2024-04-02,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002096,HCP_00736,REP_064,2024-01-15,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002097,HCP_02205,REP_054,2024-02-29,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002098,HCP_01949,REP_070,2024-01-18,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_002099,HCP_03675,REP_074,2024-02-12,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002100,HCP_00868,REP_053,2024-01-15,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_002101,HCP_00793,REP_030,2024-01-29,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_002102,HCP_02761,REP_074,2024-04-03,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002103,HCP_03251,REP_071,2024-03-06,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002104,HCP_03678,REP_005,2024-01-04,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002105,HCP_00715,REP_076,2024-02-05,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002106,HCP_04407,REP_035,2024-01-02,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_002107,HCP_02239,REP_012,2024-03-12,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002108,HCP_02128,REP_060,2024-03-01,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002109,HCP_02053,REP_022,2024-03-24,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002110,HCP_01010,REP_064,2024-02-09,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_002111,HCP_01166,REP_031,2024-05-25,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002112,HCP_03630,REP_000,2024-01-15,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_002113,HCP_03118,REP_035,2024-05-21,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_002114,HCP_03049,REP_058,2024-01-13,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002115,HCP_02566,REP_016,2024-01-30,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002116,HCP_03915,REP_001,2024-01-02,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_002117,HCP_02453,REP_073,2024-01-03,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002118,HCP_04733,REP_049,2024-01-01,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_002119,HCP_02260,REP_006,2024-02-12,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_002120,HCP_04037,REP_054,2024-01-18,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_002121,HCP_04706,REP_053,2024-01-22,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_002122,HCP_00255,REP_035,2024-05-11,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002123,HCP_03793,REP_042,2024-04-04,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_002124,HCP_01807,REP_018,2024-04-20,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002125,HCP_00987,REP_006,2024-01-10,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_002126,HCP_00972,REP_058,2024-01-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002127,HCP_02997,REP_019,2024-02-14,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002128,HCP_01510,REP_039,2024-01-09,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_002129,HCP_00304,REP_038,2024-01-07,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002130,HCP_03314,REP_074,2024-02-28,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_002131,HCP_04401,REP_057,2024-01-02,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002132,HCP_01907,REP_071,2024-01-22,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002133,HCP_03093,REP_023,2024-01-27,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_002134,HCP_04095,REP_020,2024-01-23,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_002135,HCP_02760,REP_048,2024-03-29,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002136,HCP_03370,REP_043,2024-01-23,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_002137,HCP_02146,REP_064,2024-05-02,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_002138,HCP_01486,REP_008,2024-02-22,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002139,HCP_02931,REP_062,2024-01-16,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_002140,HCP_04502,REP_037,2024-01-30,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_002141,HCP_01916,REP_052,2024-04-19,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_002142,HCP_02118,REP_027,2024-04-17,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_002143,HCP_01876,REP_046,2024-02-16,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_002144,HCP_01373,REP_072,2024-01-16,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_002145,HCP_00765,REP_023,2024-01-28,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_002146,HCP_04976,REP_042,2024-04-11,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_002147,HCP_01123,REP_075,2024-01-03,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_002148,HCP_03442,REP_058,2024-02-29,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002149,HCP_02248,REP_060,2024-03-05,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002150,HCP_04945,REP_072,2024-03-16,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_002151,HCP_04637,REP_047,2024-04-10,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002152,HCP_00454,REP_035,2024-03-09,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002153,HCP_04303,REP_034,2024-01-10,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002154,HCP_00107,REP_034,2024-02-03,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002155,HCP_03561,REP_074,2024-01-10,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002156,HCP_03898,REP_001,2024-01-06,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002157,HCP_01456,REP_021,2024-01-28,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_002158,HCP_00137,REP_073,2024-01-23,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002159,HCP_01525,REP_006,2024-02-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002160,HCP_02249,REP_012,2024-01-20,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002161,HCP_03080,REP_022,2024-02-25,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002162,HCP_01034,REP_045,2024-03-03,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_002163,HCP_03986,REP_073,2024-03-22,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002164,HCP_02588,REP_047,2024-01-26,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_002165,HCP_04035,REP_036,2024-01-03,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002166,HCP_02308,REP_037,2024-01-24,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_002167,HCP_04122,REP_022,2024-02-25,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_002168,HCP_04545,REP_019,2024-02-10,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_002169,HCP_04759,REP_063,2024-01-02,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_002170,HCP_01264,REP_015,2024-01-02,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_002171,HCP_04226,REP_001,2024-03-05,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002172,HCP_00218,REP_029,2024-01-17,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002173,HCP_01513,REP_033,2024-01-25,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_002174,HCP_02936,REP_030,2024-02-10,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002175,HCP_00897,REP_068,2024-01-23,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_002176,HCP_04680,REP_043,2024-01-19,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002177,HCP_02151,REP_041,2024-05-31,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002178,HCP_03258,REP_041,2024-02-13,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_002179,HCP_01117,REP_065,2024-02-05,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_002180,HCP_03460,REP_073,2024-03-03,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002181,HCP_00858,REP_004,2024-02-03,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_002182,HCP_02738,REP_040,2024-06-01,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_002183,HCP_02903,REP_008,2024-02-06,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002184,HCP_02213,REP_037,2024-01-31,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_002185,HCP_01666,REP_036,2024-02-02,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002186,HCP_02827,REP_021,2024-02-12,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002187,HCP_03254,REP_026,2024-01-30,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_002188,HCP_03405,REP_055,2024-01-12,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002189,HCP_00598,REP_000,2024-02-08,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_002190,HCP_04123,REP_001,2024-01-05,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_002191,HCP_00094,REP_070,2024-03-31,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002192,HCP_02693,REP_049,2024-02-05,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_002193,HCP_00933,REP_038,2024-01-01,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_002194,HCP_03206,REP_039,2024-02-01,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002195,HCP_04163,REP_023,2024-04-09,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_002196,HCP_00843,REP_077,2024-01-03,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002197,HCP_03568,REP_035,2024-02-18,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_002198,HCP_03946,REP_031,2024-05-23,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002199,HCP_02926,REP_067,2024-01-04,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002200,HCP_04844,REP_009,2024-01-07,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002201,HCP_00318,REP_032,2024-01-04,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_002202,HCP_03915,REP_061,2024-01-13,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_002203,HCP_03660,REP_077,2024-01-24,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002204,HCP_02200,REP_077,2024-03-19,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_002205,HCP_04875,REP_057,2024-01-04,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_002206,HCP_00148,REP_017,2024-02-18,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002207,HCP_03321,REP_036,2024-03-16,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002208,HCP_00841,REP_063,2024-02-17,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002209,HCP_04166,REP_015,2024-01-11,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002210,HCP_00661,REP_048,2024-01-18,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002211,HCP_00032,REP_008,2024-03-01,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_002212,HCP_03008,REP_069,2024-01-24,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_002213,HCP_01403,REP_079,2024-03-03,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002214,HCP_04713,REP_032,2024-01-17,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_002215,HCP_01852,REP_018,2024-01-30,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_002216,HCP_01479,REP_047,2024-03-03,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_002217,HCP_01611,REP_063,2024-01-10,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002218,HCP_01646,REP_074,2024-01-04,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002219,HCP_03498,REP_037,2024-01-01,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_002220,HCP_02218,REP_037,2024-01-16,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_002221,HCP_03208,REP_017,2024-01-28,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002222,HCP_00133,REP_046,2024-01-25,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_002223,HCP_00188,REP_041,2024-01-07,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002224,HCP_01287,REP_023,2024-04-09,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002225,HCP_02062,REP_030,2024-02-07,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002226,HCP_02728,REP_055,2024-02-10,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002227,HCP_00226,REP_041,2024-01-08,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_002228,HCP_04268,REP_026,2024-01-20,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002229,HCP_02803,REP_067,2024-02-04,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_002230,HCP_04511,REP_025,2024-01-29,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_002231,HCP_02420,REP_073,2024-01-10,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002232,HCP_00962,REP_065,2024-01-14,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_002233,HCP_03023,REP_061,2024-07-23,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_002234,HCP_00722,REP_036,2024-02-26,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002235,HCP_04177,REP_020,2024-01-05,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_002236,HCP_00048,REP_000,2024-01-27,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002237,HCP_04844,REP_025,2024-01-13,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002238,HCP_01397,REP_002,2024-01-03,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_002239,HCP_00392,REP_011,2024-01-14,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_002240,HCP_02021,REP_074,2024-02-12,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_002241,HCP_03627,REP_053,2024-01-18,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002242,HCP_02274,REP_036,2024-02-04,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002243,HCP_00199,REP_012,2024-01-05,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_002244,HCP_02065,REP_011,2024-01-08,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002245,HCP_01056,REP_022,2024-01-10,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_002246,HCP_03436,REP_074,2024-01-04,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_002247,HCP_02423,REP_041,2024-01-05,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_002248,HCP_02777,REP_009,2024-01-21,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_002249,HCP_04564,REP_042,2024-02-17,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_002250,HCP_01230,REP_054,2024-05-17,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_002251,HCP_00835,REP_034,2024-06-23,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002252,HCP_02268,REP_006,2024-02-28,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002253,HCP_00345,REP_042,2024-05-25,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002254,HCP_02344,REP_042,2024-02-01,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002255,HCP_04192,REP_002,2024-02-27,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_002256,HCP_04252,REP_037,2024-01-17,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_002257,HCP_03894,REP_049,2024-02-09,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_002258,HCP_04399,REP_044,2024-01-01,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002259,HCP_04964,REP_014,2024-01-03,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002260,HCP_02739,REP_000,2024-01-18,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002261,HCP_04883,REP_003,2024-01-06,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002262,HCP_01680,REP_031,2024-03-23,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_002263,HCP_00298,REP_038,2024-01-18,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_002264,HCP_00659,REP_074,2024-06-22,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_002265,HCP_03191,REP_040,2024-01-03,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_002266,HCP_02188,REP_054,2024-02-23,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_002267,HCP_02829,REP_060,2024-02-19,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_002268,HCP_03082,REP_041,2024-03-14,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_002269,HCP_02199,REP_012,2024-02-29,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002270,HCP_02503,REP_018,2024-02-27,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002271,HCP_02162,REP_002,2024-01-14,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_002272,HCP_01931,REP_057,2024-02-08,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002273,HCP_01333,REP_042,2024-01-04,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002274,HCP_01113,REP_015,2024-01-25,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_002275,HCP_01414,REP_036,2024-01-01,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_002276,HCP_00059,REP_043,2024-02-14,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_002277,HCP_04502,REP_051,2024-04-23,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_002278,HCP_04839,REP_051,2024-01-14,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_002279,HCP_02740,REP_049,2024-03-30,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_002280,HCP_03435,REP_074,2024-01-20,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_002281,HCP_02359,REP_073,2024-01-14,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002282,HCP_02935,REP_017,2024-03-07,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_002283,HCP_02109,REP_014,2024-01-03,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_002284,HCP_00037,REP_021,2024-03-29,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_002285,HCP_01981,REP_048,2024-03-01,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002286,HCP_02681,REP_040,2024-01-11,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002287,HCP_01960,REP_052,2024-01-14,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002288,HCP_03343,REP_032,2024-01-15,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_002289,HCP_04846,REP_074,2024-03-23,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_002290,HCP_03333,REP_032,2024-01-06,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_002291,HCP_01300,REP_027,2024-01-05,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002292,HCP_03724,REP_068,2024-01-06,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_002293,HCP_02241,REP_011,2024-02-24,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002294,HCP_04681,REP_078,2024-01-20,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002295,HCP_00065,REP_035,2024-01-10,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_002296,HCP_02644,REP_039,2024-01-04,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_002297,HCP_03133,REP_049,2024-03-06,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002298,HCP_02992,REP_050,2024-01-23,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002299,HCP_02835,REP_004,2024-02-02,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002300,HCP_02968,REP_059,2024-03-20,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002301,HCP_04821,REP_066,2024-01-06,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002302,HCP_03225,REP_018,2024-01-30,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_002303,HCP_00672,REP_067,2024-01-01,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_002304,HCP_00461,REP_045,2024-04-06,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_002305,HCP_01245,REP_041,2024-01-12,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002306,HCP_01111,REP_071,2024-01-08,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_002307,HCP_02774,REP_076,2024-01-01,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002308,HCP_04932,REP_045,2024-01-16,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_002309,HCP_03517,REP_047,2024-01-26,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002310,HCP_00233,REP_071,2024-01-20,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_002311,HCP_03714,REP_070,2024-01-13,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_002312,HCP_02932,REP_041,2024-03-14,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_002313,HCP_03292,REP_073,2024-01-30,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002314,HCP_02007,REP_004,2024-01-28,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_002315,HCP_04989,REP_067,2024-01-08,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_002316,HCP_04539,REP_011,2024-02-27,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002317,HCP_03152,REP_035,2024-01-05,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002318,HCP_01268,REP_050,2024-01-01,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002319,HCP_01250,REP_073,2024-02-07,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_002320,HCP_00482,REP_002,2024-01-15,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_002321,HCP_04809,REP_072,2024-02-29,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002322,HCP_01586,REP_077,2024-02-09,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002323,HCP_04627,REP_052,2024-01-06,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_002324,HCP_00080,REP_023,2024-01-28,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_002325,HCP_03619,REP_013,2024-02-11,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002326,HCP_02623,REP_052,2024-01-31,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_002327,HCP_01295,REP_079,2024-03-01,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002328,HCP_03959,REP_027,2024-01-04,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002329,HCP_01167,REP_017,2024-01-28,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_002330,HCP_00984,REP_057,2024-01-09,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002331,HCP_02000,REP_044,2024-01-10,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002332,HCP_01206,REP_071,2024-03-05,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002333,HCP_01005,REP_020,2024-02-07,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002334,HCP_03360,REP_073,2024-01-05,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002335,HCP_03357,REP_002,2024-01-15,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002336,HCP_02886,REP_021,2024-01-24,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002337,HCP_03165,REP_041,2024-04-01,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002338,HCP_03207,REP_052,2024-01-29,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_002339,HCP_00675,REP_018,2024-01-13,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002340,HCP_00784,REP_010,2024-02-19,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_002341,HCP_03368,REP_055,2024-03-05,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_002342,HCP_03720,REP_007,2024-01-13,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_002343,HCP_00421,REP_002,2024-01-22,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002344,HCP_00320,REP_049,2024-01-19,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002345,HCP_00498,REP_021,2024-01-05,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002346,HCP_04735,REP_057,2024-02-25,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_002347,HCP_00145,REP_079,2024-01-02,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002348,HCP_00603,REP_051,2024-01-23,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_002349,HCP_03251,REP_058,2024-01-13,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002350,HCP_02656,REP_065,2024-02-17,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002351,HCP_00547,REP_046,2024-01-13,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002352,HCP_04515,REP_008,2024-01-07,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_002353,HCP_01581,REP_069,2024-02-22,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_002354,HCP_04237,REP_012,2024-02-21,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002355,HCP_01234,REP_060,2024-01-04,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002356,HCP_01555,REP_005,2024-03-06,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002357,HCP_04207,REP_048,2024-01-24,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_002358,HCP_04520,REP_007,2024-01-19,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002359,HCP_03384,REP_048,2024-01-04,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002360,HCP_02384,REP_006,2024-03-06,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_002361,HCP_01647,REP_025,2024-01-07,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002362,HCP_04235,REP_030,2024-01-15,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_002363,HCP_04603,REP_053,2024-02-09,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002364,HCP_04237,REP_054,2024-01-25,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_002365,HCP_03075,REP_019,2024-04-30,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_002366,HCP_00706,REP_026,2024-02-05,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002367,HCP_03938,REP_004,2024-02-02,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002368,HCP_03595,REP_050,2024-02-19,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_002369,HCP_03013,REP_073,2024-03-12,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_002370,HCP_03075,REP_046,2024-01-03,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_002371,HCP_02263,REP_022,2024-01-05,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_002372,HCP_04797,REP_075,2024-03-28,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002373,HCP_02374,REP_064,2024-01-18,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_002374,HCP_00629,REP_061,2024-02-07,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_002375,HCP_01956,REP_042,2024-01-18,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002376,HCP_02759,REP_049,2024-02-07,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002377,HCP_04290,REP_043,2024-01-05,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002378,HCP_00361,REP_037,2024-02-17,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002379,HCP_02760,REP_079,2024-01-22,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_002380,HCP_00785,REP_019,2024-01-30,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_002381,HCP_03033,REP_039,2024-01-11,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_002382,HCP_01176,REP_027,2024-01-03,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002383,HCP_02414,REP_046,2024-01-13,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_002384,HCP_00159,REP_061,2024-01-15,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002385,HCP_03774,REP_023,2024-01-18,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002386,HCP_04551,REP_016,2024-02-13,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_002387,HCP_01812,REP_019,2024-02-28,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_002388,HCP_04569,REP_075,2024-03-03,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_002389,HCP_04069,REP_006,2024-02-15,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_002390,HCP_02286,REP_031,2024-02-11,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_002391,HCP_03887,REP_011,2024-01-17,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002392,HCP_02493,REP_076,2024-01-16,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002393,HCP_01376,REP_076,2024-02-14,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_002394,HCP_00550,REP_047,2024-07-21,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_002395,HCP_02638,REP_024,2024-02-13,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002396,HCP_03011,REP_042,2024-01-17,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002397,HCP_04290,REP_072,2024-09-01,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002398,HCP_01176,REP_053,2024-01-21,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_002399,HCP_01157,REP_061,2024-01-08,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_002400,HCP_02621,REP_074,2024-03-09,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002401,HCP_01331,REP_037,2024-03-03,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002402,HCP_02257,REP_052,2024-06-11,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002403,HCP_02446,REP_012,2024-07-22,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002404,HCP_01868,REP_048,2024-02-29,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002405,HCP_00696,REP_010,2024-01-13,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002406,HCP_03173,REP_035,2024-01-28,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002407,HCP_04914,REP_046,2024-03-21,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_002408,HCP_00291,REP_031,2024-01-07,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_002409,HCP_04378,REP_005,2024-01-31,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002410,HCP_00984,REP_072,2024-01-26,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_002411,HCP_00306,REP_038,2024-01-18,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_002412,HCP_04212,REP_055,2024-01-10,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002413,HCP_00556,REP_058,2024-01-19,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_002414,HCP_00437,REP_070,2024-01-13,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_002415,HCP_00165,REP_004,2024-01-16,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002416,HCP_01203,REP_032,2024-05-01,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002417,HCP_04858,REP_028,2024-01-20,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002418,HCP_01618,REP_008,2024-02-14,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002419,HCP_03451,REP_054,2024-05-02,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002420,HCP_02271,REP_033,2024-01-02,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_002421,HCP_03738,REP_035,2024-01-16,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_002422,HCP_03634,REP_024,2024-04-12,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002423,HCP_01811,REP_012,2024-01-23,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002424,HCP_04287,REP_005,2024-01-05,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_002425,HCP_04928,REP_003,2024-01-12,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_002426,HCP_02942,REP_043,2024-03-04,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002427,HCP_01296,REP_049,2024-06-05,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_002428,HCP_01805,REP_035,2024-01-13,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_002429,HCP_00965,REP_017,2024-01-20,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_002430,HCP_02114,REP_061,2024-02-04,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_002431,HCP_00169,REP_074,2024-01-20,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_002432,HCP_02497,REP_035,2024-02-10,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002433,HCP_01211,REP_065,2024-01-03,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002434,HCP_00367,REP_072,2024-01-07,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002435,HCP_03792,REP_044,2024-01-04,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002436,HCP_02917,REP_026,2024-02-01,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002437,HCP_04370,REP_010,2024-03-30,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_002438,HCP_02414,REP_063,2024-02-03,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002439,HCP_01760,REP_035,2024-01-01,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_002440,HCP_00863,REP_012,2024-01-15,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_002441,HCP_03694,REP_070,2024-03-18,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002442,HCP_02523,REP_030,2024-03-28,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_002443,HCP_01218,REP_075,2024-02-08,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002444,HCP_00527,REP_071,2024-03-30,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002445,HCP_02715,REP_077,2024-01-10,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_002446,HCP_01052,REP_013,2024-01-19,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_002447,HCP_03037,REP_075,2024-01-05,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002448,HCP_03485,REP_000,2024-01-25,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002449,HCP_01526,REP_056,2024-02-18,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002450,HCP_03354,REP_042,2024-01-07,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002451,HCP_00879,REP_049,2024-01-19,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002452,HCP_01496,REP_008,2024-01-25,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_002453,HCP_01422,REP_025,2024-01-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002454,HCP_02239,REP_057,2024-01-29,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002455,HCP_02714,REP_036,2024-01-06,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_002456,HCP_04399,REP_053,2024-04-12,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_002457,HCP_04556,REP_046,2024-01-16,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_002458,HCP_01543,REP_011,2024-01-21,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_002459,HCP_00352,REP_001,2024-02-14,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002460,HCP_04022,REP_058,2024-03-10,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_002461,HCP_01244,REP_012,2024-04-03,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002462,HCP_03071,REP_064,2024-02-11,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002463,HCP_02368,REP_023,2024-02-28,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002464,HCP_00027,REP_036,2024-01-28,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002465,HCP_00171,REP_042,2024-01-17,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002466,HCP_02828,REP_022,2024-01-21,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002467,HCP_02783,REP_021,2024-03-13,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_002468,HCP_02669,REP_011,2024-04-20,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_002469,HCP_04489,REP_000,2024-01-19,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_002470,HCP_03325,REP_054,2024-01-04,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002471,HCP_01837,REP_002,2024-04-03,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_002472,HCP_03140,REP_079,2024-01-06,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002473,HCP_02774,REP_071,2024-01-30,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_002474,HCP_00940,REP_044,2024-01-23,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_002475,HCP_01093,REP_031,2024-01-28,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_002476,HCP_00551,REP_038,2024-02-11,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002477,HCP_04549,REP_074,2024-01-05,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002478,HCP_04750,REP_048,2024-06-20,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002479,HCP_03804,REP_028,2024-04-19,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_002480,HCP_04947,REP_071,2024-01-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002481,HCP_00235,REP_074,2024-01-10,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_002482,HCP_01703,REP_072,2024-01-17,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_002483,HCP_04199,REP_066,2024-01-01,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_002484,HCP_00659,REP_050,2024-01-03,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_002485,HCP_01637,REP_014,2024-01-15,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002486,HCP_02668,REP_043,2024-01-21,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002487,HCP_03368,REP_026,2024-01-10,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002488,HCP_03759,REP_034,2024-01-06,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002489,HCP_00162,REP_008,2024-04-09,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_002490,HCP_00157,REP_059,2024-05-15,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_002491,HCP_02659,REP_075,2024-01-26,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002492,HCP_00586,REP_033,2024-01-09,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_002493,HCP_04488,REP_063,2024-03-30,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_002494,HCP_03555,REP_018,2024-02-05,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002495,HCP_02405,REP_018,2024-01-04,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002496,HCP_01558,REP_050,2024-05-31,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002497,HCP_02385,REP_060,2024-01-02,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_002498,HCP_01496,REP_011,2024-03-09,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_002499,HCP_00118,REP_036,2024-01-06,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002500,HCP_04885,REP_057,2024-01-08,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_002501,HCP_04807,REP_038,2024-03-13,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_002502,HCP_02038,REP_024,2024-03-03,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002503,HCP_03017,REP_057,2024-02-23,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_002504,HCP_00613,REP_012,2024-05-08,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002505,HCP_04712,REP_018,2024-01-16,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_002506,HCP_02390,REP_066,2024-02-20,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002507,HCP_04014,REP_011,2024-02-08,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_002508,HCP_01621,REP_074,2024-02-28,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_002509,HCP_01445,REP_024,2024-03-25,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_002510,HCP_00350,REP_043,2024-02-21,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_002511,HCP_04467,REP_060,2024-01-04,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002512,HCP_00445,REP_036,2024-01-13,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002513,HCP_03033,REP_066,2024-03-30,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002514,HCP_03206,REP_038,2024-01-29,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002515,HCP_03318,REP_028,2024-01-01,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002516,HCP_03277,REP_054,2024-02-03,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002517,HCP_00845,REP_045,2024-01-27,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002518,HCP_04673,REP_005,2024-02-17,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_002519,HCP_01183,REP_066,2024-03-02,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_002520,HCP_02845,REP_068,2024-01-14,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_002521,HCP_03924,REP_019,2024-01-03,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002522,HCP_01285,REP_010,2024-02-29,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002523,HCP_02707,REP_006,2024-02-03,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_002524,HCP_02003,REP_076,2024-03-11,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_002525,HCP_03383,REP_007,2024-02-14,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_002526,HCP_04481,REP_074,2024-01-26,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002527,HCP_04696,REP_053,2024-01-08,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_002528,HCP_04205,REP_060,2024-02-22,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_002529,HCP_04730,REP_067,2024-01-11,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_002530,HCP_01614,REP_015,2024-01-04,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002531,HCP_03104,REP_062,2024-01-01,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002532,HCP_04448,REP_064,2024-01-05,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002533,HCP_04635,REP_075,2024-01-06,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_002534,HCP_03765,REP_073,2024-03-06,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002535,HCP_04521,REP_023,2024-05-10,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_002536,HCP_02527,REP_012,2024-03-11,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_002537,HCP_00001,REP_030,2024-02-21,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_002538,HCP_02457,REP_033,2024-02-11,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002539,HCP_00677,REP_023,2024-04-21,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002540,HCP_00840,REP_018,2024-01-11,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002541,HCP_03579,REP_033,2024-02-19,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_002542,HCP_00314,REP_018,2024-05-04,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002543,HCP_03230,REP_049,2024-01-31,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002544,HCP_00950,REP_078,2024-01-21,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002545,HCP_03630,REP_055,2024-02-14,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_002546,HCP_02298,REP_006,2024-01-03,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002547,HCP_02717,REP_046,2024-05-12,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_002548,HCP_04271,REP_052,2024-01-08,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_002549,HCP_04152,REP_006,2024-02-02,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_002550,HCP_02271,REP_046,2024-01-28,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_002551,HCP_02467,REP_039,2024-01-18,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_002552,HCP_04487,REP_013,2024-01-19,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002553,HCP_04702,REP_029,2024-01-29,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_002554,HCP_01147,REP_068,2024-01-31,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002555,HCP_02216,REP_028,2024-02-10,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002556,HCP_00266,REP_032,2024-02-15,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002557,HCP_04588,REP_034,2024-04-16,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_002558,HCP_00181,REP_037,2024-02-03,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002559,HCP_02696,REP_020,2024-01-09,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002560,HCP_04926,REP_076,2024-01-03,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_002561,HCP_00881,REP_073,2024-01-17,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_002562,HCP_02277,REP_007,2024-01-01,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_002563,HCP_01046,REP_051,2024-01-06,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_002564,HCP_01133,REP_055,2024-03-09,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002565,HCP_02706,REP_029,2024-04-21,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_002566,HCP_00409,REP_023,2024-02-05,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_002567,HCP_00180,REP_064,2024-02-22,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002568,HCP_04889,REP_013,2024-01-17,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_002569,HCP_03680,REP_002,2024-02-13,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_002570,HCP_00360,REP_063,2024-01-21,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002571,HCP_04161,REP_038,2024-01-18,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_002572,HCP_03333,REP_040,2024-01-06,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_002573,HCP_02583,REP_035,2024-02-07,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_002574,HCP_03767,REP_016,2024-01-23,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_002575,HCP_01128,REP_041,2024-06-08,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002576,HCP_01211,REP_043,2024-02-02,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_002577,HCP_02335,REP_032,2024-01-16,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002578,HCP_03312,REP_052,2024-04-12,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_002579,HCP_01797,REP_007,2024-02-11,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002580,HCP_02671,REP_010,2024-01-21,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002581,HCP_01588,REP_046,2024-02-03,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_002582,HCP_00218,REP_076,2024-03-08,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_002583,HCP_02788,REP_004,2024-01-02,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002584,HCP_02592,REP_040,2024-04-29,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002585,HCP_02311,REP_074,2024-02-28,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002586,HCP_00249,REP_011,2024-02-10,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002587,HCP_00137,REP_075,2024-01-26,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002588,HCP_02140,REP_054,2024-01-05,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_002589,HCP_00732,REP_057,2024-01-02,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_002590,HCP_03464,REP_027,2024-03-16,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_002591,HCP_03692,REP_019,2024-01-17,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_002592,HCP_04567,REP_052,2024-01-02,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002593,HCP_04322,REP_051,2024-03-07,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002594,HCP_01808,REP_015,2024-02-23,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002595,HCP_03388,REP_018,2024-01-24,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002596,HCP_00614,REP_012,2024-02-02,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_002597,HCP_04122,REP_033,2024-02-27,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002598,HCP_04548,REP_017,2024-01-23,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002599,HCP_04538,REP_070,2024-01-25,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_002600,HCP_01825,REP_042,2024-04-08,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_002601,HCP_00721,REP_002,2024-01-31,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002602,HCP_03464,REP_007,2024-03-19,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002603,HCP_03516,REP_021,2024-01-15,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_002604,HCP_02432,REP_070,2024-01-08,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_002605,HCP_02281,REP_041,2024-02-06,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_002606,HCP_04149,REP_046,2024-01-24,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002607,HCP_00635,REP_074,2024-02-26,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002608,HCP_00030,REP_000,2024-02-24,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002609,HCP_04383,REP_041,2024-01-23,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_002610,HCP_00743,REP_053,2024-02-09,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002611,HCP_01824,REP_064,2024-02-07,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_002612,HCP_02082,REP_057,2024-03-27,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002613,HCP_03575,REP_034,2024-02-01,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_002614,HCP_04631,REP_046,2024-01-16,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_002615,HCP_00326,REP_070,2024-01-01,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_002616,HCP_02073,REP_066,2024-02-23,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002617,HCP_03668,REP_025,2024-02-12,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002618,HCP_01324,REP_051,2024-02-04,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_002619,HCP_00946,REP_051,2024-01-20,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_002620,HCP_01789,REP_030,2024-01-20,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_002621,HCP_00204,REP_005,2024-01-07,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002622,HCP_03027,REP_000,2024-01-07,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_002623,HCP_04943,REP_018,2024-01-07,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002624,HCP_03949,REP_046,2024-02-08,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_002625,HCP_02483,REP_037,2024-01-01,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_002626,HCP_04397,REP_019,2024-03-16,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_002627,HCP_01736,REP_073,2024-02-11,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002628,HCP_01409,REP_079,2024-03-01,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_002629,HCP_03423,REP_028,2024-04-06,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002630,HCP_02107,REP_051,2024-02-09,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002631,HCP_02158,REP_004,2024-02-23,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_002632,HCP_03739,REP_012,2024-07-24,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002633,HCP_03586,REP_008,2024-05-01,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002634,HCP_02019,REP_054,2024-03-12,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002635,HCP_02787,REP_007,2024-01-31,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002636,HCP_04542,REP_014,2024-01-26,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_002637,HCP_04215,REP_030,2024-01-21,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002638,HCP_02017,REP_053,2024-02-21,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002639,HCP_02986,REP_032,2024-03-09,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002640,HCP_00892,REP_041,2024-01-01,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002641,HCP_02229,REP_029,2024-03-25,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002642,HCP_03516,REP_053,2024-03-05,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_002643,HCP_01566,REP_002,2024-05-07,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_002644,HCP_00893,REP_051,2024-06-06,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002645,HCP_03470,REP_040,2024-01-17,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_002646,HCP_01920,REP_049,2024-02-17,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_002647,HCP_00982,REP_047,2024-01-26,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_002648,HCP_01302,REP_062,2024-02-15,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_002649,HCP_03627,REP_003,2024-01-13,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_002650,HCP_03416,REP_066,2024-01-12,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002651,HCP_03852,REP_035,2024-01-22,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002652,HCP_01288,REP_018,2024-02-11,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_002653,HCP_01742,REP_013,2024-02-15,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002654,HCP_04600,REP_030,2024-01-08,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_002655,HCP_03348,REP_033,2024-01-11,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_002656,HCP_03681,REP_018,2024-01-08,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002657,HCP_02816,REP_066,2024-03-26,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_002658,HCP_01244,REP_070,2024-02-07,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002659,HCP_01244,REP_047,2024-01-26,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_002660,HCP_03548,REP_028,2024-01-22,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_002661,HCP_04171,REP_025,2024-01-24,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_002662,HCP_03487,REP_066,2024-02-04,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_002663,HCP_01776,REP_003,2024-01-08,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_002664,HCP_04052,REP_061,2024-01-24,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002665,HCP_04921,REP_073,2024-03-10,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002666,HCP_03205,REP_015,2024-01-11,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002667,HCP_02199,REP_060,2024-04-02,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002668,HCP_04535,REP_017,2024-03-05,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002669,HCP_01187,REP_033,2024-01-01,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002670,HCP_01322,REP_077,2024-05-23,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_002671,HCP_02896,REP_062,2024-08-25,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_002672,HCP_01533,REP_024,2024-01-12,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002673,HCP_04182,REP_020,2024-01-02,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_002674,HCP_00233,REP_028,2024-01-09,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002675,HCP_00467,REP_019,2024-01-04,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002676,HCP_00689,REP_074,2024-02-21,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002677,HCP_02659,REP_024,2024-02-16,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_002678,HCP_01686,REP_030,2024-01-05,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002679,HCP_04218,REP_005,2024-01-07,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002680,HCP_04623,REP_048,2024-03-27,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_002681,HCP_04302,REP_031,2024-01-12,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_002682,HCP_02564,REP_059,2024-01-16,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_002683,HCP_00662,REP_009,2024-04-30,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_002684,HCP_04109,REP_062,2024-02-09,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002685,HCP_02812,REP_006,2024-02-29,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_002686,HCP_02662,REP_060,2024-02-18,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002687,HCP_02907,REP_013,2024-03-03,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_002688,HCP_04675,REP_060,2024-01-21,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_002689,HCP_00204,REP_074,2024-01-03,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_002690,HCP_00635,REP_042,2024-01-27,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_002691,HCP_01217,REP_031,2024-02-26,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002692,HCP_03727,REP_068,2024-01-07,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_002693,HCP_01581,REP_058,2024-01-13,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_002694,HCP_03318,REP_054,2024-01-12,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_002695,HCP_03243,REP_030,2024-02-15,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002696,HCP_01149,REP_050,2024-01-08,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002697,HCP_04852,REP_045,2024-02-10,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_002698,HCP_03692,REP_030,2024-01-12,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002699,HCP_01877,REP_078,2024-01-13,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_002700,HCP_03476,REP_029,2024-05-15,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_002701,HCP_00842,REP_056,2024-01-01,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002702,HCP_02171,REP_073,2024-01-31,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002703,HCP_00955,REP_006,2024-05-04,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_002704,HCP_01792,REP_047,2024-01-24,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_002705,HCP_00119,REP_008,2024-01-06,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_002706,HCP_03085,REP_012,2024-02-28,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_002707,HCP_01761,REP_042,2024-01-10,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002708,HCP_01403,REP_004,2024-02-08,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_002709,HCP_02708,REP_063,2024-01-04,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_002710,HCP_02214,REP_013,2024-01-26,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_002711,HCP_00041,REP_014,2024-01-04,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_002712,HCP_02557,REP_037,2024-02-11,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002713,HCP_02315,REP_072,2024-03-21,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002714,HCP_02227,REP_043,2024-03-09,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_002715,HCP_02206,REP_015,2024-02-04,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002716,HCP_04509,REP_013,2024-01-01,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002717,HCP_00923,REP_065,2024-01-07,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_002718,HCP_03718,REP_037,2024-01-08,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_002719,HCP_02421,REP_052,2024-01-13,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002720,HCP_04805,REP_017,2024-04-08,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002721,HCP_04540,REP_075,2024-01-10,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002722,HCP_04015,REP_017,2024-02-06,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002723,HCP_03118,REP_006,2024-03-29,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002724,HCP_02361,REP_052,2024-02-28,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_002725,HCP_00716,REP_052,2024-01-22,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_002726,HCP_01458,REP_038,2024-05-01,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002727,HCP_03268,REP_078,2024-02-27,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002728,HCP_00201,REP_049,2024-01-04,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_002729,HCP_00134,REP_015,2024-01-06,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_002730,HCP_03965,REP_024,2024-03-19,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_002731,HCP_01126,REP_057,2024-01-18,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002732,HCP_00123,REP_053,2024-01-03,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002733,HCP_01797,REP_029,2024-04-05,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_002734,HCP_00203,REP_067,2024-02-22,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002735,HCP_04481,REP_046,2024-01-15,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_002736,HCP_02503,REP_079,2024-01-14,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_002737,HCP_02896,REP_019,2024-01-07,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_002738,HCP_03395,REP_073,2024-04-02,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002739,HCP_02567,REP_038,2024-01-28,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002740,HCP_04804,REP_008,2024-03-15,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_002741,HCP_00964,REP_019,2024-02-09,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_002742,HCP_00318,REP_031,2024-02-02,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_002743,HCP_04327,REP_014,2024-06-19,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_002744,HCP_02536,REP_060,2024-01-16,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002745,HCP_04723,REP_057,2024-01-23,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002746,HCP_04590,REP_055,2024-01-03,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_002747,HCP_04793,REP_064,2024-02-12,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002748,HCP_04419,REP_036,2024-02-10,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002749,HCP_04405,REP_011,2024-02-12,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002750,HCP_01317,REP_029,2024-01-25,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_002751,HCP_00042,REP_024,2024-04-01,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_002752,HCP_03614,REP_004,2024-01-18,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002753,HCP_04191,REP_047,2024-01-15,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_002754,HCP_01318,REP_055,2024-01-21,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002755,HCP_02419,REP_022,2024-05-31,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002756,HCP_03972,REP_062,2024-02-04,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002757,HCP_04071,REP_060,2024-02-21,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002758,HCP_00374,REP_029,2024-01-15,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002759,HCP_03840,REP_056,2024-02-20,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_002760,HCP_00939,REP_078,2024-04-23,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002761,HCP_04406,REP_044,2024-01-10,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002762,HCP_00496,REP_032,2024-02-03,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_002763,HCP_02708,REP_045,2024-03-11,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002764,HCP_04271,REP_028,2024-02-15,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_002765,HCP_01765,REP_040,2024-01-02,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002766,HCP_01839,REP_078,2024-03-22,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_002767,HCP_02297,REP_075,2024-01-25,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002768,HCP_04477,REP_039,2024-01-21,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002769,HCP_01088,REP_063,2024-03-29,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_002770,HCP_02932,REP_013,2024-01-10,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002771,HCP_01815,REP_067,2024-01-02,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_002772,HCP_03189,REP_036,2024-01-02,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_002773,HCP_04061,REP_061,2024-02-16,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_002774,HCP_00858,REP_014,2024-01-22,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002775,HCP_01149,REP_053,2024-02-01,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002776,HCP_02766,REP_068,2024-01-17,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002777,HCP_01804,REP_071,2024-01-23,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002778,HCP_02476,REP_074,2024-01-07,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002779,HCP_01212,REP_023,2024-01-30,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_002780,HCP_00855,REP_025,2024-05-01,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_002781,HCP_00781,REP_018,2024-02-16,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002782,HCP_01770,REP_038,2024-04-06,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_002783,HCP_01847,REP_046,2024-03-29,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_002784,HCP_00624,REP_047,2024-02-02,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002785,HCP_02771,REP_040,2024-01-17,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002786,HCP_02140,REP_069,2024-01-05,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_002787,HCP_01826,REP_056,2024-01-11,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002788,HCP_03723,REP_032,2024-01-04,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002789,HCP_00213,REP_031,2024-01-08,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002790,HCP_01391,REP_035,2024-01-18,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_002791,HCP_00771,REP_034,2024-01-06,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_002792,HCP_04308,REP_036,2024-04-12,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002793,HCP_03503,REP_020,2024-08-17,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_002794,HCP_03090,REP_049,2024-01-13,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002795,HCP_00880,REP_031,2024-01-06,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_002796,HCP_04009,REP_032,2024-01-11,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002797,HCP_00147,REP_001,2024-03-01,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002798,HCP_03490,REP_024,2024-02-08,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_002799,HCP_01838,REP_053,2024-01-09,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002800,HCP_01788,REP_029,2024-01-28,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002801,HCP_00075,REP_070,2024-02-10,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_002802,HCP_04746,REP_028,2024-01-10,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_002803,HCP_01851,REP_053,2024-02-13,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_002804,HCP_02195,REP_071,2024-01-11,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_002805,HCP_03958,REP_011,2024-01-26,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_002806,HCP_04871,REP_072,2024-01-05,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_002807,HCP_03492,REP_028,2024-01-20,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002808,HCP_00217,REP_001,2024-01-06,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002809,HCP_03287,REP_069,2024-01-16,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_002810,HCP_00926,REP_001,2024-02-29,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_002811,HCP_04109,REP_012,2024-01-03,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002812,HCP_03444,REP_052,2024-02-22,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_002813,HCP_03696,REP_048,2024-01-25,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002814,HCP_02129,REP_075,2024-03-09,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002815,HCP_03606,REP_034,2024-01-04,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_002816,HCP_04001,REP_064,2024-03-20,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002817,HCP_01340,REP_059,2024-04-06,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002818,HCP_04686,REP_001,2024-04-02,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002819,HCP_04190,REP_060,2024-01-11,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_002820,HCP_03102,REP_026,2024-01-03,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002821,HCP_03851,REP_068,2024-05-15,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_002822,HCP_03988,REP_057,2024-01-20,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002823,HCP_01222,REP_051,2024-01-02,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_002824,HCP_01486,REP_044,2024-03-07,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_002825,HCP_00299,REP_006,2024-02-12,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_002826,HCP_02550,REP_041,2024-03-13,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_002827,HCP_02417,REP_002,2024-02-15,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_002828,HCP_01376,REP_061,2024-03-06,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002829,HCP_02177,REP_051,2024-03-01,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_002830,HCP_00521,REP_021,2024-01-31,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002831,HCP_02636,REP_032,2024-01-19,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_002832,HCP_04845,REP_066,2024-01-23,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_002833,HCP_00984,REP_016,2024-03-23,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002834,HCP_01106,REP_007,2024-02-21,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_002835,HCP_01885,REP_056,2024-03-27,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002836,HCP_00156,REP_057,2024-02-12,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002837,HCP_01020,REP_003,2024-01-09,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002838,HCP_02481,REP_060,2024-01-21,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_002839,HCP_00419,REP_029,2024-01-02,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002840,HCP_01789,REP_062,2024-01-03,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_002841,HCP_01811,REP_060,2024-01-26,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_002842,HCP_02958,REP_018,2024-01-06,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_002843,HCP_04345,REP_033,2024-01-26,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002844,HCP_02889,REP_050,2024-01-01,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_002845,HCP_03867,REP_012,2024-01-15,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_002846,HCP_00832,REP_065,2024-01-25,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002847,HCP_04343,REP_055,2024-04-11,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002848,HCP_04892,REP_036,2024-02-25,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002849,HCP_04490,REP_025,2024-01-20,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_002850,HCP_00644,REP_020,2024-04-07,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002851,HCP_00550,REP_006,2024-04-16,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002852,HCP_03371,REP_022,2024-02-29,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_002853,HCP_00809,REP_069,2024-04-29,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002854,HCP_03891,REP_031,2024-01-16,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002855,HCP_01619,REP_067,2024-03-22,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_002856,HCP_01473,REP_019,2024-03-01,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_002857,HCP_04227,REP_068,2024-01-29,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_002858,HCP_03933,REP_075,2024-01-20,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002859,HCP_00595,REP_011,2024-01-18,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002860,HCP_04891,REP_030,2024-01-05,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_002861,HCP_01388,REP_025,2024-02-09,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_002862,HCP_03811,REP_001,2024-02-22,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_002863,HCP_04328,REP_053,2024-01-24,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002864,HCP_02020,REP_077,2024-01-01,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002865,HCP_00669,REP_050,2024-02-15,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002866,HCP_03210,REP_070,2024-02-28,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002867,HCP_01860,REP_055,2024-01-02,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_002868,HCP_01828,REP_076,2024-01-04,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_002869,HCP_04949,REP_007,2024-01-16,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_002870,HCP_04422,REP_037,2024-03-02,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002871,HCP_00753,REP_037,2024-02-01,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_002872,HCP_04128,REP_059,2024-01-31,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_002873,HCP_03083,REP_061,2024-02-11,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_002874,HCP_00218,REP_037,2024-01-07,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002875,HCP_01276,REP_073,2024-02-27,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002876,HCP_02386,REP_078,2024-01-05,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_002877,HCP_00992,REP_047,2024-01-19,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002878,HCP_02824,REP_016,2024-02-01,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_002879,HCP_03326,REP_039,2024-02-07,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_002880,HCP_02283,REP_049,2024-01-11,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002881,HCP_01865,REP_036,2024-02-14,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_002882,HCP_00424,REP_042,2024-01-14,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_002883,HCP_00050,REP_002,2024-01-06,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002884,HCP_02884,REP_035,2024-01-21,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_002885,HCP_04044,REP_007,2024-02-25,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_002886,HCP_00720,REP_028,2024-01-27,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002887,HCP_00716,REP_017,2024-01-15,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002888,HCP_02300,REP_042,2024-01-07,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002889,HCP_01454,REP_033,2024-04-09,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002890,HCP_03089,REP_031,2024-03-14,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_002891,HCP_00562,REP_059,2024-01-16,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_002892,HCP_00127,REP_051,2024-03-06,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002893,HCP_00137,REP_044,2024-03-07,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_002894,HCP_03253,REP_061,2024-03-07,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002895,HCP_02121,REP_066,2024-02-25,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002896,HCP_02434,REP_005,2024-02-28,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_002897,HCP_04515,REP_022,2024-01-14,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_002898,HCP_00815,REP_046,2024-04-24,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_002899,HCP_04181,REP_051,2024-03-17,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_002900,HCP_00556,REP_018,2024-01-03,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_002901,HCP_00573,REP_069,2024-01-04,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002902,HCP_01284,REP_010,2024-01-28,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002903,HCP_00752,REP_051,2024-04-15,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_002904,HCP_01347,REP_074,2024-02-04,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_002905,HCP_03528,REP_077,2024-01-04,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_002906,HCP_03625,REP_046,2024-01-23,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_002907,HCP_02494,REP_062,2024-07-20,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002908,HCP_03215,REP_022,2024-01-03,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002909,HCP_03988,REP_007,2024-02-12,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002910,HCP_01741,REP_046,2024-02-14,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002911,HCP_03083,REP_019,2024-01-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002912,HCP_04666,REP_072,2024-02-18,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002913,HCP_04277,REP_052,2024-01-08,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_002914,HCP_01857,REP_002,2024-01-19,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002915,HCP_04542,REP_059,2024-01-16,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002916,HCP_02566,REP_062,2024-01-06,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_002917,HCP_00093,REP_068,2024-02-01,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002918,HCP_04913,REP_031,2024-02-18,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_002919,HCP_03939,REP_042,2024-01-14,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_002920,HCP_02398,REP_071,2024-01-01,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002921,HCP_04592,REP_006,2024-03-01,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_002922,HCP_01216,REP_020,2024-04-14,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_002923,HCP_01496,REP_070,2024-01-19,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002924,HCP_02075,REP_025,2024-01-09,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_002925,HCP_00738,REP_052,2024-03-18,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_002926,HCP_04162,REP_041,2024-02-01,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002927,HCP_02883,REP_006,2024-01-06,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002928,HCP_00905,REP_005,2024-01-14,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002929,HCP_03552,REP_069,2024-01-11,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_002930,HCP_03849,REP_009,2024-01-28,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_002931,HCP_04644,REP_010,2024-04-19,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002932,HCP_04324,REP_061,2024-01-16,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002933,HCP_03309,REP_039,2024-01-10,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_002934,HCP_00196,REP_073,2024-01-08,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002935,HCP_02759,REP_038,2024-05-23,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002936,HCP_04489,REP_060,2024-03-14,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_002937,HCP_03603,REP_001,2024-04-09,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_002938,HCP_01614,REP_005,2024-02-19,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_002939,HCP_01762,REP_008,2024-02-10,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_002940,HCP_02987,REP_050,2024-02-19,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002941,HCP_04356,REP_044,2024-02-22,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_002942,HCP_04081,REP_017,2024-01-02,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_002943,HCP_02390,REP_029,2024-01-10,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002944,HCP_03814,REP_017,2024-01-21,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_002945,HCP_01160,REP_077,2024-02-09,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_002946,HCP_02647,REP_056,2024-01-22,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002947,HCP_02385,REP_040,2024-02-04,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_002948,HCP_04567,REP_003,2024-01-01,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_002949,HCP_00159,REP_037,2024-01-09,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002950,HCP_03644,REP_053,2024-03-04,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_002951,HCP_01238,REP_077,2024-01-17,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002952,HCP_02772,REP_002,2024-03-29,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002953,HCP_04196,REP_072,2024-01-02,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_002954,HCP_01481,REP_068,2024-02-12,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_002955,HCP_01580,REP_078,2024-01-06,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_002956,HCP_02404,REP_016,2024-01-12,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002957,HCP_03197,REP_075,2024-01-19,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002958,HCP_02350,REP_025,2024-02-25,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_002959,HCP_02166,REP_021,2024-01-02,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002960,HCP_00251,REP_000,2024-01-05,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002961,HCP_01909,REP_043,2024-01-09,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002962,HCP_01181,REP_001,2024-01-02,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_002963,HCP_00059,REP_041,2024-01-13,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002964,HCP_00090,REP_030,2024-01-05,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_002965,HCP_02174,REP_066,2024-02-23,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_002966,HCP_02194,REP_055,2024-02-04,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_002967,HCP_03769,REP_011,2024-02-19,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_002968,HCP_00200,REP_032,2024-01-30,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_002969,HCP_02455,REP_021,2024-02-08,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_002970,HCP_00920,REP_074,2024-01-26,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002971,HCP_04299,REP_025,2024-01-07,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_002972,HCP_02699,REP_054,2024-04-18,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_002973,HCP_03245,REP_078,2024-02-21,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_002974,HCP_04435,REP_076,2024-01-30,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_002975,HCP_03607,REP_008,2024-01-13,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002976,HCP_03265,REP_028,2024-02-02,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002977,HCP_02373,REP_077,2024-04-26,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_002978,HCP_03950,REP_052,2024-03-24,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_002979,HCP_00917,REP_035,2024-01-09,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_002980,HCP_03349,REP_053,2024-01-17,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_002981,HCP_04177,REP_057,2024-03-05,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_002982,HCP_04171,REP_075,2024-02-04,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_002983,HCP_00256,REP_003,2024-01-13,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_002984,HCP_04189,REP_038,2024-01-06,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_002985,HCP_02721,REP_073,2024-01-13,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_002986,HCP_04051,REP_030,2024-03-15,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_002987,HCP_02674,REP_024,2024-01-08,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_002988,HCP_04292,REP_067,2024-01-20,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_002989,HCP_04797,REP_059,2024-01-06,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002990,HCP_04661,REP_077,2024-02-28,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_002991,HCP_01414,REP_046,2024-02-01,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_002992,HCP_00603,REP_054,2024-01-25,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_002993,HCP_04728,REP_079,2024-03-15,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002994,HCP_01699,REP_034,2024-01-28,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_002995,HCP_03163,REP_042,2024-01-26,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_002996,HCP_04603,REP_054,2024-01-01,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_002997,HCP_03418,REP_024,2024-01-27,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_002998,HCP_00227,REP_074,2024-01-03,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_002999,HCP_02918,REP_057,2024-02-15,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_003000,HCP_03579,REP_017,2024-02-17,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003001,HCP_04011,REP_047,2024-01-04,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_003002,HCP_00981,REP_070,2024-02-21,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003003,HCP_03959,REP_007,2024-01-05,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_003004,HCP_01615,REP_004,2024-01-08,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_003005,HCP_03186,REP_014,2024-01-05,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003006,HCP_00803,REP_048,2024-01-14,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003007,HCP_02227,REP_053,2024-02-07,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_003008,HCP_00966,REP_024,2024-01-01,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_003009,HCP_00119,REP_068,2024-02-05,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003010,HCP_01941,REP_041,2024-04-05,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_003011,HCP_01312,REP_075,2024-01-22,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003012,HCP_01767,REP_039,2024-08-24,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_003013,HCP_01616,REP_008,2024-03-09,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_003014,HCP_04892,REP_003,2024-01-09,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_003015,HCP_04638,REP_058,2024-05-24,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_003016,HCP_02692,REP_017,2024-01-25,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003017,HCP_02058,REP_006,2024-03-12,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003018,HCP_01041,REP_003,2024-02-29,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_003019,HCP_03613,REP_071,2024-02-11,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_003020,HCP_01232,REP_001,2024-01-08,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_003021,HCP_02815,REP_073,2024-01-13,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_003022,HCP_04861,REP_010,2024-01-13,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003023,HCP_01433,REP_067,2024-05-18,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_003024,HCP_03369,REP_018,2024-02-10,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_003025,HCP_03866,REP_073,2024-02-08,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003026,HCP_04272,REP_069,2024-01-23,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003027,HCP_01849,REP_018,2024-01-25,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_003028,HCP_03463,REP_078,2024-01-31,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003029,HCP_03206,REP_027,2024-02-13,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003030,HCP_02568,REP_029,2024-02-14,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_003031,HCP_03669,REP_011,2024-02-09,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_003032,HCP_00638,REP_046,2024-05-02,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003033,HCP_01548,REP_029,2024-03-26,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_003034,HCP_04914,REP_016,2024-02-23,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_003035,HCP_03369,REP_068,2024-01-04,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_003036,HCP_03276,REP_031,2024-01-05,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_003037,HCP_04599,REP_063,2024-01-11,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_003038,HCP_04957,REP_056,2024-01-12,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003039,HCP_01629,REP_022,2024-01-22,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003040,HCP_00897,REP_029,2024-01-30,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003041,HCP_03216,REP_011,2024-01-20,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003042,HCP_04911,REP_021,2024-01-03,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_003043,HCP_00945,REP_068,2024-01-06,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003044,HCP_00778,REP_062,2024-05-02,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_003045,HCP_01598,REP_008,2024-01-05,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003046,HCP_03455,REP_049,2024-01-30,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003047,HCP_01137,REP_052,2024-03-14,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003048,HCP_00178,REP_076,2024-01-17,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003049,HCP_02448,REP_022,2024-01-31,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_003050,HCP_03497,REP_055,2024-01-23,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003051,HCP_04402,REP_079,2024-02-29,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003052,HCP_00974,REP_025,2024-02-18,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003053,HCP_04150,REP_018,2024-01-10,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003054,HCP_02481,REP_026,2024-05-05,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_003055,HCP_03035,REP_031,2024-01-17,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_003056,HCP_00000,REP_021,2024-03-30,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003057,HCP_04271,REP_015,2024-01-28,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_003058,HCP_00508,REP_073,2024-01-15,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_003059,HCP_04080,REP_009,2024-05-05,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_003060,HCP_01008,REP_005,2024-01-10,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_003061,HCP_01440,REP_022,2024-02-07,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003062,HCP_01588,REP_029,2024-03-16,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003063,HCP_01571,REP_076,2024-01-11,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003064,HCP_03382,REP_033,2024-02-23,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_003065,HCP_02702,REP_053,2025-01-02,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_003066,HCP_00205,REP_052,2024-01-25,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_003067,HCP_00513,REP_025,2024-03-17,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_003068,HCP_02691,REP_054,2024-02-11,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_003069,HCP_04268,REP_057,2024-03-16,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003070,HCP_02448,REP_011,2024-01-12,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_003071,HCP_04237,REP_030,2024-01-10,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003072,HCP_04024,REP_002,2024-01-28,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003073,HCP_03155,REP_075,2024-01-22,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_003074,HCP_02200,REP_042,2024-01-02,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003075,HCP_00157,REP_013,2024-01-15,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_003076,HCP_01539,REP_026,2024-01-17,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_003077,HCP_04730,REP_056,2024-01-22,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_003078,HCP_04059,REP_075,2024-01-06,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003079,HCP_02159,REP_006,2024-01-08,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003080,HCP_03123,REP_034,2024-02-19,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_003081,HCP_01559,REP_076,2024-01-15,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003082,HCP_01993,REP_058,2024-04-01,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_003083,HCP_03268,REP_073,2024-04-05,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003084,HCP_00207,REP_039,2024-01-08,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_003085,HCP_02916,REP_010,2024-01-18,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003086,HCP_04860,REP_067,2024-01-29,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003087,HCP_02617,REP_056,2024-02-08,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003088,HCP_03732,REP_073,2024-01-14,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_003089,HCP_00889,REP_052,2024-01-07,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003090,HCP_03546,REP_047,2024-01-20,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_003091,HCP_01476,REP_037,2024-05-06,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_003092,HCP_01918,REP_042,2024-01-25,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_003093,HCP_03788,REP_025,2024-01-19,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003094,HCP_04240,REP_010,2024-03-01,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003095,HCP_00691,REP_059,2024-02-04,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003096,HCP_00563,REP_058,2024-03-09,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003097,HCP_01873,REP_060,2024-03-06,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_003098,HCP_00802,REP_054,2024-02-08,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_003099,HCP_03697,REP_065,2024-01-05,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003100,HCP_04000,REP_032,2024-01-02,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003101,HCP_00512,REP_039,2024-01-30,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_003102,HCP_04347,REP_033,2024-01-04,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_003103,HCP_02023,REP_035,2024-01-17,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003104,HCP_02049,REP_002,2024-06-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003105,HCP_00320,REP_050,2024-01-14,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003106,HCP_01542,REP_060,2024-01-19,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003107,HCP_04168,REP_069,2024-01-08,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_003108,HCP_00297,REP_004,2024-01-02,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003109,HCP_02463,REP_055,2024-01-08,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_003110,HCP_01347,REP_033,2024-02-20,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003111,HCP_01748,REP_047,2024-03-06,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_003112,HCP_01131,REP_027,2024-04-06,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003113,HCP_00768,REP_003,2024-02-17,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_003114,HCP_04182,REP_020,2024-01-01,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_003115,HCP_00839,REP_047,2024-01-24,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003116,HCP_02401,REP_038,2024-01-12,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003117,HCP_00809,REP_075,2024-02-26,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_003118,HCP_01080,REP_029,2024-01-08,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_003119,HCP_01888,REP_051,2024-02-26,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003120,HCP_02090,REP_015,2024-02-27,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_003121,HCP_03569,REP_039,2024-02-26,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003122,HCP_04769,REP_074,2024-02-06,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_003123,HCP_02988,REP_052,2024-03-04,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_003124,HCP_02118,REP_073,2024-01-28,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_003125,HCP_00496,REP_046,2024-04-17,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_003126,HCP_04934,REP_008,2024-01-16,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003127,HCP_02226,REP_068,2024-02-14,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003128,HCP_01409,REP_008,2024-01-29,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003129,HCP_03179,REP_047,2024-01-27,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003130,HCP_03125,REP_014,2024-03-13,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003131,HCP_04088,REP_050,2024-02-27,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_003132,HCP_04758,REP_025,2024-01-29,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003133,HCP_03367,REP_069,2024-01-23,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_003134,HCP_03126,REP_040,2024-02-09,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003135,HCP_04424,REP_021,2024-01-03,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_003136,HCP_03027,REP_046,2024-06-14,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003137,HCP_02770,REP_016,2024-02-14,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003138,HCP_04781,REP_005,2024-01-28,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_003139,HCP_03477,REP_075,2024-04-21,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_003140,HCP_02176,REP_055,2024-04-14,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003141,HCP_02523,REP_006,2024-01-03,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_003142,HCP_01834,REP_004,2024-01-11,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_003143,HCP_04028,REP_071,2024-04-14,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003144,HCP_03918,REP_010,2024-01-17,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_003145,HCP_01948,REP_049,2024-01-28,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003146,HCP_01786,REP_025,2024-01-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003147,HCP_00040,REP_078,2024-01-20,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003148,HCP_01489,REP_005,2024-02-04,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_003149,HCP_00285,REP_042,2024-01-07,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_003150,HCP_03725,REP_045,2024-01-23,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003151,HCP_04464,REP_041,2024-01-25,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_003152,HCP_03906,REP_055,2024-01-22,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_003153,HCP_02392,REP_054,2024-01-14,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003154,HCP_00460,REP_012,2024-01-27,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003155,HCP_04534,REP_040,2024-01-23,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_003156,HCP_03289,REP_005,2024-02-03,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_003157,HCP_01054,REP_065,2024-01-06,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_003158,HCP_01822,REP_055,2024-02-15,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_003159,HCP_04980,REP_039,2024-01-02,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003160,HCP_00685,REP_065,2024-01-08,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_003161,HCP_01817,REP_008,2024-01-24,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003162,HCP_03857,REP_007,2024-01-30,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003163,HCP_00726,REP_069,2024-01-01,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003164,HCP_04354,REP_073,2024-01-07,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_003165,HCP_02510,REP_052,2024-02-18,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_003166,HCP_02372,REP_033,2024-02-26,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_003167,HCP_00310,REP_053,2024-02-02,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_003168,HCP_04869,REP_077,2024-01-16,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_003169,HCP_01787,REP_018,2024-01-06,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_003170,HCP_00780,REP_076,2024-01-21,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_003171,HCP_01179,REP_046,2024-01-10,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_003172,HCP_04754,REP_015,2024-03-28,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003173,HCP_02439,REP_078,2024-01-19,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003174,HCP_01191,REP_051,2024-02-03,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_003175,HCP_04744,REP_019,2024-01-25,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_003176,HCP_04248,REP_034,2024-03-04,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_003177,HCP_01542,REP_013,2024-01-21,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003178,HCP_03192,REP_002,2024-03-14,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_003179,HCP_03791,REP_043,2024-01-19,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003180,HCP_02298,REP_011,2024-01-21,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003181,HCP_01234,REP_070,2024-01-26,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003182,HCP_03715,REP_065,2024-01-29,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_003183,HCP_00409,REP_018,2024-01-16,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003184,HCP_04143,REP_059,2024-01-30,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_003185,HCP_04852,REP_048,2024-02-09,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_003186,HCP_01098,REP_028,2024-01-18,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003187,HCP_04269,REP_048,2024-04-04,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_003188,HCP_01761,REP_021,2024-02-23,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003189,HCP_03864,REP_048,2024-04-19,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003190,HCP_00084,REP_008,2024-03-26,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003191,HCP_00083,REP_063,2024-02-19,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003192,HCP_02597,REP_052,2024-03-24,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_003193,HCP_02411,REP_059,2024-05-21,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003194,HCP_04663,REP_003,2024-02-02,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_003195,HCP_03842,REP_057,2024-03-18,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_003196,HCP_04854,REP_068,2024-03-22,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003197,HCP_03805,REP_009,2024-04-16,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_003198,HCP_03883,REP_025,2024-03-20,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_003199,HCP_01736,REP_056,2024-03-28,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003200,HCP_01888,REP_017,2024-02-01,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_003201,HCP_04063,REP_042,2024-02-21,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_003202,HCP_01274,REP_058,2024-04-18,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003203,HCP_03406,REP_062,2024-01-03,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003204,HCP_01326,REP_057,2024-01-21,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003205,HCP_00361,REP_059,2024-05-20,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003206,HCP_04486,REP_043,2024-05-05,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_003207,HCP_04465,REP_005,2024-01-01,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_003208,HCP_04806,REP_009,2024-02-16,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_003209,HCP_04016,REP_032,2024-02-07,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003210,HCP_00293,REP_039,2024-02-12,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_003211,HCP_04092,REP_067,2024-04-17,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_003212,HCP_03358,REP_000,2024-03-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003213,HCP_03477,REP_001,2024-04-08,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003214,HCP_01199,REP_029,2024-01-17,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_003215,HCP_04634,REP_048,2024-03-08,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_003216,HCP_00629,REP_010,2024-04-21,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003217,HCP_00100,REP_039,2024-05-15,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003218,HCP_04128,REP_073,2024-01-05,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_003219,HCP_04154,REP_063,2024-01-02,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_003220,HCP_02820,REP_077,2024-02-04,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003221,HCP_04707,REP_001,2024-01-23,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003222,HCP_02398,REP_052,2024-03-22,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_003223,HCP_02517,REP_015,2024-03-17,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_003224,HCP_03976,REP_074,2024-01-08,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003225,HCP_02185,REP_068,2024-02-05,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003226,HCP_00167,REP_013,2024-02-03,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_003227,HCP_01163,REP_058,2024-03-08,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003228,HCP_04438,REP_015,2024-01-10,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003229,HCP_03079,REP_008,2024-01-11,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_003230,HCP_01364,REP_069,2024-01-31,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003231,HCP_01167,REP_036,2024-03-05,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_003232,HCP_04573,REP_012,2024-01-08,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_003233,HCP_02187,REP_062,2024-02-07,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_003234,HCP_01455,REP_072,2024-01-27,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003235,HCP_03536,REP_042,2024-01-01,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_003236,HCP_02591,REP_031,2024-02-11,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003237,HCP_01799,REP_027,2024-01-23,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003238,HCP_04674,REP_059,2024-01-03,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003239,HCP_00605,REP_039,2024-01-10,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_003240,HCP_01213,REP_055,2024-01-11,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_003241,HCP_02190,REP_010,2024-01-07,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_003242,HCP_01615,REP_001,2024-01-15,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003243,HCP_01177,REP_076,2024-01-14,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003244,HCP_03007,REP_071,2024-02-05,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_003245,HCP_01823,REP_015,2024-01-23,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003246,HCP_04936,REP_049,2024-02-29,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003247,HCP_01784,REP_060,2024-02-05,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_003248,HCP_00792,REP_075,2024-01-03,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_003249,HCP_02063,REP_013,2024-01-02,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003250,HCP_02020,REP_040,2024-02-21,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_003251,HCP_04783,REP_078,2024-02-07,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_003252,HCP_03492,REP_042,2024-02-13,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_003253,HCP_04050,REP_040,2024-01-12,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_003254,HCP_00658,REP_001,2024-02-21,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_003255,HCP_04432,REP_028,2024-01-18,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003256,HCP_02952,REP_025,2024-03-13,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_003257,HCP_00017,REP_001,2024-02-04,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003258,HCP_01218,REP_046,2024-01-25,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_003259,HCP_01098,REP_014,2024-01-06,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_003260,HCP_02499,REP_062,2024-01-30,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_003261,HCP_00428,REP_060,2024-01-27,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_003262,HCP_00084,REP_007,2024-02-15,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_003263,HCP_01439,REP_016,2024-01-05,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_003264,HCP_04178,REP_003,2024-01-12,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003265,HCP_01487,REP_003,2024-02-26,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_003266,HCP_01087,REP_041,2024-01-08,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003267,HCP_02932,REP_057,2024-01-08,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003268,HCP_02578,REP_002,2024-03-16,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_003269,HCP_01746,REP_032,2024-01-22,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003270,HCP_00625,REP_014,2024-01-19,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003271,HCP_03077,REP_074,2024-01-05,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_003272,HCP_04779,REP_043,2024-01-12,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003273,HCP_00518,REP_060,2024-01-16,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003274,HCP_01940,REP_032,2024-01-28,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003275,HCP_01880,REP_040,2024-01-06,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_003276,HCP_01375,REP_055,2024-01-01,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_003277,HCP_03147,REP_021,2024-03-15,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003278,HCP_02881,REP_014,2024-04-18,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_003279,HCP_02419,REP_042,2024-01-14,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_003280,HCP_00726,REP_067,2024-02-09,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003281,HCP_01464,REP_062,2024-05-08,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_003282,HCP_01869,REP_019,2024-02-11,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_003283,HCP_03498,REP_061,2024-01-10,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003284,HCP_04524,REP_024,2024-01-21,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003285,HCP_00951,REP_042,2024-02-18,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_003286,HCP_02105,REP_005,2024-02-12,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_003287,HCP_04412,REP_025,2024-01-02,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003288,HCP_02986,REP_029,2024-02-10,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003289,HCP_04904,REP_010,2024-01-09,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003290,HCP_01500,REP_078,2024-01-26,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_003291,HCP_04568,REP_033,2024-01-14,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003292,HCP_02798,REP_005,2024-01-04,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003293,HCP_00140,REP_007,2024-04-07,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003294,HCP_03609,REP_028,2024-02-29,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_003295,HCP_01465,REP_011,2024-02-20,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_003296,HCP_01628,REP_061,2024-01-19,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_003297,HCP_00872,REP_032,2024-01-30,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003298,HCP_04518,REP_038,2024-01-24,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_003299,HCP_02335,REP_034,2024-01-18,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003300,HCP_00614,REP_009,2024-04-23,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003301,HCP_02160,REP_061,2024-03-08,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003302,HCP_01961,REP_002,2024-01-01,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003303,HCP_00228,REP_040,2024-01-09,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_003304,HCP_04378,REP_039,2024-02-05,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003305,HCP_04179,REP_029,2024-07-20,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_003306,HCP_04940,REP_042,2024-03-12,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_003307,HCP_00980,REP_000,2024-03-27,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_003308,HCP_00024,REP_035,2024-01-13,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003309,HCP_00295,REP_003,2024-03-03,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_003310,HCP_00781,REP_035,2024-01-09,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_003311,HCP_03812,REP_079,2024-02-16,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003312,HCP_02420,REP_044,2024-01-08,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003313,HCP_04243,REP_026,2024-01-27,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_003314,HCP_02518,REP_010,2024-03-08,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_003315,HCP_02656,REP_014,2024-01-08,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003316,HCP_01794,REP_053,2024-02-17,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003317,HCP_01140,REP_078,2024-01-11,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003318,HCP_02249,REP_078,2024-01-19,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003319,HCP_03021,REP_027,2024-02-28,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003320,HCP_03651,REP_002,2024-04-30,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003321,HCP_01234,REP_074,2024-01-17,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003322,HCP_03907,REP_051,2024-02-11,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_003323,HCP_01610,REP_073,2024-04-23,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003324,HCP_03721,REP_014,2024-04-01,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_003325,HCP_00079,REP_026,2024-02-14,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_003326,HCP_03744,REP_067,2024-01-11,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_003327,HCP_00712,REP_023,2024-02-11,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003328,HCP_03269,REP_025,2024-01-05,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003329,HCP_00168,REP_060,2024-03-05,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003330,HCP_00064,REP_053,2024-01-11,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003331,HCP_04326,REP_004,2024-01-31,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003332,HCP_03778,REP_013,2024-03-05,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003333,HCP_01050,REP_015,2024-01-20,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_003334,HCP_04809,REP_041,2024-01-18,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_003335,HCP_02116,REP_011,2024-01-08,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_003336,HCP_03149,REP_012,2024-01-28,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003337,HCP_00583,REP_060,2024-01-12,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003338,HCP_03949,REP_062,2024-01-23,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003339,HCP_00183,REP_023,2024-04-28,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_003340,HCP_03652,REP_022,2024-02-25,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003341,HCP_00082,REP_047,2024-01-15,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_003342,HCP_04865,REP_063,2024-05-17,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003343,HCP_03310,REP_041,2024-01-09,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_003344,HCP_01664,REP_069,2024-06-12,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_003345,HCP_03187,REP_036,2024-01-30,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003346,HCP_00528,REP_063,2024-01-28,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003347,HCP_00677,REP_036,2024-01-14,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003348,HCP_02557,REP_021,2024-02-26,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_003349,HCP_03717,REP_056,2024-02-17,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_003350,HCP_00287,REP_031,2024-01-14,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003351,HCP_02457,REP_067,2024-02-01,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003352,HCP_00656,REP_051,2024-01-18,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003353,HCP_00890,REP_005,2024-02-10,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_003354,HCP_01115,REP_063,2024-02-16,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003355,HCP_01181,REP_001,2024-01-01,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_003356,HCP_04674,REP_062,2024-01-20,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_003357,HCP_00306,REP_000,2024-01-26,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003358,HCP_02883,REP_054,2024-01-06,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_003359,HCP_01827,REP_013,2024-02-03,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_003360,HCP_00409,REP_077,2024-01-20,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003361,HCP_03276,REP_015,2024-01-19,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003362,HCP_00538,REP_002,2024-02-06,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_003363,HCP_01529,REP_056,2024-01-08,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003364,HCP_01304,REP_058,2024-02-02,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003365,HCP_03042,REP_005,2024-01-10,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_003366,HCP_02486,REP_017,2024-02-25,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003367,HCP_00900,REP_039,2024-02-03,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003368,HCP_01818,REP_027,2024-02-28,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003369,HCP_04250,REP_003,2024-01-31,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_003370,HCP_01757,REP_030,2024-01-08,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_003371,HCP_02854,REP_062,2024-04-01,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_003372,HCP_04732,REP_028,2024-02-07,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_003373,HCP_01578,REP_072,2024-02-18,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_003374,HCP_01531,REP_003,2024-01-17,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003375,HCP_00696,REP_068,2024-01-03,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003376,HCP_02660,REP_056,2024-04-03,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003377,HCP_02587,REP_039,2024-03-14,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_003378,HCP_00450,REP_057,2024-02-11,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003379,HCP_02117,REP_068,2024-02-06,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003380,HCP_04562,REP_073,2024-01-14,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003381,HCP_03070,REP_059,2024-01-20,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_003382,HCP_01802,REP_016,2024-02-13,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003383,HCP_00869,REP_014,2024-03-03,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003384,HCP_03774,REP_048,2024-01-25,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_003385,HCP_03443,REP_059,2024-01-14,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003386,HCP_02150,REP_060,2024-04-04,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_003387,HCP_04395,REP_028,2024-03-08,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_003388,HCP_02673,REP_076,2024-02-01,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_003389,HCP_04793,REP_045,2024-01-03,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003390,HCP_01869,REP_008,2024-02-01,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_003391,HCP_00902,REP_015,2024-01-06,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_003392,HCP_01763,REP_052,2024-03-10,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_003393,HCP_00472,REP_060,2024-01-20,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_003394,HCP_01146,REP_002,2024-01-07,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_003395,HCP_01070,REP_013,2024-01-18,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_003396,HCP_03392,REP_039,2024-02-03,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_003397,HCP_04098,REP_024,2024-02-24,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_003398,HCP_01596,REP_030,2024-04-06,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003399,HCP_03254,REP_055,2024-02-14,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_003400,HCP_04370,REP_010,2024-01-14,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003401,HCP_03956,REP_047,2024-03-05,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_003402,HCP_01377,REP_036,2024-01-14,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003403,HCP_01647,REP_015,2024-02-18,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003404,HCP_02763,REP_051,2024-02-03,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_003405,HCP_00460,REP_039,2024-01-01,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_003406,HCP_03957,REP_053,2024-01-28,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003407,HCP_02644,REP_078,2024-01-02,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003408,HCP_02355,REP_067,2024-02-21,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003409,HCP_02020,REP_034,2024-01-19,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_003410,HCP_02971,REP_027,2024-01-01,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003411,HCP_00089,REP_026,2024-01-08,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_003412,HCP_00583,REP_054,2024-02-15,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003413,HCP_01560,REP_032,2024-04-05,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_003414,HCP_02587,REP_050,2024-01-09,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003415,HCP_03687,REP_072,2024-05-01,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003416,HCP_03658,REP_005,2024-01-04,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_003417,HCP_02393,REP_009,2024-02-27,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003418,HCP_00535,REP_027,2024-01-24,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_003419,HCP_03063,REP_067,2024-01-05,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003420,HCP_00253,REP_045,2024-01-06,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003421,HCP_02240,REP_045,2024-01-30,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003422,HCP_00336,REP_010,2024-03-04,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_003423,HCP_04163,REP_024,2024-01-15,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_003424,HCP_04590,REP_067,2024-03-09,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003425,HCP_04107,REP_019,2024-02-28,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003426,HCP_01293,REP_043,2024-04-10,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_003427,HCP_02922,REP_035,2024-04-01,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003428,HCP_00100,REP_050,2024-01-09,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_003429,HCP_04472,REP_006,2024-02-13,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003430,HCP_02210,REP_022,2024-02-27,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003431,HCP_03101,REP_016,2024-01-07,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_003432,HCP_00070,REP_079,2024-01-18,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_003433,HCP_01281,REP_024,2024-01-12,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003434,HCP_03702,REP_038,2024-01-18,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003435,HCP_01216,REP_017,2024-04-07,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003436,HCP_02729,REP_018,2025-01-01,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_003437,HCP_03606,REP_016,2024-01-08,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_003438,HCP_03986,REP_055,2024-01-16,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003439,HCP_03603,REP_025,2024-01-21,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003440,HCP_00901,REP_053,2024-01-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003441,HCP_03674,REP_021,2024-01-07,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003442,HCP_01711,REP_060,2024-01-25,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003443,HCP_00079,REP_057,2024-02-28,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003444,HCP_04604,REP_063,2024-04-21,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003445,HCP_04023,REP_047,2024-01-02,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_003446,HCP_00657,REP_043,2024-02-12,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003447,HCP_00404,REP_018,2024-01-04,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_003448,HCP_04538,REP_025,2024-01-07,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003449,HCP_04421,REP_077,2024-01-01,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003450,HCP_02809,REP_048,2024-04-21,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003451,HCP_02944,REP_058,2024-01-12,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_003452,HCP_04116,REP_041,2024-02-01,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_003453,HCP_03706,REP_033,2024-01-13,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003454,HCP_04654,REP_051,2024-01-11,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003455,HCP_03883,REP_022,2024-01-17,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_003456,HCP_00605,REP_061,2024-03-11,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003457,HCP_00884,REP_045,2024-01-04,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_003458,HCP_04517,REP_046,2024-07-04,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003459,HCP_00271,REP_017,2024-01-12,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003460,HCP_02470,REP_031,2024-02-17,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_003461,HCP_01428,REP_007,2024-02-23,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_003462,HCP_03785,REP_013,2024-01-24,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003463,HCP_03321,REP_061,2024-01-19,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_003464,HCP_01667,REP_026,2024-01-08,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_003465,HCP_00667,REP_031,2024-01-17,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_003466,HCP_04802,REP_032,2024-03-11,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003467,HCP_03159,REP_048,2024-01-21,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003468,HCP_03488,REP_078,2024-03-15,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003469,HCP_00526,REP_001,2024-01-28,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003470,HCP_04522,REP_026,2024-01-05,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_003471,HCP_01356,REP_031,2024-01-23,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_003472,HCP_04993,REP_076,2024-01-18,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_003473,HCP_01199,REP_012,2024-02-18,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_003474,HCP_01695,REP_063,2024-03-17,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003475,HCP_02462,REP_040,2024-01-13,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_003476,HCP_00039,REP_075,2024-01-01,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003477,HCP_02392,REP_030,2024-01-18,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003478,HCP_00181,REP_077,2024-02-12,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003479,HCP_03005,REP_024,2024-01-07,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003480,HCP_04782,REP_045,2024-01-02,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_003481,HCP_02794,REP_042,2024-01-09,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_003482,HCP_00778,REP_008,2024-01-04,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_003483,HCP_04474,REP_003,2024-01-16,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_003484,HCP_00852,REP_047,2024-02-04,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_003485,HCP_00295,REP_038,2024-01-18,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_003486,HCP_01677,REP_048,2024-01-13,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003487,HCP_00144,REP_055,2024-01-08,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_003488,HCP_03097,REP_071,2024-02-11,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003489,HCP_04227,REP_047,2024-02-14,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_003490,HCP_03528,REP_008,2024-01-15,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_003491,HCP_02651,REP_079,2024-02-12,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003492,HCP_01254,REP_048,2024-03-17,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_003493,HCP_01498,REP_020,2024-03-30,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_003494,HCP_03811,REP_012,2024-01-20,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003495,HCP_04359,REP_028,2024-01-23,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003496,HCP_00241,REP_038,2024-01-11,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_003497,HCP_00150,REP_008,2024-01-06,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_003498,HCP_04469,REP_066,2024-01-04,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_003499,HCP_01378,REP_001,2024-01-13,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003500,HCP_03528,REP_078,2024-03-04,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003501,HCP_01654,REP_018,2024-01-15,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_003502,HCP_01312,REP_066,2024-01-01,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_003503,HCP_00197,REP_027,2024-04-15,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_003504,HCP_04315,REP_048,2024-01-11,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_003505,HCP_04452,REP_048,2024-03-04,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003506,HCP_02946,REP_009,2024-02-21,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_003507,HCP_00250,REP_023,2024-03-26,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003508,HCP_00158,REP_071,2024-01-05,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_003509,HCP_03054,REP_008,2024-03-01,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_003510,HCP_02493,REP_024,2024-02-07,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003511,HCP_00551,REP_028,2024-01-03,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003512,HCP_03180,REP_024,2024-01-25,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_003513,HCP_00799,REP_073,2024-01-17,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003514,HCP_02150,REP_000,2024-01-03,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003515,HCP_01763,REP_029,2024-01-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003516,HCP_01212,REP_011,2024-03-05,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_003517,HCP_01296,REP_019,2024-03-10,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_003518,HCP_00222,REP_034,2024-01-02,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_003519,HCP_04292,REP_060,2024-01-23,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003520,HCP_03083,REP_076,2024-03-10,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003521,HCP_00468,REP_054,2024-01-17,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003522,HCP_02898,REP_029,2024-01-16,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003523,HCP_00177,REP_053,2024-04-08,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_003524,HCP_04695,REP_021,2024-04-15,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_003525,HCP_01464,REP_066,2024-03-10,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_003526,HCP_04203,REP_049,2024-01-02,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_003527,HCP_00012,REP_058,2024-01-21,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003528,HCP_01694,REP_073,2024-04-13,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_003529,HCP_02413,REP_039,2024-01-19,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_003530,HCP_01971,REP_000,2024-02-16,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_003531,HCP_01469,REP_003,2024-03-06,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003532,HCP_03617,REP_027,2024-04-03,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_003533,HCP_00714,REP_076,2024-02-02,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_003534,HCP_00495,REP_042,2024-03-09,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003535,HCP_00688,REP_056,2024-02-24,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_003536,HCP_01226,REP_050,2024-01-12,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_003537,HCP_00454,REP_002,2024-01-07,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_003538,HCP_02902,REP_070,2024-02-21,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_003539,HCP_01740,REP_065,2024-04-01,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_003540,HCP_04254,REP_009,2024-02-28,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003541,HCP_03746,REP_068,2024-01-18,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_003542,HCP_03248,REP_026,2024-05-21,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_003543,HCP_01758,REP_017,2024-02-07,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003544,HCP_00956,REP_012,2024-01-04,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_003545,HCP_02366,REP_056,2024-01-01,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_003546,HCP_04589,REP_049,2024-02-15,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_003547,HCP_01138,REP_069,2024-02-01,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003548,HCP_02419,REP_062,2024-01-09,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_003549,HCP_04997,REP_013,2024-01-16,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_003550,HCP_00055,REP_005,2024-01-07,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_003551,HCP_04990,REP_063,2024-04-16,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003552,HCP_03019,REP_043,2024-02-16,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003553,HCP_01492,REP_069,2024-01-15,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_003554,HCP_04183,REP_034,2024-02-10,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003555,HCP_03986,REP_047,2024-01-11,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_003556,HCP_02703,REP_047,2024-01-16,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003557,HCP_04352,REP_050,2024-02-04,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003558,HCP_03930,REP_048,2024-03-31,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_003559,HCP_03471,REP_014,2024-01-18,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_003560,HCP_03279,REP_061,2024-01-31,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_003561,HCP_02508,REP_023,2024-01-14,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_003562,HCP_04041,REP_060,2024-01-19,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003563,HCP_00134,REP_071,2024-03-07,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003564,HCP_03363,REP_013,2024-02-24,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_003565,HCP_02332,REP_049,2024-06-19,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_003566,HCP_04135,REP_047,2024-01-02,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003567,HCP_00326,REP_077,2024-01-08,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003568,HCP_04098,REP_072,2024-03-23,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_003569,HCP_02174,REP_008,2024-02-03,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_003570,HCP_00957,REP_077,2024-01-14,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_003571,HCP_04382,REP_062,2024-05-16,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003572,HCP_00391,REP_057,2024-02-14,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003573,HCP_01009,REP_042,2024-02-07,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003574,HCP_00870,REP_067,2024-01-06,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003575,HCP_04229,REP_052,2024-03-19,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003576,HCP_02544,REP_047,2024-01-20,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003577,HCP_01299,REP_023,2024-01-28,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003578,HCP_02557,REP_011,2024-01-10,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003579,HCP_03026,REP_022,2024-01-26,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003580,HCP_01055,REP_027,2024-02-25,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003581,HCP_03564,REP_014,2024-03-07,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003582,HCP_03595,REP_072,2024-01-03,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_003583,HCP_01944,REP_065,2024-01-17,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003584,HCP_04873,REP_027,2024-01-01,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_003585,HCP_03893,REP_077,2024-05-26,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_003586,HCP_03828,REP_069,2024-04-19,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003587,HCP_01507,REP_018,2024-01-06,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003588,HCP_04862,REP_073,2024-01-02,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_003589,HCP_01959,REP_008,2024-01-27,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_003590,HCP_02489,REP_013,2024-06-12,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003591,HCP_04490,REP_038,2024-01-02,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003592,HCP_03424,REP_047,2024-01-05,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003593,HCP_03274,REP_054,2024-02-06,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_003594,HCP_02128,REP_017,2024-03-25,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003595,HCP_04628,REP_010,2024-04-04,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_003596,HCP_03725,REP_004,2024-01-10,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003597,HCP_03383,REP_015,2024-04-15,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_003598,HCP_04470,REP_006,2024-01-17,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_003599,HCP_04698,REP_002,2024-01-07,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_003600,HCP_02481,REP_029,2024-05-14,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003601,HCP_01952,REP_002,2024-01-20,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003602,HCP_04458,REP_021,2024-01-02,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003603,HCP_01552,REP_066,2024-01-03,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_003604,HCP_03502,REP_041,2024-03-03,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_003605,HCP_02512,REP_066,2024-03-16,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003606,HCP_02391,REP_077,2024-03-25,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_003607,HCP_02821,REP_078,2024-04-13,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003608,HCP_02368,REP_058,2024-03-13,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003609,HCP_03177,REP_070,2024-01-09,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_003610,HCP_04846,REP_064,2024-02-22,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003611,HCP_04909,REP_039,2024-05-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003612,HCP_04459,REP_005,2024-01-13,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003613,HCP_00840,REP_057,2024-02-24,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_003614,HCP_04210,REP_002,2024-01-12,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003615,HCP_01511,REP_034,2024-02-11,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_003616,HCP_03691,REP_041,2024-01-07,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003617,HCP_02090,REP_011,2024-05-01,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_003618,HCP_00338,REP_015,2024-01-23,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003619,HCP_02518,REP_029,2024-03-28,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_003620,HCP_03116,REP_034,2024-01-11,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_003621,HCP_02197,REP_035,2024-03-11,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003622,HCP_03109,REP_051,2024-03-22,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003623,HCP_00493,REP_018,2024-04-02,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_003624,HCP_03010,REP_049,2024-02-12,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003625,HCP_00609,REP_059,2024-02-10,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003626,HCP_02663,REP_071,2024-01-28,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003627,HCP_00350,REP_065,2024-01-27,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003628,HCP_00014,REP_069,2024-03-22,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_003629,HCP_00871,REP_072,2024-02-18,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_003630,HCP_01981,REP_044,2024-01-09,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003631,HCP_04712,REP_055,2024-01-09,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_003632,HCP_03919,REP_066,2024-03-09,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_003633,HCP_01103,REP_032,2024-01-02,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003634,HCP_01926,REP_064,2024-01-03,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_003635,HCP_01200,REP_028,2024-01-01,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_003636,HCP_00499,REP_002,2024-02-01,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_003637,HCP_02164,REP_021,2024-01-15,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003638,HCP_00703,REP_031,2024-02-03,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003639,HCP_01678,REP_001,2024-01-21,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_003640,HCP_00900,REP_033,2024-02-18,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_003641,HCP_00345,REP_061,2024-01-27,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003642,HCP_03155,REP_076,2024-02-29,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_003643,HCP_04840,REP_016,2024-03-13,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_003644,HCP_01830,REP_077,2024-02-15,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_003645,HCP_01553,REP_079,2024-01-14,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_003646,HCP_02103,REP_011,2024-02-12,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003647,HCP_02520,REP_075,2024-01-02,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003648,HCP_00686,REP_041,2024-01-18,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003649,HCP_00279,REP_011,2024-01-06,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_003650,HCP_00771,REP_008,2024-02-13,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_003651,HCP_04880,REP_052,2024-04-03,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003652,HCP_04667,REP_076,2024-01-20,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_003653,HCP_03104,REP_018,2024-01-06,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003654,HCP_02749,REP_041,2024-01-02,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003655,HCP_02761,REP_010,2024-01-09,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_003656,HCP_03520,REP_002,2024-01-21,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_003657,HCP_00296,REP_004,2024-01-17,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_003658,HCP_00846,REP_009,2024-02-29,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_003659,HCP_04052,REP_016,2024-05-09,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003660,HCP_02489,REP_023,2024-01-21,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003661,HCP_01319,REP_036,2024-04-10,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_003662,HCP_04605,REP_038,2024-04-01,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_003663,HCP_02676,REP_068,2024-01-08,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003664,HCP_04720,REP_046,2024-01-03,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_003665,HCP_02573,REP_077,2024-01-09,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003666,HCP_03127,REP_024,2024-02-27,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_003667,HCP_03712,REP_046,2024-06-05,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_003668,HCP_00884,REP_030,2024-01-09,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_003669,HCP_00297,REP_018,2024-03-21,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003670,HCP_04416,REP_030,2024-02-14,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003671,HCP_03721,REP_022,2024-01-24,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003672,HCP_04296,REP_040,2024-01-06,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_003673,HCP_01424,REP_051,2024-01-18,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003674,HCP_03455,REP_017,2024-01-02,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003675,HCP_04481,REP_005,2024-01-16,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_003676,HCP_03691,REP_044,2024-01-15,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003677,HCP_02818,REP_059,2024-01-25,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_003678,HCP_02283,REP_057,2024-02-19,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003679,HCP_02515,REP_053,2024-01-18,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_003680,HCP_03247,REP_074,2024-03-07,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003681,HCP_04556,REP_042,2024-02-09,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003682,HCP_00099,REP_002,2024-01-11,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_003683,HCP_02571,REP_044,2024-05-26,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_003684,HCP_03394,REP_076,2024-01-02,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003685,HCP_04796,REP_079,2024-01-05,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003686,HCP_01221,REP_061,2024-01-05,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_003687,HCP_04196,REP_017,2024-01-22,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_003688,HCP_02359,REP_059,2024-02-19,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_003689,HCP_04398,REP_005,2024-01-27,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003690,HCP_00076,REP_036,2024-03-31,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003691,HCP_00061,REP_024,2024-02-11,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_003692,HCP_03451,REP_012,2024-01-23,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003693,HCP_02904,REP_075,2024-03-14,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_003694,HCP_04529,REP_064,2024-01-14,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_003695,HCP_04489,REP_036,2024-05-18,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_003696,HCP_03584,REP_047,2024-03-03,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003697,HCP_04135,REP_048,2024-01-21,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_003698,HCP_00679,REP_049,2024-01-29,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003699,HCP_02554,REP_021,2024-01-15,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003700,HCP_04916,REP_034,2024-01-12,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003701,HCP_03778,REP_013,2024-01-07,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_003702,HCP_03448,REP_071,2024-02-09,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003703,HCP_03185,REP_068,2024-03-21,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003704,HCP_02204,REP_016,2024-02-21,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_003705,HCP_02164,REP_008,2024-01-07,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003706,HCP_04553,REP_063,2024-01-14,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_003707,HCP_00832,REP_021,2024-02-07,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003708,HCP_01718,REP_061,2024-03-29,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003709,HCP_03986,REP_025,2024-05-11,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003710,HCP_01498,REP_071,2024-01-11,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_003711,HCP_02507,REP_020,2024-01-14,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003712,HCP_02410,REP_020,2024-03-01,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003713,HCP_00242,REP_030,2024-01-23,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_003714,HCP_01759,REP_060,2024-03-22,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_003715,HCP_04616,REP_023,2024-02-04,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003716,HCP_01740,REP_071,2024-03-22,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_003717,HCP_03661,REP_062,2024-01-20,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003718,HCP_04228,REP_010,2024-03-27,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003719,HCP_02703,REP_079,2024-01-08,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003720,HCP_04238,REP_034,2024-03-23,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_003721,HCP_04431,REP_054,2024-01-16,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_003722,HCP_02994,REP_026,2024-03-11,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003723,HCP_02511,REP_040,2024-05-12,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003724,HCP_04626,REP_004,2024-01-13,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_003725,HCP_01167,REP_018,2024-02-13,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_003726,HCP_00406,REP_030,2024-01-31,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003727,HCP_00363,REP_024,2024-01-28,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003728,HCP_03797,REP_040,2024-01-22,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_003729,HCP_01040,REP_075,2024-01-08,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003730,HCP_00464,REP_060,2024-01-13,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003731,HCP_03421,REP_001,2024-01-28,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003732,HCP_03446,REP_023,2024-02-22,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003733,HCP_04198,REP_069,2024-04-12,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003734,HCP_00937,REP_018,2024-01-22,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003735,HCP_00498,REP_032,2024-02-22,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_003736,HCP_03328,REP_040,2024-01-01,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_003737,HCP_00862,REP_016,2024-02-11,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_003738,HCP_04343,REP_050,2024-01-10,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003739,HCP_04439,REP_010,2024-02-05,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_003740,HCP_01144,REP_007,2024-01-12,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003741,HCP_03670,REP_014,2024-02-09,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003742,HCP_02041,REP_062,2024-01-26,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003743,HCP_04776,REP_002,2024-02-14,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_003744,HCP_01024,REP_069,2024-01-05,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003745,HCP_04416,REP_036,2024-03-23,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_003746,HCP_04916,REP_005,2024-03-22,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003747,HCP_01685,REP_022,2024-04-02,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_003748,HCP_00755,REP_052,2024-02-23,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003749,HCP_00728,REP_007,2024-02-12,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_003750,HCP_03355,REP_071,2024-03-07,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003751,HCP_02988,REP_009,2024-02-15,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_003752,HCP_04511,REP_048,2024-01-31,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003753,HCP_04747,REP_070,2024-02-19,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003754,HCP_03991,REP_048,2024-02-06,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003755,HCP_04444,REP_001,2024-01-16,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_003756,HCP_00236,REP_016,2024-03-14,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_003757,HCP_02408,REP_054,2024-02-14,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003758,HCP_00568,REP_012,2024-01-26,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003759,HCP_04712,REP_048,2024-01-09,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003760,HCP_04671,REP_020,2024-03-02,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003761,HCP_02878,REP_017,2024-03-20,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003762,HCP_02260,REP_033,2024-01-29,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_003763,HCP_02991,REP_049,2024-01-06,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003764,HCP_01208,REP_065,2024-03-06,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003765,HCP_03948,REP_044,2024-02-24,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_003766,HCP_03454,REP_023,2024-02-28,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_003767,HCP_00051,REP_013,2024-03-16,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003768,HCP_01588,REP_069,2024-01-26,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003769,HCP_03213,REP_034,2024-01-04,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003770,HCP_04717,REP_048,2024-04-29,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003771,HCP_03212,REP_067,2024-01-10,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_003772,HCP_04405,REP_058,2024-01-09,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_003773,HCP_04226,REP_011,2024-05-27,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003774,HCP_04565,REP_008,2024-01-30,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_003775,HCP_00939,REP_075,2024-02-21,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003776,HCP_03611,REP_060,2024-04-21,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003777,HCP_03928,REP_040,2024-02-04,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003778,HCP_01890,REP_056,2024-01-06,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_003779,HCP_02085,REP_070,2024-03-10,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_003780,HCP_04065,REP_010,2024-04-15,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003781,HCP_04586,REP_031,2024-03-30,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003782,HCP_01358,REP_018,2024-04-16,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003783,HCP_01878,REP_035,2024-02-27,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_003784,HCP_01634,REP_027,2024-01-25,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_003785,HCP_00751,REP_027,2024-01-28,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_003786,HCP_01019,REP_037,2024-01-06,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003787,HCP_00508,REP_008,2024-02-23,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_003788,HCP_00205,REP_042,2024-01-06,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_003789,HCP_01078,REP_039,2024-03-10,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_003790,HCP_04688,REP_075,2024-02-05,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003791,HCP_01700,REP_057,2024-03-16,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_003792,HCP_00072,REP_045,2024-03-09,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003793,HCP_04923,REP_057,2024-02-19,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_003794,HCP_03644,REP_047,2024-02-21,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003795,HCP_02788,REP_051,2024-01-22,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_003796,HCP_01510,REP_009,2024-02-12,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_003797,HCP_01320,REP_063,2024-01-14,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003798,HCP_02818,REP_026,2024-02-17,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_003799,HCP_04539,REP_055,2024-03-26,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_003800,HCP_04175,REP_078,2024-01-30,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_003801,HCP_03243,REP_043,2024-03-13,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_003802,HCP_01183,REP_046,2024-01-01,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_003803,HCP_03366,REP_041,2024-01-26,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003804,HCP_03486,REP_005,2024-04-08,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_003805,HCP_01790,REP_034,2024-02-03,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_003806,HCP_04068,REP_026,2024-03-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003807,HCP_04024,REP_025,2024-02-03,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_003808,HCP_03514,REP_065,2024-01-06,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_003809,HCP_03614,REP_074,2024-01-13,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_003810,HCP_01501,REP_061,2024-01-29,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_003811,HCP_04894,REP_071,2024-01-15,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003812,HCP_03727,REP_029,2024-01-01,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_003813,HCP_02034,REP_039,2024-01-05,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003814,HCP_00137,REP_019,2024-04-02,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003815,HCP_01639,REP_036,2024-01-28,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003816,HCP_04108,REP_007,2024-02-27,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_003817,HCP_04513,REP_025,2024-02-08,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_003818,HCP_03209,REP_053,2024-01-02,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_003819,HCP_04042,REP_054,2024-01-10,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_003820,HCP_00446,REP_047,2024-05-21,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003821,HCP_03503,REP_023,2024-02-11,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_003822,HCP_04896,REP_059,2024-02-13,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_003823,HCP_02287,REP_006,2024-02-23,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003824,HCP_03483,REP_078,2024-01-18,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_003825,HCP_00819,REP_061,2024-01-01,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_003826,HCP_02314,REP_032,2024-01-02,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_003827,HCP_03016,REP_025,2024-02-19,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003828,HCP_02295,REP_016,2024-02-05,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003829,HCP_01099,REP_019,2024-01-04,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003830,HCP_01052,REP_040,2024-02-14,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003831,HCP_00520,REP_045,2024-01-13,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_003832,HCP_02631,REP_063,2024-01-13,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003833,HCP_03357,REP_030,2024-03-09,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_003834,HCP_03659,REP_075,2024-01-16,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003835,HCP_01026,REP_021,2024-01-02,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_003836,HCP_04663,REP_066,2024-03-05,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_003837,HCP_00685,REP_033,2024-01-15,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003838,HCP_00301,REP_029,2024-01-07,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003839,HCP_02620,REP_045,2024-03-04,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_003840,HCP_00743,REP_044,2024-01-10,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_003841,HCP_02569,REP_015,2024-01-09,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003842,HCP_04570,REP_046,2024-01-02,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003843,HCP_00863,REP_076,2024-02-14,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_003844,HCP_02631,REP_073,2024-02-29,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_003845,HCP_00379,REP_059,2024-01-09,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_003846,HCP_00536,REP_007,2024-01-25,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_003847,HCP_04294,REP_061,2024-04-06,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003848,HCP_02380,REP_024,2024-01-30,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003849,HCP_04133,REP_047,2024-01-02,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003850,HCP_01528,REP_046,2024-01-14,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003851,HCP_01292,REP_022,2024-03-11,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003852,HCP_00098,REP_064,2024-01-26,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_003853,HCP_04811,REP_055,2024-02-20,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003854,HCP_02545,REP_007,2024-02-09,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_003855,HCP_03172,REP_074,2024-01-13,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_003856,HCP_03334,REP_024,2024-01-28,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_003857,HCP_03298,REP_044,2024-03-17,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003858,HCP_04040,REP_064,2024-01-30,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_003859,HCP_01258,REP_006,2024-01-26,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_003860,HCP_02248,REP_006,2024-02-26,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003861,HCP_01902,REP_031,2024-01-26,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_003862,HCP_03516,REP_054,2024-04-01,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003863,HCP_00359,REP_079,2024-03-12,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_003864,HCP_00229,REP_027,2024-01-02,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_003865,HCP_02674,REP_018,2024-01-07,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003866,HCP_01861,REP_017,2024-05-14,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_003867,HCP_00231,REP_057,2024-03-01,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_003868,HCP_03889,REP_017,2024-05-25,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003869,HCP_04507,REP_004,2024-01-01,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_003870,HCP_02154,REP_004,2024-01-07,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003871,HCP_04005,REP_035,2024-03-08,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_003872,HCP_02610,REP_064,2024-02-19,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003873,HCP_04126,REP_036,2024-02-12,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003874,HCP_03588,REP_034,2024-02-23,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003875,HCP_01985,REP_067,2024-01-07,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_003876,HCP_00856,REP_072,2024-02-09,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003877,HCP_04821,REP_060,2024-01-19,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_003878,HCP_04462,REP_022,2024-02-15,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003879,HCP_02913,REP_069,2024-01-19,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_003880,HCP_04451,REP_014,2024-04-14,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003881,HCP_03872,REP_046,2024-04-04,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_003882,HCP_04086,REP_064,2024-01-04,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_003883,HCP_01343,REP_006,2024-01-05,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_003884,HCP_01943,REP_007,2024-02-22,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_003885,HCP_01924,REP_037,2024-05-04,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003886,HCP_03189,REP_003,2024-01-17,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_003887,HCP_03047,REP_039,2024-01-08,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003888,HCP_01230,REP_073,2024-05-17,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_003889,HCP_04429,REP_011,2024-01-17,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_003890,HCP_04111,REP_031,2024-01-21,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003891,HCP_01839,REP_066,2024-05-09,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_003892,HCP_04702,REP_039,2024-05-25,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003893,HCP_04053,REP_078,2024-01-10,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_003894,HCP_04120,REP_037,2024-01-13,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_003895,HCP_03238,REP_022,2024-01-18,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_003896,HCP_02869,REP_049,2024-01-01,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_003897,HCP_02981,REP_019,2024-01-11,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_003898,HCP_02641,REP_014,2024-02-24,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003899,HCP_02000,REP_027,2024-03-08,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003900,HCP_02507,REP_014,2024-02-14,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003901,HCP_02479,REP_060,2024-05-03,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_003902,HCP_04760,REP_072,2024-01-20,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003903,HCP_04966,REP_057,2024-02-25,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003904,HCP_02028,REP_033,2024-01-03,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_003905,HCP_00060,REP_065,2024-02-11,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003906,HCP_03356,REP_018,2024-02-15,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_003907,HCP_03334,REP_044,2024-02-22,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_003908,HCP_02293,REP_009,2024-01-04,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003909,HCP_00897,REP_071,2024-01-03,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_003910,HCP_00703,REP_055,2024-04-12,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_003911,HCP_01530,REP_014,2024-01-24,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_003912,HCP_02505,REP_066,2024-01-22,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_003913,HCP_03405,REP_078,2024-01-22,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003914,HCP_02403,REP_077,2024-01-16,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003915,HCP_00431,REP_075,2024-01-25,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_003916,HCP_02208,REP_027,2024-01-15,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003917,HCP_01185,REP_020,2024-02-03,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_003918,HCP_00970,REP_047,2024-01-20,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_003919,HCP_01097,REP_063,2024-01-23,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_003920,HCP_00619,REP_069,2024-01-05,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_003921,HCP_04452,REP_006,2024-02-09,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003922,HCP_00165,REP_015,2024-01-15,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_003923,HCP_01080,REP_067,2024-06-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003924,HCP_00078,REP_003,2024-04-01,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_003925,HCP_04834,REP_049,2024-02-23,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_003926,HCP_04561,REP_052,2024-02-11,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003927,HCP_03689,REP_065,2024-01-25,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_003928,HCP_02965,REP_041,2024-01-12,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_003929,HCP_01737,REP_048,2024-01-08,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003930,HCP_01746,REP_018,2024-02-13,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003931,HCP_00592,REP_071,2024-01-14,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_003932,HCP_02124,REP_006,2024-02-05,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003933,HCP_01092,REP_016,2024-02-05,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003934,HCP_03056,REP_020,2024-01-19,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003935,HCP_00523,REP_016,2024-02-07,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003936,HCP_03534,REP_072,2024-04-22,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003937,HCP_02473,REP_051,2024-01-24,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003938,HCP_02555,REP_015,2024-05-03,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_003939,HCP_03550,REP_072,2024-03-01,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003940,HCP_04635,REP_046,2024-01-29,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003941,HCP_03523,REP_066,2024-02-07,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003942,HCP_00391,REP_071,2024-01-24,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_003943,HCP_04129,REP_040,2024-01-20,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_003944,HCP_00258,REP_021,2024-02-21,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_003945,HCP_04358,REP_060,2024-01-31,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_003946,HCP_01061,REP_021,2024-01-09,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_003947,HCP_01490,REP_034,2024-03-22,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003948,HCP_04125,REP_014,2024-03-12,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_003949,HCP_03034,REP_004,2024-01-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003950,HCP_03433,REP_038,2024-04-12,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_003951,HCP_01394,REP_070,2024-01-12,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003952,HCP_03935,REP_010,2024-04-07,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_003953,HCP_01507,REP_016,2024-03-18,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_003954,HCP_02078,REP_076,2024-01-01,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003955,HCP_01684,REP_043,2024-02-11,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003956,HCP_03884,REP_055,2024-01-31,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003957,HCP_00119,REP_026,2024-01-11,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003958,HCP_00194,REP_069,2024-01-08,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_003959,HCP_02707,REP_032,2024-02-04,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_003960,HCP_03068,REP_076,2024-02-15,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_003961,HCP_01130,REP_048,2024-03-10,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003962,HCP_03334,REP_060,2024-01-28,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_003963,HCP_01041,REP_014,2024-02-24,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003964,HCP_02984,REP_018,2024-04-10,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003965,HCP_02507,REP_018,2024-01-02,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_003966,HCP_04114,REP_048,2024-04-11,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_003967,HCP_02748,REP_027,2024-02-14,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_003968,HCP_04975,REP_030,2024-05-18,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_003969,HCP_01514,REP_041,2024-01-09,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_003970,HCP_00091,REP_069,2024-01-13,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_003971,HCP_02302,REP_045,2024-02-26,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_003972,HCP_00045,REP_031,2024-01-30,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003973,HCP_00651,REP_018,2024-02-01,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_003974,HCP_02130,REP_079,2024-06-14,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_003975,HCP_04394,REP_022,2024-01-23,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_003976,HCP_03342,REP_077,2024-01-11,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_003977,HCP_03464,REP_070,2024-05-01,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_003978,HCP_04655,REP_051,2024-08-12,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_003979,HCP_02098,REP_006,2024-01-02,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003980,HCP_01065,REP_049,2024-01-05,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_003981,HCP_00605,REP_035,2024-03-25,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_003982,HCP_04317,REP_062,2024-01-08,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_003983,HCP_03783,REP_073,2024-02-09,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_003984,HCP_03078,REP_019,2024-02-05,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_003985,HCP_04239,REP_032,2024-02-12,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_003986,HCP_00054,REP_016,2024-01-09,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_003987,HCP_03124,REP_079,2024-02-15,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_003988,HCP_02580,REP_000,2024-01-15,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_003989,HCP_04906,REP_075,2024-02-16,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003990,HCP_02276,REP_015,2024-01-02,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_003991,HCP_00072,REP_066,2024-04-14,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_003992,HCP_03073,REP_078,2024-02-28,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_003993,HCP_00522,REP_009,2024-02-17,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_003994,HCP_03759,REP_033,2024-01-07,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_003995,HCP_04139,REP_012,2024-01-08,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_003996,HCP_01785,REP_065,2024-01-03,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_003997,HCP_00659,REP_069,2024-01-09,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_003998,HCP_02545,REP_010,2024-01-17,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_003999,HCP_02095,REP_078,2024-01-27,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_004000,HCP_02105,REP_053,2024-02-03,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004001,HCP_04498,REP_018,2024-03-22,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004002,HCP_00076,REP_018,2024-01-16,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004003,HCP_04227,REP_024,2024-01-15,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004004,HCP_02466,REP_035,2024-02-17,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004005,HCP_00538,REP_071,2024-03-22,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_004006,HCP_04138,REP_051,2024-02-06,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_004007,HCP_02912,REP_003,2024-01-17,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004008,HCP_03488,REP_030,2024-01-21,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_004009,HCP_01859,REP_037,2024-01-03,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_004010,HCP_04297,REP_007,2024-01-24,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004011,HCP_02138,REP_062,2024-01-19,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_004012,HCP_01111,REP_037,2024-02-03,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004013,HCP_00984,REP_056,2024-02-17,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_004014,HCP_00284,REP_032,2024-01-06,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_004015,HCP_04066,REP_055,2024-03-22,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004016,HCP_02602,REP_004,2024-02-17,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_004017,HCP_04997,REP_029,2024-02-29,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004018,HCP_03738,REP_025,2024-01-17,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004019,HCP_04194,REP_013,2024-01-01,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004020,HCP_00280,REP_011,2024-01-16,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004021,HCP_03854,REP_008,2024-01-23,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004022,HCP_04889,REP_040,2024-05-20,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_004023,HCP_04188,REP_023,2024-01-04,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_004024,HCP_01811,REP_052,2024-01-08,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_004025,HCP_04633,REP_066,2024-01-05,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_004026,HCP_01821,REP_008,2024-02-23,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_004027,HCP_02455,REP_028,2024-02-27,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004028,HCP_01912,REP_006,2024-01-27,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004029,HCP_02013,REP_015,2024-01-17,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_004030,HCP_01494,REP_055,2024-02-04,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_004031,HCP_03903,REP_012,2024-01-24,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004032,HCP_04153,REP_042,2024-02-27,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_004033,HCP_02500,REP_057,2024-01-14,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_004034,HCP_02629,REP_066,2024-01-10,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_004035,HCP_03322,REP_056,2024-02-13,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_004036,HCP_02918,REP_069,2024-03-19,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004037,HCP_04160,REP_055,2024-01-03,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004038,HCP_03188,REP_077,2024-04-21,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_004039,HCP_04366,REP_004,2024-01-23,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_004040,HCP_03851,REP_013,2024-01-06,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_004041,HCP_00167,REP_052,2024-01-11,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004042,HCP_00023,REP_039,2024-02-03,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004043,HCP_02172,REP_067,2024-04-02,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004044,HCP_00109,REP_077,2024-01-05,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_004045,HCP_04655,REP_057,2024-02-17,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_004046,HCP_04381,REP_066,2024-01-09,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004047,HCP_00962,REP_065,2024-02-19,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_004048,HCP_03425,REP_010,2024-01-13,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_004049,HCP_03490,REP_039,2024-01-12,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004050,HCP_00132,REP_027,2024-03-04,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004051,HCP_02956,REP_011,2024-03-26,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004052,HCP_00293,REP_031,2024-03-05,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004053,HCP_02196,REP_049,2024-01-01,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004054,HCP_00471,REP_024,2024-01-24,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004055,HCP_01437,REP_053,2024-02-24,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004056,HCP_03487,REP_018,2024-03-20,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004057,HCP_00302,REP_014,2024-01-17,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004058,HCP_04048,REP_020,2024-03-10,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_004059,HCP_03513,REP_029,2024-01-03,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004060,HCP_03829,REP_048,2024-01-10,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_004061,HCP_01180,REP_050,2024-01-16,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004062,HCP_02384,REP_043,2024-01-13,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004063,HCP_03183,REP_003,2024-03-05,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_004064,HCP_01370,REP_076,2024-01-01,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004065,HCP_03303,REP_033,2024-01-07,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_004066,HCP_00063,REP_033,2024-02-25,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004067,HCP_00006,REP_049,2024-03-27,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004068,HCP_03309,REP_041,2024-02-01,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_004069,HCP_03808,REP_000,2024-02-11,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004070,HCP_00339,REP_038,2024-01-06,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004071,HCP_01305,REP_025,2024-01-26,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_004072,HCP_02608,REP_005,2024-03-22,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004073,HCP_00720,REP_028,2024-01-07,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004074,HCP_03326,REP_056,2024-04-19,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004075,HCP_03953,REP_065,2024-02-27,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004076,HCP_02496,REP_073,2024-01-19,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_004077,HCP_04008,REP_036,2024-01-04,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004078,HCP_04241,REP_023,2024-01-11,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_004079,HCP_02731,REP_059,2024-02-29,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004080,HCP_04595,REP_058,2024-01-30,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_004081,HCP_03162,REP_052,2024-02-17,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_004082,HCP_03986,REP_048,2024-03-22,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_004083,HCP_04535,REP_033,2024-02-09,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004084,HCP_04943,REP_048,2024-01-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004085,HCP_04791,REP_053,2024-01-13,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004086,HCP_02075,REP_018,2024-01-21,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_004087,HCP_02780,REP_024,2024-02-07,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004088,HCP_00820,REP_051,2024-03-21,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004089,HCP_02769,REP_059,2024-01-16,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004090,HCP_02543,REP_073,2024-05-21,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004091,HCP_01667,REP_043,2024-01-11,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_004092,HCP_04672,REP_002,2024-01-29,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_004093,HCP_02479,REP_045,2024-01-20,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_004094,HCP_02252,REP_022,2024-02-16,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004095,HCP_04367,REP_067,2024-02-29,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_004096,HCP_01387,REP_011,2024-03-31,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004097,HCP_00066,REP_034,2024-01-01,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004098,HCP_01647,REP_056,2024-02-29,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004099,HCP_02708,REP_050,2024-04-03,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_004100,HCP_03611,REP_057,2024-03-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004101,HCP_03030,REP_056,2024-02-15,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004102,HCP_02975,REP_070,2024-01-07,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004103,HCP_02112,REP_004,2024-02-27,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_004104,HCP_01282,REP_033,2024-06-28,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004105,HCP_00571,REP_045,2024-01-10,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_004106,HCP_00893,REP_074,2024-01-01,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_004107,HCP_01269,REP_034,2024-03-11,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_004108,HCP_00109,REP_011,2024-02-01,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004109,HCP_02496,REP_026,2024-01-08,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_004110,HCP_01640,REP_033,2024-01-07,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_004111,HCP_02304,REP_015,2024-01-13,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004112,HCP_04155,REP_017,2024-01-05,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004113,HCP_02109,REP_032,2024-02-17,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004114,HCP_00692,REP_077,2024-03-11,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004115,HCP_03023,REP_075,2024-01-01,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004116,HCP_01873,REP_023,2024-02-15,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004117,HCP_04558,REP_035,2024-01-05,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004118,HCP_00714,REP_077,2024-02-18,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_004119,HCP_02031,REP_072,2024-01-12,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_004120,HCP_03637,REP_068,2024-02-18,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_004121,HCP_01633,REP_038,2024-01-17,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004122,HCP_02778,REP_046,2024-04-04,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_004123,HCP_02503,REP_010,2024-02-10,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004124,HCP_02827,REP_003,2024-01-11,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004125,HCP_04036,REP_078,2024-01-05,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004126,HCP_03230,REP_039,2024-01-01,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004127,HCP_01003,REP_047,2024-01-15,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004128,HCP_02355,REP_050,2024-01-01,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004129,HCP_04845,REP_028,2024-02-16,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004130,HCP_02071,REP_002,2024-02-09,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004131,HCP_00389,REP_004,2024-02-19,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_004132,HCP_00177,REP_054,2024-01-04,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004133,HCP_00028,REP_015,2024-01-27,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004134,HCP_02745,REP_034,2024-02-12,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004135,HCP_02909,REP_000,2024-01-11,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004136,HCP_02952,REP_066,2024-03-24,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004137,HCP_01639,REP_019,2024-01-01,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004138,HCP_00252,REP_030,2024-01-29,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004139,HCP_01322,REP_028,2024-01-19,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004140,HCP_02415,REP_042,2024-03-15,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004141,HCP_03881,REP_035,2024-01-15,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_004142,HCP_04678,REP_027,2024-01-07,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004143,HCP_02746,REP_005,2024-01-26,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004144,HCP_03673,REP_074,2024-01-20,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004145,HCP_01105,REP_023,2024-01-20,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_004146,HCP_00345,REP_016,2024-01-19,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004147,HCP_01723,REP_003,2024-02-11,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004148,HCP_01968,REP_017,2024-01-10,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004149,HCP_04850,REP_073,2024-03-06,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004150,HCP_04251,REP_027,2024-01-20,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_004151,HCP_01735,REP_067,2024-01-30,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_004152,HCP_00442,REP_026,2024-01-21,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004153,HCP_01481,REP_004,2024-03-19,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004154,HCP_01861,REP_078,2024-01-02,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_004155,HCP_02638,REP_074,2024-01-16,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004156,HCP_02132,REP_020,2024-03-05,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004157,HCP_02970,REP_013,2024-01-30,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004158,HCP_00550,REP_075,2024-04-11,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_004159,HCP_03175,REP_010,2024-01-16,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004160,HCP_02993,REP_015,2024-01-22,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004161,HCP_04651,REP_014,2024-02-09,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004162,HCP_00212,REP_056,2024-02-18,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004163,HCP_04874,REP_032,2024-01-03,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004164,HCP_00151,REP_028,2024-01-22,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004165,HCP_01851,REP_016,2024-01-06,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004166,HCP_00371,REP_025,2024-01-08,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_004167,HCP_02726,REP_053,2024-01-03,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_004168,HCP_02845,REP_077,2024-02-02,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_004169,HCP_02909,REP_011,2024-01-29,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_004170,HCP_01539,REP_054,2024-01-21,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004171,HCP_03163,REP_026,2024-02-17,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_004172,HCP_01959,REP_052,2024-01-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004173,HCP_02595,REP_003,2024-01-29,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004174,HCP_02865,REP_031,2024-03-12,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004175,HCP_04420,REP_079,2024-01-03,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_004176,HCP_04701,REP_004,2024-02-10,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004177,HCP_03116,REP_051,2024-01-29,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_004178,HCP_00774,REP_064,2024-01-04,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004179,HCP_01890,REP_004,2024-01-07,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_004180,HCP_03144,REP_063,2024-01-23,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_004181,HCP_03039,REP_003,2024-02-20,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004182,HCP_03607,REP_035,2024-01-10,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004183,HCP_01769,REP_001,2024-01-04,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_004184,HCP_03931,REP_019,2024-03-24,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004185,HCP_01047,REP_046,2024-01-05,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_004186,HCP_00651,REP_037,2024-01-08,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_004187,HCP_04964,REP_042,2024-07-01,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004188,HCP_00980,REP_011,2024-02-08,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004189,HCP_02033,REP_029,2024-01-08,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_004190,HCP_04670,REP_060,2024-02-16,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004191,HCP_00935,REP_005,2024-01-05,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004192,HCP_04508,REP_029,2024-04-27,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004193,HCP_04499,REP_075,2024-03-18,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004194,HCP_03334,REP_039,2024-01-23,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_004195,HCP_01293,REP_070,2024-01-26,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_004196,HCP_01043,REP_048,2024-03-12,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004197,HCP_00436,REP_070,2024-05-15,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_004198,HCP_01057,REP_012,2024-03-12,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_004199,HCP_00420,REP_001,2024-03-21,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004200,HCP_02783,REP_054,2024-01-07,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_004201,HCP_00976,REP_034,2024-01-14,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004202,HCP_00001,REP_049,2024-01-20,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_004203,HCP_02661,REP_019,2024-01-31,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004204,HCP_04161,REP_040,2024-02-20,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004205,HCP_04691,REP_049,2024-01-13,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004206,HCP_04332,REP_015,2024-03-18,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004207,HCP_00093,REP_008,2024-02-23,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004208,HCP_04987,REP_014,2024-01-17,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004209,HCP_01771,REP_079,2024-02-13,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_004210,HCP_04768,REP_079,2024-03-16,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_004211,HCP_01620,REP_068,2024-01-13,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004212,HCP_00560,REP_018,2024-02-15,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_004213,HCP_04849,REP_007,2024-01-07,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_004214,HCP_04341,REP_057,2024-02-10,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004215,HCP_04197,REP_024,2024-02-24,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_004216,HCP_04344,REP_045,2024-06-09,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004217,HCP_03438,REP_041,2024-01-01,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004218,HCP_04981,REP_011,2024-04-03,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004219,HCP_04282,REP_005,2024-01-19,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004220,HCP_03939,REP_072,2024-01-10,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004221,HCP_03739,REP_031,2024-01-06,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_004222,HCP_04313,REP_009,2024-01-07,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_004223,HCP_04223,REP_075,2024-03-18,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004224,HCP_04448,REP_072,2024-02-09,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004225,HCP_00243,REP_008,2024-01-17,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004226,HCP_00627,REP_048,2024-02-07,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004227,HCP_04822,REP_074,2024-02-06,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_004228,HCP_00081,REP_074,2024-01-31,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_004229,HCP_04223,REP_012,2024-03-02,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004230,HCP_01665,REP_022,2024-01-10,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004231,HCP_01337,REP_069,2024-03-27,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004232,HCP_02079,REP_045,2024-01-04,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_004233,HCP_01909,REP_002,2024-01-14,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_004234,HCP_04599,REP_060,2024-01-01,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004235,HCP_02040,REP_068,2024-01-31,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_004236,HCP_03848,REP_019,2024-01-06,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004237,HCP_00110,REP_014,2024-01-07,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_004238,HCP_00560,REP_003,2024-03-18,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_004239,HCP_03150,REP_005,2024-01-04,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_004240,HCP_03727,REP_024,2024-03-02,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_004241,HCP_03985,REP_005,2024-01-30,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004242,HCP_03480,REP_012,2024-03-18,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004243,HCP_01897,REP_009,2024-01-06,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_004244,HCP_03356,REP_073,2024-02-12,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004245,HCP_03544,REP_064,2024-02-04,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_004246,HCP_01755,REP_053,2024-03-06,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004247,HCP_00899,REP_004,2024-03-08,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004248,HCP_01472,REP_059,2024-02-15,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_004249,HCP_02234,REP_007,2024-01-29,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_004250,HCP_03437,REP_058,2024-02-09,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004251,HCP_01569,REP_078,2024-03-04,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004252,HCP_01712,REP_071,2024-01-11,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_004253,HCP_02751,REP_032,2024-01-14,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_004254,HCP_03656,REP_063,2024-02-22,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004255,HCP_03938,REP_022,2024-03-11,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004256,HCP_00254,REP_076,2024-02-07,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004257,HCP_01928,REP_003,2024-01-02,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004258,HCP_04183,REP_041,2024-03-27,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_004259,HCP_04386,REP_001,2024-02-28,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_004260,HCP_01476,REP_028,2024-01-10,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004261,HCP_00301,REP_060,2024-04-04,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004262,HCP_03937,REP_006,2024-05-27,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_004263,HCP_01923,REP_029,2024-01-25,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004264,HCP_03887,REP_047,2024-01-27,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004265,HCP_00032,REP_054,2024-06-12,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004266,HCP_02229,REP_027,2024-01-13,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004267,HCP_00313,REP_047,2024-02-25,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004268,HCP_01245,REP_027,2024-01-11,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004269,HCP_03512,REP_027,2024-02-07,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004270,HCP_03057,REP_033,2024-01-24,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004271,HCP_01619,REP_049,2024-02-16,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004272,HCP_00342,REP_053,2024-01-26,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_004273,HCP_00675,REP_057,2024-01-22,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004274,HCP_00112,REP_009,2024-01-28,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004275,HCP_01175,REP_079,2024-01-30,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_004276,HCP_04423,REP_055,2024-03-22,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_004277,HCP_01562,REP_032,2024-01-03,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004278,HCP_02494,REP_078,2024-01-25,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004279,HCP_02872,REP_048,2024-01-06,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_004280,HCP_00618,REP_011,2024-02-07,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004281,HCP_04312,REP_024,2024-04-01,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004282,HCP_00169,REP_046,2024-01-31,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_004283,HCP_01394,REP_006,2024-01-25,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004284,HCP_04408,REP_076,2024-03-25,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_004285,HCP_00702,REP_000,2024-01-13,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004286,HCP_01661,REP_015,2024-03-21,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004287,HCP_04723,REP_023,2024-01-07,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004288,HCP_04027,REP_001,2024-03-03,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004289,HCP_01571,REP_024,2024-01-19,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004290,HCP_03457,REP_060,2024-01-11,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004291,HCP_00572,REP_054,2024-02-18,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_004292,HCP_04656,REP_029,2024-01-02,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_004293,HCP_04650,REP_009,2024-02-04,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004294,HCP_00710,REP_069,2024-02-12,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_004295,HCP_02535,REP_008,2024-03-02,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004296,HCP_00488,REP_037,2024-02-16,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_004297,HCP_02954,REP_004,2024-01-11,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004298,HCP_01975,REP_033,2024-02-01,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_004299,HCP_01653,REP_030,2024-02-10,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004300,HCP_01077,REP_023,2024-05-14,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004301,HCP_03552,REP_006,2024-02-23,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004302,HCP_04214,REP_020,2024-02-02,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_004303,HCP_02532,REP_010,2024-01-09,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004304,HCP_03460,REP_051,2024-04-05,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_004305,HCP_02310,REP_018,2024-03-08,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004306,HCP_00009,REP_073,2024-04-07,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_004307,HCP_02879,REP_001,2024-01-19,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004308,HCP_03669,REP_072,2024-01-27,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_004309,HCP_02467,REP_063,2024-01-02,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_004310,HCP_04938,REP_033,2024-04-11,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004311,HCP_04148,REP_017,2024-02-11,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004312,HCP_00098,REP_075,2024-01-19,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004313,HCP_02658,REP_025,2024-02-02,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004314,HCP_03737,REP_077,2024-04-04,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004315,HCP_02775,REP_025,2024-01-27,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004316,HCP_01971,REP_011,2024-03-28,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004317,HCP_04165,REP_072,2024-01-17,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004318,HCP_02215,REP_064,2024-01-02,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_004319,HCP_02178,REP_014,2024-01-27,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004320,HCP_02860,REP_077,2024-02-25,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004321,HCP_03643,REP_053,2024-01-02,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_004322,HCP_00791,REP_074,2024-02-09,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_004323,HCP_04018,REP_069,2024-01-10,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004324,HCP_01388,REP_004,2024-02-20,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_004325,HCP_02450,REP_059,2024-02-15,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004326,HCP_01262,REP_029,2024-01-27,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_004327,HCP_00255,REP_072,2024-01-14,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004328,HCP_00995,REP_033,2024-04-21,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004329,HCP_01551,REP_006,2024-02-16,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_004330,HCP_04147,REP_043,2024-01-21,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_004331,HCP_01000,REP_005,2024-03-04,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004332,HCP_03092,REP_030,2024-01-03,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004333,HCP_04745,REP_066,2024-01-23,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_004334,HCP_00791,REP_079,2024-01-30,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004335,HCP_02321,REP_063,2024-01-23,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004336,HCP_01722,REP_043,2024-02-15,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_004337,HCP_02727,REP_073,2024-03-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004338,HCP_03010,REP_000,2024-02-09,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004339,HCP_02297,REP_026,2024-01-02,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004340,HCP_04334,REP_040,2024-05-09,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_004341,HCP_02465,REP_001,2024-01-12,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_004342,HCP_03295,REP_051,2024-01-13,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004343,HCP_01248,REP_029,2024-01-28,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_004344,HCP_01728,REP_063,2024-01-31,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_004345,HCP_03516,REP_065,2024-01-07,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_004346,HCP_02039,REP_023,2024-03-02,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004347,HCP_03930,REP_024,2024-01-02,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004348,HCP_00983,REP_071,2024-02-04,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004349,HCP_01825,REP_010,2024-02-26,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_004350,HCP_04726,REP_007,2024-03-22,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_004351,HCP_02120,REP_006,2024-06-26,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_004352,HCP_03933,REP_028,2024-02-19,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004353,HCP_00893,REP_039,2024-03-17,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004354,HCP_00014,REP_030,2024-04-07,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_004355,HCP_00924,REP_006,2024-01-17,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004356,HCP_01826,REP_049,2024-03-13,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004357,HCP_00554,REP_039,2024-01-16,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004358,HCP_02245,REP_004,2024-01-01,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_004359,HCP_02627,REP_001,2024-05-11,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004360,HCP_02102,REP_009,2024-03-23,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004361,HCP_01612,REP_071,2024-01-15,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_004362,HCP_00594,REP_054,2024-02-14,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004363,HCP_03314,REP_034,2024-02-21,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_004364,HCP_02499,REP_022,2024-05-29,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_004365,HCP_04848,REP_061,2024-01-12,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_004366,HCP_01180,REP_046,2024-01-05,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_004367,HCP_01818,REP_047,2024-01-04,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_004368,HCP_01710,REP_027,2024-05-10,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004369,HCP_02224,REP_047,2024-02-13,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004370,HCP_04174,REP_062,2024-03-14,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004371,HCP_01097,REP_059,2024-01-26,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_004372,HCP_04748,REP_061,2024-02-08,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_004373,HCP_01856,REP_068,2024-03-17,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004374,HCP_01247,REP_074,2024-01-27,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004375,HCP_02131,REP_025,2024-01-07,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004376,HCP_03946,REP_078,2024-02-10,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004377,HCP_01813,REP_015,2024-02-02,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004378,HCP_04161,REP_074,2024-01-15,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004379,HCP_04270,REP_034,2024-02-01,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004380,HCP_04333,REP_078,2024-02-14,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004381,HCP_04760,REP_015,2024-04-26,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_004382,HCP_04919,REP_003,2024-01-18,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_004383,HCP_01874,REP_078,2024-02-09,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004384,HCP_00635,REP_074,2024-01-14,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004385,HCP_00696,REP_048,2024-01-28,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_004386,HCP_01527,REP_049,2024-01-04,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004387,HCP_00993,REP_022,2024-04-09,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004388,HCP_01458,REP_069,2024-06-30,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004389,HCP_02224,REP_074,2024-01-10,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_004390,HCP_03271,REP_002,2024-09-07,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_004391,HCP_01212,REP_010,2024-01-15,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_004392,HCP_02592,REP_039,2024-04-30,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_004393,HCP_04814,REP_055,2024-03-23,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004394,HCP_00888,REP_072,2024-02-03,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004395,HCP_00820,REP_048,2024-01-20,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004396,HCP_01963,REP_039,2024-01-14,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_004397,HCP_02075,REP_004,2024-01-08,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004398,HCP_04597,REP_005,2024-01-30,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004399,HCP_03160,REP_064,2024-04-26,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_004400,HCP_00798,REP_023,2024-01-26,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004401,HCP_00414,REP_013,2024-01-18,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_004402,HCP_02055,REP_013,2024-02-24,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_004403,HCP_01427,REP_013,2024-01-06,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004404,HCP_02622,REP_026,2024-01-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004405,HCP_00085,REP_039,2024-01-18,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_004406,HCP_01334,REP_057,2024-03-06,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_004407,HCP_03468,REP_016,2024-03-19,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004408,HCP_01185,REP_027,2024-02-03,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004409,HCP_00966,REP_075,2024-01-12,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004410,HCP_00042,REP_061,2024-04-30,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_004411,HCP_04059,REP_042,2024-05-21,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004412,HCP_04795,REP_033,2024-02-02,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004413,HCP_04251,REP_062,2024-01-02,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004414,HCP_01035,REP_017,2024-01-29,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004415,HCP_02652,REP_066,2024-02-04,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_004416,HCP_02389,REP_075,2024-05-26,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004417,HCP_00563,REP_010,2024-03-30,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_004418,HCP_02094,REP_008,2024-02-10,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004419,HCP_02377,REP_040,2024-02-25,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_004420,HCP_00955,REP_054,2024-02-06,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004421,HCP_01468,REP_013,2024-01-03,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004422,HCP_04681,REP_002,2024-06-29,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004423,HCP_03497,REP_062,2024-01-05,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_004424,HCP_04504,REP_011,2024-01-24,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004425,HCP_00855,REP_050,2024-04-07,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_004426,HCP_02972,REP_073,2024-01-20,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_004427,HCP_00918,REP_056,2024-02-10,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_004428,HCP_03586,REP_063,2024-01-21,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004429,HCP_00024,REP_061,2024-05-04,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004430,HCP_03773,REP_055,2024-01-17,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_004431,HCP_02732,REP_003,2024-01-02,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_004432,HCP_00672,REP_073,2024-05-13,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_004433,HCP_02625,REP_067,2024-01-16,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004434,HCP_03586,REP_054,2024-01-23,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004435,HCP_03784,REP_005,2024-01-11,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_004436,HCP_02976,REP_048,2024-02-03,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_004437,HCP_02277,REP_004,2024-01-26,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004438,HCP_02187,REP_008,2024-01-23,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_004439,HCP_00468,REP_024,2024-01-12,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_004440,HCP_02634,REP_054,2024-01-29,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004441,HCP_04382,REP_022,2024-01-02,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_004442,HCP_03840,REP_001,2024-04-19,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004443,HCP_00221,REP_056,2024-02-08,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_004444,HCP_01551,REP_017,2024-01-27,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004445,HCP_02878,REP_014,2024-02-01,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004446,HCP_04905,REP_008,2024-01-24,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004447,HCP_03585,REP_077,2024-01-11,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_004448,HCP_04697,REP_062,2024-01-01,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_004449,HCP_00223,REP_054,2024-02-23,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004450,HCP_01872,REP_030,2024-01-15,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004451,HCP_01102,REP_053,2024-01-04,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004452,HCP_04806,REP_071,2024-02-26,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004453,HCP_01778,REP_069,2024-02-06,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_004454,HCP_01353,REP_056,2024-03-26,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_004455,HCP_04520,REP_005,2024-02-08,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_004456,HCP_00147,REP_047,2024-01-11,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_004457,HCP_00695,REP_049,2024-01-03,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_004458,HCP_03736,REP_018,2024-01-18,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_004459,HCP_02767,REP_074,2024-01-23,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004460,HCP_02090,REP_049,2024-03-15,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004461,HCP_03947,REP_058,2024-03-25,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_004462,HCP_03560,REP_057,2024-03-08,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004463,HCP_01941,REP_040,2024-01-16,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004464,HCP_00153,REP_064,2024-01-16,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_004465,HCP_03097,REP_036,2024-01-30,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_004466,HCP_02690,REP_005,2024-04-01,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004467,HCP_00969,REP_016,2024-01-01,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004468,HCP_04917,REP_030,2024-01-04,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004469,HCP_04839,REP_057,2024-01-04,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_004470,HCP_00378,REP_079,2024-02-06,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004471,HCP_02499,REP_074,2024-01-28,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004472,HCP_02786,REP_068,2024-01-30,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004473,HCP_03427,REP_006,2024-01-03,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004474,HCP_01057,REP_076,2024-04-16,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004475,HCP_01597,REP_045,2024-01-02,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004476,HCP_04478,REP_047,2024-02-02,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_004477,HCP_02226,REP_001,2024-01-26,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_004478,HCP_02237,REP_075,2024-02-21,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004479,HCP_04976,REP_025,2024-01-22,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_004480,HCP_02229,REP_024,2024-01-04,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004481,HCP_00250,REP_052,2024-02-14,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004482,HCP_02676,REP_040,2024-01-11,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_004483,HCP_00848,REP_070,2024-02-01,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004484,HCP_03574,REP_003,2024-01-12,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004485,HCP_03620,REP_051,2024-03-24,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_004486,HCP_04501,REP_034,2024-01-26,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004487,HCP_02795,REP_066,2024-02-09,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004488,HCP_04768,REP_049,2024-01-12,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004489,HCP_04694,REP_056,2024-01-29,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004490,HCP_01390,REP_064,2024-01-27,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004491,HCP_03679,REP_076,2024-05-18,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004492,HCP_00453,REP_029,2024-01-23,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_004493,HCP_04212,REP_079,2024-01-26,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_004494,HCP_04194,REP_013,2024-01-29,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004495,HCP_03124,REP_064,2024-01-02,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_004496,HCP_01607,REP_022,2024-03-14,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004497,HCP_03416,REP_026,2024-01-10,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004498,HCP_02928,REP_022,2024-02-28,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_004499,HCP_02066,REP_047,2024-01-17,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_004500,HCP_00205,REP_004,2024-01-15,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004501,HCP_03378,REP_030,2024-02-04,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_004502,HCP_02436,REP_006,2024-01-11,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004503,HCP_01609,REP_050,2024-01-17,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_004504,HCP_01858,REP_060,2024-01-08,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_004505,HCP_01748,REP_051,2024-02-14,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004506,HCP_01733,REP_043,2024-01-11,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004507,HCP_00052,REP_033,2024-01-24,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_004508,HCP_03161,REP_030,2024-01-14,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_004509,HCP_03241,REP_043,2024-02-22,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004510,HCP_02254,REP_020,2024-01-13,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_004511,HCP_03822,REP_032,2024-01-11,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004512,HCP_04851,REP_061,2024-01-07,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_004513,HCP_04687,REP_063,2024-01-05,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004514,HCP_04783,REP_040,2024-04-09,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_004515,HCP_02821,REP_014,2024-09-03,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004516,HCP_01014,REP_078,2024-01-29,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_004517,HCP_01298,REP_039,2024-02-19,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004518,HCP_00914,REP_004,2024-01-21,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004519,HCP_02019,REP_033,2024-01-07,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_004520,HCP_04922,REP_027,2024-01-01,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_004521,HCP_03875,REP_035,2024-01-02,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004522,HCP_02532,REP_033,2024-03-18,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004523,HCP_00825,REP_060,2024-01-11,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_004524,HCP_04571,REP_068,2024-02-02,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004525,HCP_02534,REP_013,2024-01-25,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_004526,HCP_00671,REP_039,2024-01-22,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004527,HCP_04794,REP_029,2024-01-18,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004528,HCP_02647,REP_009,2024-03-20,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004529,HCP_04639,REP_016,2024-03-23,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004530,HCP_02431,REP_076,2024-02-04,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_004531,HCP_01366,REP_009,2024-05-16,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_004532,HCP_02554,REP_058,2024-02-09,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004533,HCP_02959,REP_046,2024-01-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004534,HCP_00125,REP_071,2024-02-06,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004535,HCP_00356,REP_059,2024-01-18,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004536,HCP_04743,REP_002,2024-01-23,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_004537,HCP_01507,REP_035,2024-01-09,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004538,HCP_03369,REP_039,2024-02-13,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004539,HCP_00876,REP_041,2024-01-26,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004540,HCP_01398,REP_065,2024-01-24,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004541,HCP_01066,REP_041,2024-01-17,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004542,HCP_02496,REP_040,2024-01-12,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_004543,HCP_02500,REP_016,2024-02-06,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004544,HCP_01232,REP_025,2024-02-03,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004545,HCP_01463,REP_026,2024-03-15,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_004546,HCP_01932,REP_060,2024-02-15,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004547,HCP_04179,REP_025,2024-02-02,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_004548,HCP_00700,REP_054,2024-01-14,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004549,HCP_03556,REP_059,2024-03-22,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_004550,HCP_00511,REP_071,2024-02-22,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004551,HCP_03653,REP_044,2024-01-02,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004552,HCP_01298,REP_056,2024-02-19,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_004553,HCP_00025,REP_022,2024-01-25,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004554,HCP_03136,REP_058,2024-04-30,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004555,HCP_02316,REP_013,2024-01-29,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004556,HCP_03889,REP_038,2024-01-10,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004557,HCP_02736,REP_056,2024-02-19,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004558,HCP_02746,REP_067,2024-01-02,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_004559,HCP_03985,REP_045,2024-01-26,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004560,HCP_03213,REP_052,2024-01-05,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_004561,HCP_00864,REP_004,2024-01-24,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_004562,HCP_03667,REP_051,2024-04-01,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_004563,HCP_04896,REP_034,2024-04-07,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004564,HCP_00541,REP_035,2024-03-08,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_004565,HCP_00957,REP_022,2024-01-17,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_004566,HCP_03376,REP_006,2024-01-02,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_004567,HCP_02541,REP_076,2024-07-03,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004568,HCP_02540,REP_074,2024-02-20,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_004569,HCP_04185,REP_005,2024-05-14,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004570,HCP_00936,REP_019,2024-01-07,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004571,HCP_00377,REP_005,2024-02-18,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004572,HCP_00116,REP_071,2024-01-13,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004573,HCP_03570,REP_077,2024-03-28,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_004574,HCP_00174,REP_007,2024-06-09,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_004575,HCP_02041,REP_011,2024-01-12,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_004576,HCP_04806,REP_012,2024-02-23,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004577,HCP_00214,REP_004,2024-01-29,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_004578,HCP_02073,REP_040,2024-01-15,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004579,HCP_03640,REP_045,2024-02-16,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004580,HCP_02875,REP_069,2024-01-03,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004581,HCP_02989,REP_020,2024-01-23,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004582,HCP_02742,REP_033,2024-01-23,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004583,HCP_04203,REP_045,2024-02-02,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_004584,HCP_01394,REP_072,2024-02-18,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004585,HCP_01436,REP_068,2024-02-01,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004586,HCP_02527,REP_003,2024-01-26,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004587,HCP_04444,REP_033,2024-01-03,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_004588,HCP_04732,REP_003,2024-02-14,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004589,HCP_00192,REP_047,2024-01-21,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_004590,HCP_00084,REP_021,2024-01-17,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004591,HCP_02012,REP_011,2024-02-09,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_004592,HCP_01314,REP_062,2024-07-13,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004593,HCP_04223,REP_034,2024-01-27,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004594,HCP_00797,REP_019,2024-01-26,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004595,HCP_00967,REP_044,2024-02-08,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004596,HCP_02883,REP_029,2024-01-10,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004597,HCP_02586,REP_036,2024-02-24,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_004598,HCP_04133,REP_005,2024-01-13,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_004599,HCP_03832,REP_032,2024-02-09,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_004600,HCP_01838,REP_070,2024-06-02,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_004601,HCP_02842,REP_034,2024-03-05,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004602,HCP_01535,REP_048,2024-01-03,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_004603,HCP_03928,REP_068,2024-03-31,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_004604,HCP_00882,REP_076,2024-02-02,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_004605,HCP_00392,REP_042,2024-02-28,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004606,HCP_03033,REP_026,2024-03-11,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004607,HCP_03388,REP_065,2024-06-12,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004608,HCP_03968,REP_071,2024-01-23,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004609,HCP_03791,REP_015,2024-01-07,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_004610,HCP_01874,REP_036,2024-06-30,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004611,HCP_03077,REP_063,2024-03-19,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_004612,HCP_03808,REP_055,2024-01-02,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_004613,HCP_04125,REP_076,2024-02-22,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004614,HCP_00198,REP_043,2024-01-26,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_004615,HCP_03957,REP_052,2024-02-05,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004616,HCP_02757,REP_061,2024-03-03,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_004617,HCP_01945,REP_011,2024-01-18,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_004618,HCP_04725,REP_057,2024-03-07,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned prefers competitor.
CALL_004619,HCP_01050,REP_012,2024-01-23,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_004620,HCP_03654,REP_003,2024-02-11,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_004621,HCP_02646,REP_017,2024-01-01,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004622,HCP_01812,REP_021,2024-02-22,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004623,HCP_01829,REP_066,2024-03-15,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004624,HCP_03158,REP_016,2024-01-10,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004625,HCP_00532,REP_006,2024-02-21,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_004626,HCP_01604,REP_021,2024-01-22,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_004627,HCP_02967,REP_076,2024-01-24,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004628,HCP_04195,REP_047,2024-05-07,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004629,HCP_04121,REP_040,2024-01-10,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004630,HCP_04489,REP_034,2024-03-24,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004631,HCP_00661,REP_013,2024-05-04,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned needs more data.
CALL_004632,HCP_00441,REP_011,2024-01-26,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004633,HCP_00303,REP_002,2024-01-11,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004634,HCP_03828,REP_077,2024-01-11,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004635,HCP_02691,REP_021,2024-03-23,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_004636,HCP_03375,REP_041,2024-02-08,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_004637,HCP_03063,REP_050,2024-04-18,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004638,HCP_01801,REP_061,2024-02-11,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004639,HCP_01819,REP_049,2024-01-15,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_004640,HCP_01701,REP_012,2024-01-18,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004641,HCP_03316,REP_043,2024-01-12,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_004642,HCP_03142,REP_020,2024-01-10,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004643,HCP_03877,REP_060,2024-02-19,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_004644,HCP_02111,REP_000,2024-01-31,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004645,HCP_02342,REP_060,2024-02-14,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004646,HCP_02494,REP_063,2024-01-27,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004647,HCP_01036,REP_071,2024-03-05,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004648,HCP_01360,REP_006,2024-03-01,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_004649,HCP_01418,REP_028,2024-05-09,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_004650,HCP_02851,REP_023,2024-01-26,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004651,HCP_04030,REP_055,2024-01-05,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004652,HCP_01084,REP_040,2024-01-23,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_004653,HCP_02107,REP_008,2024-03-24,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004654,HCP_01304,REP_003,2024-03-31,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_004655,HCP_04402,REP_079,2024-02-05,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004656,HCP_03876,REP_019,2024-02-24,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_004657,HCP_00737,REP_023,2024-02-09,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004658,HCP_00554,REP_076,2024-03-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004659,HCP_00352,REP_021,2024-01-01,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004660,HCP_04768,REP_051,2024-01-09,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_004661,HCP_04920,REP_017,2024-01-13,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004662,HCP_02330,REP_042,2024-01-05,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004663,HCP_04029,REP_009,2024-01-13,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004664,HCP_02769,REP_024,2024-01-16,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004665,HCP_03259,REP_028,2024-02-07,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_004666,HCP_03118,REP_022,2024-01-14,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_004667,HCP_04974,REP_059,2024-02-20,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004668,HCP_04544,REP_078,2024-02-29,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_004669,HCP_01291,REP_044,2024-02-22,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004670,HCP_00661,REP_056,2024-01-05,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004671,HCP_01248,REP_076,2024-09-17,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004672,HCP_04282,REP_024,2024-02-07,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_004673,HCP_03124,REP_051,2024-01-05,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_004674,HCP_01358,REP_029,2024-01-23,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_004675,HCP_03877,REP_076,2024-01-10,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_004676,HCP_02693,REP_068,2024-02-21,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_004677,HCP_03755,REP_067,2024-04-04,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004678,HCP_02414,REP_036,2024-01-03,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_004679,HCP_01510,REP_054,2024-01-03,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_004680,HCP_00230,REP_021,2024-02-06,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004681,HCP_03432,REP_047,2024-04-08,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004682,HCP_03184,REP_065,2024-01-10,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_004683,HCP_00873,REP_043,2024-01-01,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned needs more data.
CALL_004684,HCP_03176,REP_056,2024-01-19,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004685,HCP_03992,REP_050,2024-02-20,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004686,HCP_03900,REP_004,2024-01-31,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004687,HCP_00779,REP_063,2024-01-06,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004688,HCP_03414,REP_010,2024-02-16,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004689,HCP_04807,REP_071,2024-03-13,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004690,HCP_02763,REP_021,2024-01-20,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004691,HCP_02466,REP_071,2024-02-29,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_004692,HCP_04179,REP_033,2024-01-18,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004693,HCP_01048,REP_033,2024-01-04,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_004694,HCP_00687,REP_074,2024-01-03,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004695,HCP_01450,REP_053,2024-02-04,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004696,HCP_02603,REP_007,2024-02-13,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_004697,HCP_01516,REP_051,2024-03-22,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_004698,HCP_04635,REP_054,2024-02-19,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004699,HCP_01766,REP_060,2024-02-02,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_004700,HCP_02907,REP_071,2024-01-10,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004701,HCP_00655,REP_007,2024-02-11,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004702,HCP_01864,REP_013,2024-01-18,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004703,HCP_00855,REP_053,2024-02-02,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004704,HCP_04298,REP_021,2024-03-05,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004705,HCP_03138,REP_013,2024-01-24,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_004706,HCP_03258,REP_078,2024-02-28,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004707,HCP_03282,REP_043,2024-02-20,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004708,HCP_03658,REP_059,2024-03-21,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004709,HCP_02782,REP_001,2024-02-25,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004710,HCP_03343,REP_004,2024-10-12,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_004711,HCP_03519,REP_060,2024-01-07,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_004712,HCP_02301,REP_051,2024-05-06,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_004713,HCP_04653,REP_012,2024-01-05,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004714,HCP_00419,REP_063,2024-01-11,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004715,HCP_04058,REP_009,2024-01-13,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_004716,HCP_03492,REP_001,2024-01-10,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004717,HCP_04237,REP_005,2024-01-03,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_004718,HCP_00932,REP_045,2024-01-24,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004719,HCP_01820,REP_047,2024-01-10,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004720,HCP_00539,REP_026,2024-01-14,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_004721,HCP_00933,REP_046,2024-02-12,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004722,HCP_01368,REP_048,2024-01-10,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised new indication and mentioned cost too high.
CALL_004723,HCP_03974,REP_047,2024-02-03,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004724,HCP_04194,REP_075,2024-02-11,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004725,HCP_00952,REP_067,2024-01-05,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004726,HCP_00655,REP_008,2024-02-17,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_004727,HCP_03301,REP_016,2024-03-13,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004728,HCP_04622,REP_022,2024-03-21,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004729,HCP_00047,REP_014,2024-01-02,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004730,HCP_01478,REP_023,2024-03-15,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004731,HCP_00556,REP_013,2024-01-15,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_004732,HCP_00304,REP_039,2024-02-24,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004733,HCP_03125,REP_003,2024-02-01,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004734,HCP_03233,REP_063,2024-03-13,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_004735,HCP_00191,REP_065,2024-01-03,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_004736,HCP_00156,REP_046,2024-01-23,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004737,HCP_00752,REP_004,2024-02-13,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004738,HCP_04513,REP_024,2024-02-02,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004739,HCP_00285,REP_017,2024-01-03,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_004740,HCP_03437,REP_035,2024-05-16,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned formulary restrictions.
CALL_004741,HCP_01688,REP_060,2024-01-03,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_004742,HCP_02038,REP_029,2024-01-29,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_004743,HCP_01163,REP_046,2024-03-29,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_004744,HCP_03643,REP_063,2024-01-18,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004745,HCP_02179,REP_079,2024-03-08,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_004746,HCP_04649,REP_015,2024-02-04,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004747,HCP_03302,REP_044,2024-01-10,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004748,HCP_03995,REP_051,2024-02-19,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_004749,HCP_03011,REP_017,2024-03-15,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004750,HCP_03239,REP_065,2024-02-22,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004751,HCP_04977,REP_025,2024-03-05,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned prefers competitor.
CALL_004752,HCP_02400,REP_046,2024-04-12,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_004753,HCP_02301,REP_014,2024-02-04,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned cost too high.
CALL_004754,HCP_00987,REP_075,2024-01-23,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004755,HCP_03172,REP_059,2024-01-08,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_004756,HCP_02516,REP_006,2024-03-14,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_004757,HCP_00312,REP_050,2024-01-07,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004758,HCP_02548,REP_011,2024-01-30,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_004759,HCP_00774,REP_023,2024-01-31,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004760,HCP_03710,REP_041,2024-01-13,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004761,HCP_03693,REP_041,2024-01-10,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_004762,HCP_03816,REP_031,2024-01-22,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004763,HCP_02854,REP_057,2024-02-09,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_004764,HCP_01892,REP_079,2024-02-26,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_004765,HCP_01633,REP_005,2024-01-25,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_004766,HCP_01316,REP_020,2024-01-17,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_004767,HCP_03328,REP_078,2024-01-01,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_004768,HCP_04870,REP_014,2024-03-31,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_004769,HCP_02542,REP_072,2024-02-06,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004770,HCP_04696,REP_066,2024-04-13,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004771,HCP_03229,REP_062,2024-01-31,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004772,HCP_03575,REP_024,2024-01-24,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004773,HCP_01588,REP_041,2024-02-22,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004774,HCP_01264,REP_079,2024-01-15,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004775,HCP_04826,REP_043,2024-05-18,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_004776,HCP_00203,REP_020,2024-01-18,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_004777,HCP_00123,REP_065,2024-01-27,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004778,HCP_02159,REP_018,2024-05-28,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_004779,HCP_02499,REP_073,2024-05-02,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004780,HCP_01810,REP_060,2024-04-20,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_004781,HCP_00707,REP_063,2024-03-06,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_004782,HCP_02877,REP_068,2024-01-11,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned cost too high.
CALL_004783,HCP_00543,REP_064,2024-02-01,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_004784,HCP_00116,REP_074,2024-03-26,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_004785,HCP_01792,REP_010,2024-03-04,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_004786,HCP_02871,REP_010,2024-01-09,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned needs more data.
CALL_004787,HCP_04256,REP_067,2024-01-23,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004788,HCP_03435,REP_022,2024-02-20,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised access / prior auth and mentioned cost too high.
CALL_004789,HCP_03383,REP_036,2024-02-07,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004790,HCP_02967,REP_017,2024-03-14,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004791,HCP_04254,REP_062,2024-02-10,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004792,HCP_04610,REP_051,2024-03-07,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004793,HCP_02625,REP_064,2024-01-01,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_004794,HCP_04290,REP_079,2024-02-16,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_004795,HCP_01278,REP_057,2024-05-20,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004796,HCP_04477,REP_043,2024-01-12,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004797,HCP_02171,REP_035,2024-01-12,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004798,HCP_04693,REP_039,2024-01-08,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_004799,HCP_01354,REP_024,2024-01-02,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_004800,HCP_03695,REP_001,2024-01-07,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004801,HCP_04018,REP_005,2024-01-05,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004802,HCP_03254,REP_074,2024-01-16,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004803,HCP_03485,REP_063,2024-01-27,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_004804,HCP_04136,REP_015,2024-01-04,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004805,HCP_04686,REP_066,2024-03-11,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004806,HCP_00271,REP_043,2024-01-29,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_004807,HCP_02060,REP_002,2024-02-10,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_004808,HCP_00100,REP_030,2024-03-02,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004809,HCP_04718,REP_011,2024-03-01,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_004810,HCP_00178,REP_057,2024-03-09,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004811,HCP_03393,REP_026,2024-01-19,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004812,HCP_04211,REP_016,2024-01-21,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned workflow complexity.
CALL_004813,HCP_01982,REP_065,2024-01-12,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_004814,HCP_01897,REP_030,2024-02-01,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004815,HCP_00023,REP_015,2024-01-03,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004816,HCP_02184,REP_028,2024-01-09,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004817,HCP_02922,REP_046,2024-01-22,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004818,HCP_02144,REP_029,2024-06-27,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_004819,HCP_03452,REP_063,2024-01-25,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004820,HCP_02702,REP_056,2024-04-22,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004821,HCP_04297,REP_048,2024-01-18,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_004822,HCP_00410,REP_069,2024-04-02,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004823,HCP_00782,REP_029,2024-01-12,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004824,HCP_02199,REP_063,2024-01-08,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004825,HCP_00291,REP_006,2024-02-22,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_004826,HCP_02480,REP_067,2024-02-26,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_004827,HCP_03373,REP_061,2024-02-01,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_004828,HCP_03379,REP_035,2024-02-18,HCP raised safety concern and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised safety concern and mentioned no suitable patients yet.
CALL_004829,HCP_00732,REP_010,2024-02-03,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned needs more data.
CALL_004830,HCP_04883,REP_046,2024-02-12,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004831,HCP_00975,REP_024,2024-03-01,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_004832,HCP_01506,REP_018,2024-02-04,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004833,HCP_04363,REP_010,2024-02-07,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_004834,HCP_00957,REP_076,2024-09-25,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_004835,HCP_00791,REP_006,2024-02-07,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_004836,HCP_03647,REP_031,2024-02-21,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004837,HCP_02107,REP_076,2024-01-05,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised safety concern and mentioned cost too high.
CALL_004838,HCP_01681,REP_004,2024-01-13,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004839,HCP_03589,REP_034,2024-02-15,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_004840,HCP_00818,REP_059,2024-02-18,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004841,HCP_03157,REP_027,2024-01-12,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004842,HCP_02320,REP_065,2024-04-13,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_004843,HCP_02607,REP_059,2024-01-18,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004844,HCP_04265,REP_011,2024-01-18,HCP raised access / prior auth and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned no suitable patients yet.
CALL_004845,HCP_00717,REP_075,2024-02-02,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned cost too high.
CALL_004846,HCP_00404,REP_023,2024-02-27,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004847,HCP_01978,REP_071,2024-01-01,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004848,HCP_02720,REP_057,2024-02-03,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004849,HCP_01189,REP_043,2024-02-08,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004850,HCP_00247,REP_007,2024-04-02,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_004851,HCP_02263,REP_033,2024-04-10,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_004852,HCP_03483,REP_052,2024-01-03,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_004853,HCP_03405,REP_044,2024-02-18,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned needs more data.
CALL_004854,HCP_04187,REP_026,2024-02-27,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_004855,HCP_00277,REP_072,2024-01-12,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004856,HCP_02307,REP_039,2024-01-01,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_004857,HCP_04826,REP_023,2024-01-06,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004858,HCP_01355,REP_011,2024-01-18,HCP raised new indication and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned no suitable patients yet.
CALL_004859,HCP_00816,REP_044,2024-04-20,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_004860,HCP_04858,REP_052,2024-03-08,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned needs more data.
CALL_004861,HCP_01353,REP_061,2024-02-09,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004862,HCP_03873,REP_008,2024-02-02,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_004863,HCP_01021,REP_050,2024-05-21,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_004864,HCP_00611,REP_042,2024-02-17,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_004865,HCP_02639,REP_028,2024-02-26,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004866,HCP_01479,REP_065,2024-02-09,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004867,HCP_04850,REP_028,2024-02-15,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004868,HCP_01716,REP_067,2024-02-23,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004869,HCP_02518,REP_053,2024-02-09,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004870,HCP_04887,REP_000,2024-01-06,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004871,HCP_00454,REP_048,2024-03-18,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised new indication and mentioned workflow complexity.
CALL_004872,HCP_02654,REP_007,2024-01-17,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_004873,HCP_00951,REP_012,2024-01-15,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004874,HCP_02687,REP_077,2024-01-16,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004875,HCP_01478,REP_006,2024-02-17,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004876,HCP_04442,REP_017,2024-02-18,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned needs more data.
CALL_004877,HCP_03952,REP_068,2024-01-08,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned workflow complexity.
CALL_004878,HCP_02736,REP_075,2024-02-04,HCP raised safety concern and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned needs more data.
CALL_004879,HCP_02983,REP_038,2024-01-28,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_004880,HCP_02474,REP_076,2024-01-18,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_004881,HCP_02425,REP_064,2024-01-19,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_004882,HCP_02949,REP_003,2024-01-21,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_004883,HCP_03221,REP_049,2024-02-08,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_004884,HCP_01919,REP_056,2024-02-09,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_004885,HCP_01129,REP_059,2024-02-06,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004886,HCP_03290,REP_014,2024-01-04,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised new indication and mentioned workflow complexity.
CALL_004887,HCP_01300,REP_006,2024-01-28,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004888,HCP_03747,REP_029,2024-01-20,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised new indication and mentioned prefers competitor.
CALL_004889,HCP_04004,REP_032,2024-01-20,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned cost too high.
CALL_004890,HCP_01976,REP_007,2024-02-04,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_004891,HCP_04225,REP_028,2024-02-25,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004892,HCP_01128,REP_013,2024-01-01,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_004893,HCP_01864,REP_029,2024-02-12,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_004894,HCP_00779,REP_056,2024-01-04,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_004895,HCP_01241,REP_044,2024-01-30,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004896,HCP_02456,REP_043,2024-02-12,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised safety concern and mentioned cost too high.
CALL_004897,HCP_00163,REP_025,2024-01-19,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_004898,HCP_00401,REP_019,2024-02-27,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_004899,HCP_01613,REP_015,2024-03-26,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004900,HCP_00993,REP_020,2024-04-20,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised access / prior auth and mentioned needs more data.
CALL_004901,HCP_00478,REP_004,2024-01-08,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
CALL_004902,HCP_03567,REP_059,2024-01-17,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004903,HCP_02626,REP_067,2024-01-16,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004904,HCP_04872,REP_008,2024-01-04,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised side effect management and mentioned workflow complexity.
CALL_004905,HCP_01530,REP_068,2024-04-11,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004906,HCP_00925,REP_064,2024-03-20,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004907,HCP_02299,REP_059,2024-01-18,HCP raised side effect management and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned cost too high.
CALL_004908,HCP_01654,REP_026,2024-01-07,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_004909,HCP_04537,REP_064,2024-01-03,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004910,HCP_04626,REP_040,2024-01-11,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004911,HCP_00410,REP_028,2024-01-02,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004912,HCP_00833,REP_020,2024-01-05,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004913,HCP_02460,REP_028,2024-01-20,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004914,HCP_04055,REP_067,2024-01-29,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004915,HCP_03246,REP_000,2024-01-16,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004916,HCP_02978,REP_057,2024-01-02,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004917,HCP_00763,REP_016,2024-06-11,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned needs more data.
CALL_004918,HCP_01105,REP_063,2024-04-26,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004919,HCP_04107,REP_017,2024-01-02,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004920,HCP_03443,REP_025,2024-02-16,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004921,HCP_02691,REP_052,2024-01-12,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_004922,HCP_03746,REP_040,2024-03-21,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004923,HCP_03338,REP_053,2024-02-05,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised new indication and mentioned formulary restrictions.
CALL_004924,HCP_04656,REP_066,2024-01-09,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004925,HCP_00428,REP_044,2024-05-25,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004926,HCP_01371,REP_072,2024-01-01,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004927,HCP_01578,REP_010,2024-01-17,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised patient support program and mentioned cost too high.
CALL_004928,HCP_01243,REP_072,2024-01-02,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004929,HCP_04715,REP_079,2024-02-02,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004930,HCP_01753,REP_018,2024-01-14,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004931,HCP_01595,REP_004,2024-01-09,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004932,HCP_00373,REP_061,2024-01-12,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned cost too high.
CALL_004933,HCP_04700,REP_036,2024-02-10,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004934,HCP_02006,REP_042,2024-01-05,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004935,HCP_03358,REP_028,2024-02-14,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised safety concern and mentioned workflow complexity.
CALL_004936,HCP_02160,REP_006,2024-03-07,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004937,HCP_03690,REP_050,2024-01-09,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004938,HCP_02700,REP_068,2024-03-19,HCP raised access / prior auth and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned needs more data.
CALL_004939,HCP_01246,REP_053,2024-01-14,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004940,HCP_01374,REP_071,2024-01-10,HCP raised side effect management and mentioned needs more data. Discussed study results and aligned on connect with MSL. HCP interest level: medium.,HCP raised side effect management and mentioned needs more data.
CALL_004941,HCP_02676,REP_035,2024-03-29,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised patient support program and mentioned prefers competitor.
CALL_004942,HCP_01626,REP_020,2024-01-28,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_004943,HCP_03704,REP_039,2024-02-07,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_004944,HCP_02064,REP_029,2024-02-05,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004945,HCP_04360,REP_078,2024-02-23,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004946,HCP_03555,REP_030,2024-02-16,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004947,HCP_01458,REP_006,2024-02-11,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004948,HCP_00774,REP_009,2024-04-28,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned workflow complexity.
CALL_004949,HCP_04378,REP_053,2024-03-13,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004950,HCP_02862,REP_014,2024-02-21,HCP raised new indication and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised new indication and mentioned formulary restrictions.
CALL_004951,HCP_00477,REP_064,2024-01-16,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004952,HCP_00144,REP_029,2024-01-27,HCP raised new indication and mentioned cost too high. Discussed study results and aligned on provide starter kits. HCP interest level: low.,HCP raised new indication and mentioned cost too high.
CALL_004953,HCP_04900,REP_078,2024-04-03,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004954,HCP_02853,REP_005,2024-03-15,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised patient support program and mentioned needs more data.
CALL_004955,HCP_03513,REP_054,2024-01-17,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_004956,HCP_01287,REP_027,2024-01-17,HCP raised efficacy improvement and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised efficacy improvement and mentioned no suitable patients yet.
CALL_004957,HCP_03308,REP_032,2024-01-16,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004958,HCP_00931,REP_012,2024-01-22,HCP raised access / prior auth and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised access / prior auth and mentioned workflow complexity.
CALL_004959,HCP_04662,REP_000,2024-02-02,HCP raised side effect management and mentioned workflow complexity. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised side effect management and mentioned workflow complexity.
CALL_004960,HCP_01064,REP_040,2024-02-19,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_004961,HCP_04952,REP_028,2024-02-03,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_004962,HCP_04970,REP_035,2024-01-11,HCP raised patient support program and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised patient support program and mentioned formulary restrictions.
CALL_004963,HCP_04922,REP_009,2024-02-19,HCP raised access / prior auth and mentioned formulary restrictions. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised access / prior auth and mentioned formulary restrictions.
CALL_004964,HCP_01218,REP_076,2024-01-12,HCP raised patient support program and mentioned no suitable patients yet. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised patient support program and mentioned no suitable patients yet.
CALL_004965,HCP_01686,REP_048,2024-01-14,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004966,HCP_01421,REP_027,2024-03-10,HCP raised patient support program and mentioned needs more data. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned needs more data.
CALL_004967,HCP_02836,REP_022,2024-04-21,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_004968,HCP_00236,REP_016,2024-01-29,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004969,HCP_00791,REP_042,2024-03-04,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised new indication and mentioned prefers competitor.
CALL_004970,HCP_03792,REP_064,2024-01-29,HCP raised efficacy improvement and mentioned needs more data. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned needs more data.
CALL_004971,HCP_03610,REP_069,2024-01-11,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on send clinical reprint. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004972,HCP_04831,REP_009,2024-02-05,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned workflow complexity.
CALL_004973,HCP_02848,REP_004,2024-01-27,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004974,HCP_01399,REP_053,2024-01-24,HCP raised side effect management and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised side effect management and mentioned formulary restrictions.
CALL_004975,HCP_01066,REP_029,2024-04-28,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned prefers competitor.
CALL_004976,HCP_01322,REP_049,2024-01-11,HCP raised safety concern and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised safety concern and mentioned workflow complexity.
CALL_004977,HCP_02171,REP_021,2024-02-27,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: medium.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004978,HCP_04977,REP_020,2024-01-05,HCP raised new indication and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised new indication and mentioned prefers competitor.
CALL_004979,HCP_00900,REP_023,2024-04-21,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004980,HCP_02425,REP_037,2024-01-21,HCP raised side effect management and mentioned no suitable patients yet. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned no suitable patients yet.
CALL_004981,HCP_01160,REP_007,2024-02-24,HCP raised efficacy improvement and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: low.,HCP raised efficacy improvement and mentioned prefers competitor.
CALL_004982,HCP_03014,REP_036,2024-03-20,HCP raised access / prior auth and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: high.,HCP raised access / prior auth and mentioned cost too high.
CALL_004983,HCP_02577,REP_025,2024-01-15,HCP raised efficacy improvement and mentioned cost too high. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised efficacy improvement and mentioned cost too high.
CALL_004984,HCP_04995,REP_012,2024-01-17,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on share copay info. HCP interest level: high.,HCP raised patient support program and mentioned prefers competitor.
CALL_004985,HCP_03563,REP_052,2024-03-24,HCP raised patient support program and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised patient support program and mentioned workflow complexity.
CALL_004986,HCP_04537,REP_041,2024-01-10,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on connect with MSL. HCP interest level: low.,HCP raised safety concern and mentioned prefers competitor.
CALL_004987,HCP_00029,REP_049,2024-01-28,HCP raised new indication and mentioned needs more data. Discussed study results and aligned on send clinical reprint. HCP interest level: medium.,HCP raised new indication and mentioned needs more data.
CALL_004988,HCP_04694,REP_001,2024-03-04,HCP raised patient support program and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised patient support program and mentioned prefers competitor.
CALL_004989,HCP_03612,REP_044,2024-01-07,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on provide starter kits. HCP interest level: high.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004990,HCP_01991,REP_032,2024-05-25,HCP raised safety concern and mentioned prefers competitor. Discussed study results and aligned on provide starter kits. HCP interest level: medium.,HCP raised safety concern and mentioned prefers competitor.
CALL_004991,HCP_04729,REP_057,2024-02-25,HCP raised safety concern and mentioned cost too high. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised safety concern and mentioned cost too high.
CALL_004992,HCP_03643,REP_071,2024-02-06,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004993,HCP_00518,REP_016,2024-01-17,HCP raised new indication and mentioned workflow complexity. Discussed study results and aligned on share copay info. HCP interest level: medium.,HCP raised new indication and mentioned workflow complexity.
CALL_004994,HCP_03206,REP_005,2024-01-01,HCP raised patient support program and mentioned cost too high. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised patient support program and mentioned cost too high.
CALL_004995,HCP_03309,REP_046,2024-03-18,HCP raised safety concern and mentioned formulary restrictions. Discussed study results and aligned on connect with MSL. HCP interest level: high.,HCP raised safety concern and mentioned formulary restrictions.
CALL_004996,HCP_04327,REP_042,2024-01-06,HCP raised efficacy improvement and mentioned formulary restrictions. Discussed study results and aligned on share copay info. HCP interest level: low.,HCP raised efficacy improvement and mentioned formulary restrictions.
CALL_004997,HCP_02846,REP_067,2024-02-25,HCP raised efficacy improvement and mentioned workflow complexity. Discussed study results and aligned on schedule follow-up visit. HCP interest level: medium.,HCP raised efficacy improvement and mentioned workflow complexity.
CALL_004998,HCP_03576,REP_052,2024-01-03,HCP raised access / prior auth and mentioned prefers competitor. Discussed study results and aligned on schedule follow-up visit. HCP interest level: low.,HCP raised access / prior auth and mentioned prefers competitor.
CALL_004999,HCP_01999,REP_041,2024-01-30,HCP raised side effect management and mentioned prefers competitor. Discussed study results and aligned on wait for formulary decision. HCP interest level: high.,HCP raised side effect management and mentioned prefers competitor.
